Annual Report
2024-2025

JMI Hospital Requisite Manufacturing Ltd.
(A Joint Venture Enterprise with Republic of South Korea)

The Founder

Mr. Md. Abdur Razzaq, a prominent Bangladeshi business leader, has been awarded the prestigious "CIP" (large industry, Manufacturing, Export trade) award for the third time. His significant contributions to the nation's economic growth are evident in his involvement in manufacturing life-saving drugs, medical devices, and accessories. These products are now exported to over 41 countries worldwide, meeting both domestic and international demand. JMI Group, under Mr. Razzaq's leadership, has diversified into a wide range of sectors. These include liquefied petroleum gas (LPG), industrial gas, cylinder and auto tank manufacturing, real estate, printing and packaging, engineering, clinical trials, restaurants, transport and logistics, media, agriculture, and education. The group operates 41 strategic business units and has formed joint ventures with renowned global companies like NIPRO Corporation-Japan, South Korea, Turkey, and China. Born in 1963 into a respected Muslim family in Noakhali District, Mr. Razzaq holds a Master's degree in Economics from the University of Chittagong. His expertise in manufacturing medical devices was acquired through extensive experience in Japan. Mr. Razzaq's dynamic and innovative approach has propelled JMI Group to become a leading business conglomerate in Bangladesh. His relentless efforts have garnered international recognition, with features in publications like NY Market Reports news and other global media. Committed to social and economic development, Mr. Razzaq's business philosophy is centered around serving humanity. He has traveled to 82 countries worldwide, envisioning a "Mini Bangladesh" in each. Mr. Razzaq believes that Bangladesh's young generation has the potential to work hard and lead the country to a prominent position in the global market.



Md. Abdur Razzaq, CIP
Founder, Managing Director
JMI Group

About the Company



JMI Hospital Requisite Manufacturing Limited (JHRML) is a joint venture company with the Republic of South Korea. It is an import substitute industry and the pioneer manufacturer of health and hospicare products in Bangladesh. Incorporated on 20 August 2008 as a Private Limited company and converted to public limited company on 30th November, 2014. The company has listed with DSE and CSE on March 23, 2022 and trading started on March 31, 2022 with DSE & CSE. The authorized capital of the company is BDT 300.00 Crore and the paid-up capital is BDT 125,29,41,200.00. Plant is located at Vitikandi, Gazaria, Munshigonj adjacent to Dhaka Chittagong Highway. The Manufacturing part of the Company has gone into commercial operation on 17th January 2013 and Trading business from 2010. The company holds 65% stake in JMI Specialized Hospital Ltd (subsidiary of JHRML).

JMI Hospital Requisite Manufacturing Limited has a world-class manufacturing plant, where we maintain a cleanroom environment to facilitate production of medical devices and components compliant to international guidelines.

A highly qualified, skilled and dedicated team of professionals are engaged in our manufacturing plant. JMI Hospital Requisite Manufacturing Limited produces a wide range of health & hospicare products.

Innovation is an integral part of JMI business that always leads to work with new concepts and ideas. As a leading manufacturer of medical devices in locally, we have setup a benchmark and brought a new dimension in the healthcare sector in Bangladesh.

It has started a new era ensuring industrial growth to a new height making the medical devices available at a reasonable price and striving hard to make the country self-reliant and cutting down the budget for importing healthcare products.

Autoclave, sterilization equipment is also being manufactured at JMI Hospital Requisite Manufacturing plant.

In the way of successive pioneer ship, in recent times, the company has established a highly technical, and import substitute clinical product named “SUTURE”, a kind of surgical thread with needle, pioneer manufacturing facility through adapting sophisticated, most modern, cutting-edge European technology has enabled us for a break-through in the domain of suture products and its use in Bangladesh with a slogan “stitch with confidence”.

The modern patient care system creates demand of PP & PVC, Cannula, Bulk Needle, Film, Blood Transfusion Set, Infusion Set, Scalp Vein Set, and many other types of equipment in home and abroad. JMI is proud to supply its product to many reputed organizations. Most of the public and private hospitals are using JMI suture and hospicare products. The Company has been working for the international market as well.

Letter of Transmittal

December 15, 2025

The Respected Shareholders
Bangladesh Securities and Exchange Commission
Dhaka Stock Exchange PLC
Chittagong Stock Exchange PLC

Annual Report for the year ended June 30, 2025.

Dear Sir (s),

We are pleased to enclose a copy of the Annual Report containing the Directors' Report and Auditors' report along with Audited Financial Statements including Statement of Financial Position as at June 30, 2025, Statement of Profit or Loss and other comprehensive Income, Cash Flows, Changes in Equity for the year ended June 30, 2025, along with notes thereon of the JMI Hospital Requisite Manufacturing Limited and all related statements for your kind record and necessary measures.

With best regards,

Md. Safiqur Rahaman, FCS
Company Secretary

Notice of The 17th Annual General Meeting

Notice is hereby given that the 17th Annual General Meeting of JMI Hospital Requisite Manufacturing Limited will be held on **Thursday, January 22, 2026, at 11:00 a.m.** through a hybrid system in combining the physical presence of shareholders at the venue in **Sky City Hotel (8th floor), 47, Siddeshwari, Circular Road, Malibag, Dhaka** and participation via the digital platform at ***https://jmihrml.bdvirtualagm.com*** to transact the following businesses:

AGENDA

Ordinary business:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended June 30, 2025, together with the reports of the Directors and the Auditors thereon.
2. To approve the proposed dividend for the year ended June 30, 2025.
3. To elect/re-elect Directors of the company.
4. To appoint Statutory Auditors and fix their remuneration for the year ended June 30, 2026.
5. To appoint Compliance Auditors and fix their remuneration for the year ended June 30, 2026.

Special business:

1. To approve related party transactions for the year ended June 30, 2025.

"Resolved that the related party transactions as disclosed in note number 29 of the audited financial statement for the year ended June 30, 2025, are approved by the board of directors, that the matter be placed before the 17th AGM for approval by the shareholders."

2. To approve the partial change in IPO use of proceeds and extension of fund utilization time.

"Resolved that the Board has approved and recommended revising the utilization of IPO proceeds and extending the timeline up to 31 December 2026 due to additional utility expenses for project completion, subject to approval by the shareholders at the 17th AGM and the BSEC."

3. To approve the Investment Adjustment in JMI Specialized Hospital Limited.

"Resolved that JMI Hospital Requisite Manufacturing Limited has made an additional investment of Tk. 106,070,000 in its subsidiary, JMI Specialized Hospital Limited, totaling Tk. 316,070,000. The Board approved not to further invest and reduce its shareholding to below 50%, after which JSHL will become an associate company. This will be placed before the 17th AGM for approval by the shareholders."

By order of the Board



Md. Safiqur Rahaman, FCS
Company Secretary

Dated: December 28, 2025

Notes:

1. November 26, 2025 was the Record Date for the 17th AGM. The Shareholders whose names appeared in the Central Depository System (CDBL) / Register of the members on the record date would be eligible to attend the Meeting and be entitled to the dividend.
2. A shareholder entitled to attend and vote in the AGM may appoint a proxy in his stead. The proxy form duly stamped must be sent through email at cs@jhrml-bd.com or submitted to the corporate office of the company, not later than 72 hours before the meeting.
3. The corporate shareholders need to send their authorization letter through email at cs@jhrml-bd.com or corporate office of the company at least 72 hours before the commencement of the AGM.
4. The shareholders will join the virtual AGM through the link; *https://jmihrml.bdvirtualagm.com*
5. The shareholders will be able to submit their questions/comments and vote electronically before 72 hours of the AGM and during the AGM.
6. Pursuant to the BSEC Notification No. BSEC/CMRRCD/2009-193/75/PRD150, Dated: 20 February 2024, Copy of the Annual Report to be sent to the email address of the shareholders maintained with CDBL.
7. The concerned Merchant Banks and all Depository Participants (DPs) are requested to provide copies of the list of margin clients along with the bank details for entitlement of dividends on or before 15 January 2026 as per the following:
   a) Hard copy: Registered mail or courier to; Company Affairs, JMI Hospital Requisite Manufacturing Limited. Unique Heights (Level-5), 117, Kazi Nazrul Islam Avenue, Ramna, Dhaka-1217
   b) E-mail: cs@jhrml-bd.com
8. This Notice and Annual Report is available on the website of the company; www.jhrml-bd.com.

Table of Contents

PARTICULARS	PAGE NO.
01. About the Company	01
02. Letter of Transmittal	02
03. Notice of 17th Annual General Meeting	03
04. Corporate Directory	05
05. Corporate Achievements	08
06. Vision, Mission & Values	11
07. The Board of Directors	12
08. Massage from the Chairman	13
09. Message from the Managing Director	14
10. Corporate Social Responsibility (CSR)	15
11. Our Products	16
12. Production Procedure	30
13. Financial Calendar	32
14. Performance at a Glance	33

PARTICULARS	PAGE NO.
15. Graphical Presentation	34
16. Director's Report to the Shareholders	36
17. Report of the Audit Committee	51
18. Report of the Nomination & Remuneration Committee	53
19. Dividend Distribution Policy	54
20. Management Discussion & Analysis	57
21. Declaration by CEO & CFO	58
22. Statement of Corporate Governance	59
23. Certificate of Compliance	60
24. Checklist on Corporate Governance Code	61
25. Audited Financial Statements for the year ended 30 June, 2025	74
26. **SUBSIDIARY PROFILE :** JMI Specialized Hospital Ltd.	127
27. Certificates	148
28. Proxy Form	152

Corporate Directory

Name of the Issuer	JMI Hospital Requisite Manufacturing Limited
Logo	
Legal Position	Public Limited Company
Date of Incorporation	20 August 2008
Company Registration No.	C-72728 (770)/08
Date of Commercial Operation	Trading 2010, Production 17.01.2013
Changes in Denomination of Face Value of Shares	26/09/2012, Face value of each shares Tk. 100.00 to Tk. 10.00
Date of Conversion into a Public Limited Company	30 November 2014
Opening Date for Subscription	27 February, 2022
Closing Date for Subscription	03 March, 2022
Listing in DSE & CSE	23 March, 2022
Trading in DSE & CSE	31 March, 2022
Market Category	"B"
Electronic Share	Yes
Face Value	Tk. 10.00
Authorized Capital	BDT 300.00 Crore
Paid-up Capital	BDT 1,252,941,200.00
Registered office	72/C, Progoti Shoroni, Middle Badda, Dhaka-1212.
Corporate office and Investor's inquiry	Unique Heights (Level-11), 117 Kazi Nazrul Islam Avenue, Ramna, Dhaka-1217. Telephone : +88 02 55138723-24 Fax : +88 02 55138725 Email : cs@jhrml-bd.com Website : www.jhrml-bd.com
Board of Directors	6 Directors (including two Independent Directors)
Statutory Auditor	G. Kibria Co, Chartered Accountants Plot 51, Floor-2, Road-14, Block-G, Niketon, Gulshan-1, Dhaka-1212. Tel: +88-02-223388071 Website: http://gkibriaandco.com
Compliance Auditor	Artisan, Chartered Accountants Address : Sonargaon Terrace (2nd Floor), House-52, Road-13C, Block-E, Banani, Dhaka-1213. Website : www.artisan-ca.com
Subsidiaries	JMI Specialized Hospital Ltd.

Board of Directors

Mr. Md. Abdur Razzaq	: Chairman
Mrs. Suriya Akther Rina	: Managing Director
Mr. Hoi Kwan Kim	: Director
Mr. Ranjit Chakraborty, FCMA	: Nominee director
Mr. Abdul Wahab Khan	: Independent Director
Mr. Jahanara Pervin	: Independent Director

Key Management Personnel's

Mrs. Suriya Akther Rina	: Managing Director
Md. Mostafa Zaman (Bhutto)	: Executive Director, HR & Administration (Factory)
Asit Ranjan Sarker	: Executive Director, Technical Operations
Brig Gen Md Sharif Hossain (Retd.)	: Executive Director, SCM, JMI Group
Md. Nurul Alam	: General Manager, Commercial, JMI Group
Md Tousiful Karim FCA	: General Manager, MD's Secretariat
Md. Asaduzzaman	: Chief Sales & Marketing Officer (GM)
Abdullah Al Faruki	: Deputy General Manager, Group Administration
Subas Chandra Banik	: Chief Financial Officer
Md. Safiqur Rahman, FCS	: Company Secretary
Md. Abdur Rashid	: Sr. AGM, Supply Chain & VAT Department
Mr. Tanvir Ahmed	: AGM, Production
Mr. Md. Rakibul Haque Pradhan	: Head of Internal Audit & Compliance

Audit Committee

Mr. Abdul Wahab Khan	- Independent Director	Chairman
Mr. Ranjit Chakraborty, FCMA	- Nominee Director	Member
Mr. Hoi Kwan Kim	- Director	Member
Mr. Md. Safiqur Rahman, FCS	- Company Secretary	Secretary

Nomination and Remuneration Committee (NRC)

Mr. Abdul Wahab Khan	- Independent Director	Chairman
Mr. Ranjit Chakraborty, FCMA	- Nominee Director	Member
Mr. Hoi Kwan Kim	- Director	Member
Mr. Md. Safiqur Rahman, FCS	- Company Secretary	Secretary

Main Bankers

Janata Bank PLC
Pubali Bank PLC
Dutch-Bangla Bank PLC
Uttara Bank PLC
Standard Bank PLC
Mutual Trust Bank PLC
BRAC Bank PLC

Stock information

Dhaka Stock Exchange PLC
Chittagong Stock Exchange PLC
Stock Code: JHRML

JMI is introducing...

Javelin

Central Venous Catheter Set

(Antimicrobial)

ANTIMICROBIAL

Advanced Infection Protection for Safer Patient Outcomes

*Our catheter is made of **polyurethane** mixed with **silver-containing zirconium phosphate** at the nanometer level.*

*Once inside the body, **Ag^+ ions** are slowly released, providing continuous antibacterial action.*

☑ Effective Against:

- Gram-positive bacteria
- Gram-negative bacteria
- Fungi

☑ Key Benefits:

- ▶ Reduces infection risk by up to 80%
- ▶ Lowers mortality from infections by 10–20%
- ▶ Prevents 75% of bacteremia cases
- ▶ Longer in-body duration than regular catheters
- ▶ Non-toxic & safe - mechanism different from the antibiotics
- ▶ Minimizes development of drug resistance

☑ Antimicrobial Effectiveness:

Pathogen	Inhibition Rate
Staphylococcus	☑ High
Enterococcus	☑ High
Candida	☑ High

1ST TIME Manufacturing in Bangladesh



Corporate Achievement

2008-2025



2008

Registration of the Company as a Private Limited Company on 20th August, 2008

2010

- Membership Certificate from DCCI
- Commencement of commercial operation Trading 2010
- Achievement of Import Registration Certificate (IRC) office of the Chief Controller of Imports & Exports, Bangladesh

2011

- Environment Clearance Certificate from Department of Environment
- Tied up with Nipro Corporation, Japan through marketing and distribution of Hemodialysis and Blood Glucose Monitoring products.

2012

- Get Export Registration Certificate (ERC) office of the Chief Controller of Imports & Exports, Bangladesh.
- License from Board of Investment (BOI)
- Obtain Fire License
- Obtain License from Department of Inspection for Factories and Establishments

2013

- Commencement of Commercial Operation Production
- NBR approved of Tax holiday facilities.

2014

- Conversion in to Public Limited Company from Private Limited Company
- Get Drug License from Directorate General of Drugs Administration & Licensing Authority (Drugs)

2017

- Launching of Surgical Suture for the first time in Bangladesh
- Deploy JMI Marketing Ltd. as Sales, Marketing, and Distribution partner

2018

Launching of Atraumatic Needle for Peripheral Anesthesia and Surgical Scalpel for the first time in Bangladesh as local manufacturer.

2019

- Certificate of Good Manufacturing Practice (GMP) for Pharmaceutical Product's
- Quality Management Systems (QMS) from BSTI
- Road Show for Initial Public Offer (IPO)
- Application submit to BSEC for Initial Public Offer (IPO)

2020

- 4 Layered JMI Non-woven Face Mask launched with PTFE Filter
- JMI Respirator KN95 Mask got registration from DGDA for the first time in Bangladesh.

2021

- Received ISO Certification (ISO 13485)
- Achieved Prestigious CE Certification (CE 0068)
- Obtain Consent letter from BSEC for raising capital through IPO

2022

Trading started with DSE & CSE on March 31, 2022

2023

- Received ISO Certification (ISO 13485:2016)
- Received ISO Certification (ISO 14001:2015)
- Establish a subsidiary named JMI Specialized Hospital Ltd.
- Environment Management System (EMS) from BSTI

2024

- Vacuum Blood Collection Tube and Urine Drainage Bag have been successfully developed, with the user trial process completed.
- For the first time in Bangladesh, we have developed a Central Venous Catheter, Blood Pressure Transducer, Foley Balloon Catheter, Pressure Monitoring Line, Anesthesia Circuit, Breathing Circuit, Huber Needle, and Breathing Mask. The user trial process has successfully evaluated the development.
- Successfully designed fully Automatic (PLC Controlled) Vacuum/Pulsation & Jacket Chamber Enriched 300-litre Steam Sterilizer for the first time in Bangladesh.
- Obtained ISO 13485:2016 Certification.

2025

- Launch of JMI Specialized Hospital Limited.

Successfully inaugurated JMI Specialized Hospital Limited, a subsidiary of JMI Hospital Requisite Manufacturing Limited, marking a significant milestone in advancing world-class healthcare services in Bangladesh.

- Product Line Expansion

a) Javelin (Central Venous Catheter Set, including an antimicrobial version).
b) Jemocath (Hemodialysis Catheter Set), Jeducer (Blood Pressure Transducer Kit), Jeflex (Latex Foley Balloon Catheter), JAC (Anesthesia Circuit), JCFlow (Breathing Mask), and Jovex (Examination Gloves).
c) 4 new SKUs of 22G Butterfly Needle for blood collection.
d) Registered a new series of surgical sutures.
e) Obtained primary approval for 13 upcoming products.

- Major Facility and Equipment Upgrades

a) Blood Collection Tube production unit.
b) SVS Assembling Machine.
c) Extruder Machine.
d) High-Frequency Welding Machine.
e) Blister Packaging Facility.

Vision, Mission & Values



VISION

Create brand image and reputation, explore export potential market and become market leader in medical devices sector of Bangladesh.



MISSION

Provide healthcare service to ailing people with the help of locally manufactured global standard healthcare products, particularly medical devices at affordable prices.



VALUES

Quality

Creativity

Trust

Social Responsibility

Team Work

Growth

The Board of Directors



Mr. Md. Abdur Razzaq
(Chairman)



Mrs. Suriya Akther Rina
(Managing Director)



Mr. Hoi Kwan Kim
(Director)



Mr. Ranjit Chakraborty, FCMA
(Nominee Director of
JMI Vaccine Limited)



Mr. Abdul Wahab Khan
(Independent director)



Mrs. Jahanara Pervin
(Independent director)

Message from the Chairman



Respected Shareholders,
Assalamu Alaikum Wa Rahmatullah.

On behalf of the Board of Directors of JMI Hospital Requisite Manufacturing Limited (JHRML), I am pleased to extend my warm greetings and welcome you to the 17th Annual General Meeting.

The financial year ended June 30, 2025, was shaped by persistent global challenges, including supply chain disruptions, rising inflation, and widespread uncertainty in the global business environment. Despite these external pressures, JHRML demonstrated resilience through prudent financial management, operational excellence, and an unwavering focus on our core strengths.

Our talented workforce, integration of advanced technologies, and robust factory management systems have enabled us to sustain high productivity while consistently delivering quality products to our valued customers. These capabilities have not only safeguarded our market position but have also contributed to stable and healthy profitability.

In line with our sustainable dividend policy, the Board of Directors is pleased to recommend a 5% cash dividend to general shareholders, excluding sponsors and directors, for the year under review, subject to your approval.

I take this opportunity to express my sincere appreciation to our employees, fellow Board members, shareholders, customers, suppliers, and all stakeholders for their continued trust, support, and cooperation. Together, we will continue to strengthen JHRML's leadership in the medical devices industry and work towards sustainable growth in the years ahead.

With best wishes,

Md. Abdur Razzaq
Chairman

Message from the Managing Director



Dear Respected Shareholders, Ladies and Gentlemen,
Assalamu Alaikum Wa Rahmatullah.

It is my pleasure to welcome you to the 17th Annual General Meeting of JMI Hospital Requisite Manufacturing Limited. I am honored to present the Annual Report 2024–2025, which includes the Directors' Report and the Audited Financial Statements, for your kind review.

The year was not without challenges. Rising raw material costs, supply chain disruptions, and L/C opening difficulties tested our resilience. With the dedication of our team and timely strategic decisions, we worked hard to overcome these obstacles.

Notable achievements in 2024–2025 include the successful development of Javelin (Central Venous Catheter Set, including an antimicrobial version), Jemocath (Hemodialysis Catheter Set), Jeducer (Blood Pressure Transducer Kit), Jeflex (Latex Foley Balloon Catheter), JAC (Anesthesia Circuit), JCFlow (Breathing Mask), and Jovex (Examination Gloves). In addition, we successfully registered a new suture series.

We are pleased to announce the inauguration of JMI Specialized Hospital Limited, a subsidiary of JMI Hospital Requisite Manufacturing Limited, which is expected to play a significant role in delivering world-class healthcare services in Bangladesh through the joint collaboration of Apollo Health and Lifestyles Limited, India.

On behalf of the company, I express my deepest gratitude to our partners, supporters, regulatory bodies, and all stakeholders for their continued trust and cooperation.

May Almighty Allah bless us all.

Suriya Akther Rina
Managing Director

JMI Group
Observes International Day of Peace 2025



Every year, the International Day of Peace is observed around the world on 21st September. The theme for 2025, "Act Now for a Peaceful World," emphasizes the urgent need for both individual and collective efforts to build peace, prevent conflict, and advance the global "Act Now" campaign to achieve the Sustainable Development Goals (SDGs).

On this occasion, Mr. Md. Abdur Razzaq, Founder and Honorable Managing Director of JMI Group, emphasized the significance of the theme "Act Now for a Peaceful World." He urged for immediate and collective action, reflecting on his personal commitment to peace since 2008. Mr. Razzaq highlighted the essential roles of institutions, society, and individuals in promoting harmony and acknowledged JMI Group's contributions to peace and social well-being. He also underscored the importance of education, awareness, and empathy, particularly among youth, calling upon all stakeholders to unite in fostering a peaceful and inclusive society grounded in shared human values.

As part of the observance, JMI Hospital Requisite Mfg. Ltd. (JHRML) actively participated in the International Peace Day celebration held on 21st September 2025. A discussion session was organized at the Corporate Office of JMI Group, where distinguished speakers highlighted the importance of promoting public awareness, social harmony, and peace for all—irrespective of caste, religion, or ethnicity.

The Honorable Chairman of JMI Group also addressed the gathering, emphasizing the 2025 Peace Day theme and the group's humanitarian contributions, including its significant role in the COVID-19 vaccination campaign through the production of AD syringes. He reaffirmed that peace is a shared responsibility rooted in fairness, inclusivity, and justice, and encouraged everyone to work collectively to eliminate discrimination and nurture a compassionate, equitable world.

The celebration concluded with a Peace Rally starting from Doel Chattar and ending at Dhaka University's TSC, enthusiastically joined by JMI Group employees, symbolizing the organization's unwavering commitment to promoting peace and unity.



Our Products

SURGICAL ITEMS

1. JMI Surgical Suture





J-CRYL

Braided Coated Polyglactin 910
Absorbable Surgical Suture

Features:

- Absorbable material
- Excellent thread & needle assembling
- Needle sharpness remains the same with multipass
- Smooth texture allows for easy and gentle passage through tissue
- Gradually breaks down in the body through hydrolysis
- Sterilization (sterile version): EtO
- Available size: 1, 1-0, 2-0, 3-0, 4-0, 5-0, 6-0 (USP)





J-GUT

Catgut - Plain & Chromic
Absorbable Surgical Suture

Features:

- Short term (Plain) and mid-term(Chromic) absorption profile
- Excellent thread & needle assembling
- Thread from certified TSE & BSE free source
- Extremely smooth textile, resulting minimal tissue trauma
- High flexibility with excellent knot security
- Sterilization (sterile version): Gamma
- Available size: Plain= 3-0, 4-0, 5-0 (USP), Chromic=2, 1, 1-0, 2-0, 3-0, 4-0 (USP)





J-LENE

Monofilament Polypropylene Blue
Non-Absorbable Surgical Suture

Features:

- Non Absorbable Synthetic Monofilament suture
- Extremely smooth textile, resulting minimal tissue trauma
- High Strength and Flexibility
- Biocompatible polypropylene
- Excellent needle sharpness
- Sterilization (sterile version): EtO
- Available size: 1, 1-0, 2-0, 3-0, 4-0, 5-0, 6-0, 7-0, 8-0 (USP)





J-SILK

Braided Silk Black
Non-Absorbable Surgical Suture

Features:

- Non Absorbable Natural Braided Multifilament suture
- Coated with wax facilitate smooth pass through tissue
- Extremely smooth textile, resulting minimal tissue trauma
- High tensile strength ensures excellent tissue support
- Excellent needle sharpness
- Sterilization (sterile version): EtO
- Available size: 1, 1-0, 2-0, 3-0, 4-0 (USP)

SURGICAL ITEMS

2. JMI Latex Surgical Gloves (Powdered)



Features:

- Natural high-quality latex rubber for extra strength and elasticity
- Textured micro-roughened surface provides excellent wet and dry grip
- Hand specific, complete anatomically designed to reduce hand fatigue
- Beaded cuff ensures ease of donning and helps to prevent rolling back
- USP grade absorbable cornstarch as lubricating agent
- Sterilized by EO gas
- Available size : 6.0, 6.5, 7.0, 7.5, 8.0

3. JMI Latex Surgical Gloves (Powder Free)



Features:

- Natural high-quality latex rubber for extra strength and elasticity
- Textured microroughened surface provides excellent wet and dry grip
- Hand specific, complete anatomically designed to reduce hand fatigue
- Beaded cuff ensures ease of donning and helps to prevent rolling back
- Sterilized by EO gas
- Available size : 6.0, 6.5, 7.0, 7.5, 8.0

4. JMI Sterile Surgical Blade



Features:

- Carbon Steel Blades made of Swiss Steel Grade 125 Crl
- Individually packed in easy-peel colour-coded foil
- Fits all makes of handles. Conforms to ISO 7740
- Sterilized by Gamma Radiation to a minimum dosage of 2.5 MRads
- Blades conform to BS 2982 and Medical Devices Directive 93/42/EEC
- Available size: 10, 11, 12, 15, 20, 21, 22, 23 & 24

5. JMI Sterile Disposable Scalpel



Features:

- Better sharpness, Better grip, Better feel, Better performance
- Stainless Steel Blades made of premium Swedish Steel
- ABS Plastic handle ensures greater strength
- Graduated scale for convenience
- Available size: 10, 11, 12, 15, 20, 21, 22, 23 & 24

RESPIRATORY

1. JMI Nasal Oxygen Cannula



Features:

- Soft, curved nasal prongs relieve pressure behind the ears thus minimize irritation and soreness
- Notch between nasal prongs provides flexibility and a more customized fit
- Star-lumen design provides crush and kink-proof tubing for continuous flow
- Available size : Child & Adult

2. JMI Nebulizer Mask with Chamber & Tubing



Features:

- Lightweight with soft, comfortable edges
- Clear mask and tube for easy visibility
- Elastic band and nose clip for proper fit
- Suitable for patients lying horizontally
- Connectors on both tube ends for easy setup
- Star-lumen tubing prevents kinks and ensures continuous flow
- Available size: Small, Medium & Large

3. JMI Oxygen Mask with Tubing



Features:

- Lightweight design with soft, feathered edges for enhanced patient comfort
- Elastic band and aluminum nose clip is provided on the mask for proper adjustment on nasal area
- Tube is provided with connectors at both ends for easy connection with oxygen source
- Start lumen design provides crushed and kink proof tubing for continuous flow
- Available size: S, M, L & XL

4. Jebon (Breathing Circuit)



Features:

- Durable and safe high-quality medical-grade components
- Secure leak-proof connection
- Transparent tubing for clear visibility and monitoring
- Water collectors ensure optimal flow without any obstruction
- Size: Child & Adult

ANESTHESIA

1. JMI Sononed (Atraumatic Needle)



Features:

- Atraumatic 30° or 45° bevel
- Non-toxic, non-pyrogenic
- Sterilized by EO gas
- Available Size : 23G X 60mm & 21G X 100mm

2. JMI Endotracheal Tube



Features:

- Beveled Tip ensures easy passage through vocal cords with better visibility
- Murphy Eye prevents blockage during gas flow.
- PVC tubes contain a radio-opaque line, which makes them visible on chest radiographs
- Latex-free, non-toxic, pyrogen-free and ethylene oxide gas (EO) sterilized
- Available size (mm) : 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0 ,6.5, 7,7.5, 8.0 & 8.5

3. JAC (Anesthesia Circuit)



Features:

- Durable and safe high-quality medical-grade components
- Secure leak-proof connection
- Transparent tubing for clear visibility and monitoring
- Minimizes adverse effects and enhances patient comfort
- Breathing bag available
- Available size : Adult & Child

4. JCFlow (Breathing Mask)



Features:

- Durable and safe high-quality medical-grade components
- Soft and well-sealing design for optimal fit
- Transparent materials for easy visibility and monitoring
- Standardized joints for compatibility with various systems
- Sterilization: EO
- Available Size: 00, 01, 02, 03, 04, 05 & 06

ORTHOPEDIC


1. JMI Synthetic Casting Padding (Soft Roll)



Features:

- Synthetic casting padding provides protection and patient comfort
- Strong and durable padding is easy to tear
- Conforms easily to bond contours
- Porous to allow the skin to breathe
- Can be used with all casting materials, plaster & synthetic
- Available size: 4in X 2.7m & 6in X 2.7m

2. JMI Crepe Bandage



Features:

- Unparallel elasticity
- Reusable
- Skin colour
- Washable
- Air permeable
- Available size: 4in X 4m & 6in X 4m

3. JMI Plaster of Paris (POP) Bandage



Features:

- Moisture resistant packaging
- Less powder loss
- Minimum plaster setting time
- High set/dry plaster retention
- User friendly
- Available size: 4in X 2.7m & 6in X 2.7m

UROLOGY & RENAL

1. Jeflex (Foley Balloon Catheter)



Features:

- Latex & Silicone version available
- Round and smooth tip of the catheter reduces trauma during insertion
- Perfect drainage eye provides maximum drainage
- Colour-coded balloon port for identification of catheter size
- Needle-free injection valve
- Available types: Latex/Silicone, 2-way/3-way

2. JMI Male External Catheter



Features:

- Made of high-quality latex; commonly known as a latex male external (condom) catheter
- Non-invasive drainage for patients with paralysis or urosepsis
- Easy roll-on application over the penis
- Distal end connects to drainage tubing
- Adhesive strap ensures secure, non-constrictive fit
- Available size: Small, Medium, Large, and XL

3. J Pbag (Urine Drainage Bag)



Features:

- Sterile & Non-sterile version available
- Leak-Proof, Non-Sticky Design
- Non-Return Valve Prevents backflow of urine
- Easy discharge of urine
- Convenient Graduation marks

4. Jemocath (Hemodialysis Catheter Set)



Features:

- Durable and safe high-quality medical-grade components
- Multiple lumens ensure optimum flow rate for seamless dialysis treatment
- Radiopaque catheter has a smooth inner and outer surface
- Even & soft tip reduces vessel trauma
- Silicone-made extension tube and rotatable suture wing enhance user convenience
- Available Spec: Single, Double & Triple Lumens Jugular/Femoral Version

TRANSFUSION & INFUSION

1. JMI Buret Set



Features:

- Clear, soft, cylindrical and calibrated measured volume chamber with graduation mark
- Silicone Injection port of buret chamber facilitates to inject medication into the mixture/chamber
- Flow regulator for accurate dispensing of solution and precise flow control
- Air vented spike with 15 µm filter
- 100 µm fluid filter & 100 mL chamber
- Approximately 60 drops/ml
- Transparent, Soft and kink resistant PVC tubing
- Luer lock connector with 23G Needle
- Latex-free, non-toxic, pyrogen-free
- Available type: Isoprene & Y-Injection Port

2. JMI Blood Bag



Features:

- Made with high molecular weight medical grade PVC
- Steam sterilization process is used for sterilization
- Advanced and standardized coiling method to ensure a free flow during collection and separation
- Ensures a better yield of components without damage during blood collection
- Very clear printing over the tubes ensures easy identification of samples
- Stable wall thickness and inner diameter ensures the smooth flow and collection of blood
- Each outlet port is fitted with a hermetically sealed protector to maintain sterility of the internal surface
- Can be opened with single handed operation
- Available type : Single, Double & Triple

DIAGNOSTIC

1. J-VAC (Vacuum Blood Collection Tube)



Features:

- High quality serum separation gel
- Smoky spray into a tube for mixing reagents and collecting blood
- Product specific packaging technology. Aluminium foil pack for PT tube & ESR tube to get maximum shelf life
- Evacuated by pre-determined vacuum for drawing exact volume of blood
- Transparent tube for easy visualization
- Analyzer friendly stopper
- Available type: Serum tube, Gel tube, EDTA tube, PT tube, ESR tube, Heparin Tube, Glucose tube

2. JMI Blood Collection Needle



Features:

- Tri bevel cut hypodermic needle for blood collection needle offers smooth venipuncture
- Flashback chamber of needle ensures confirmation of vein-puncture through easy visualization
- Sterilization (sterile version): EtO
- Available type: Straight & Flashback

3. JMI Butterfly Needle for Blood Collection



Features:

- Standard Tube Length
- Soft and Flexible Butterfly Wings
- Vacuum Tube-Compatible Adapter
- High-Quality Needle Sharpness
- Sterilization (sterile version): EtO
- Available Size: 22G, 23G & 25G

4. JMI Alcohol Prep Pad



Features:

- 70% V/V Isopropyl Alcohol for optimum antibacterial action
- Soft as sponge and absorbent non-woven pad

DIAGNOSTIC


5. Jovex (Examination Gloves)



Features:

- Ambidextrous and straight fingers design for easy donning
- Natural high-quality latex rubber for extra strength and elasticity
- Beaded cuff ensures easy donning and helps to prevent rolling back
- USP grade absorbable corn starch as lubricating agent
- Available type: Latex & Nitrile
- Available size: Small, Medium & Large

6. JMI Disposable Vaginal Speculum



Features:

- High-strength, clear non-toxic plastic
- Single-use helps to reduce the risk of cross-contamination
- Easily adjustment & strong grip with middle screw
- Clear plastic ensure easy visualization of the vaginal canal
- Smooth outside will not pinch or bind tissue for improved patient satisfaction
- Available Size: Small, Medium & Large

7. JMI Specimen Collection Container



Features:

- For single Use
- Transparent container for easy visualization
- Screw cap ensures proper lock
- Leakproof
- Available type: Sputum, Urine & Stool

HOSPITAL SAFETY

1. JMI Face Mask



Features:

- Advanced 4 layer design ensures maximum protection from dust, liquid splash and particulate matters
- Poly-tetra-fluoro-ethylene (PTFE) membrane filter effectively inhibits germs permeability
- Ultrasonic sealing of ear loop offers maximum fixation stability
- Fluid repellent outer layer prevents liquid entering in the mask
- Flexible nose clip for fine adjustment with perfect fit
- Quality ensured by DGDA enlisted global standard testing laboratory

2. JMI Respirator (KN95 Mask)



Features:

- Filtration efficiency ≥95%
- Conforms all specifications legislated by GB 2626-2006 for KN95 Mask
- Quality parameters are assured from both home (SGS, AIRY) and abroad (GTTC which is a CNAS affiliated lab)
- Non-allergic, Non-toxic, Latex free, Glue free
- Soft inner layer offers maximum comfort
- First-ever sterilized KN95 mask in Bangladesh

3. JMI Non-Woven Clip Cap & Beard Cover



Features:

- Made of high-quality CPE
- Non-irritant, comfortable
- Breathable, health, comfortable, non-irritant, economically, Eco-friendly
- Hygienic, Universal fitting, Disposable, Lightweight
- Universal fitting, Hygienic
- Keeps place dust-free

4. JMI Non-Woven Shoe Cover



Features:

- Light-weight
- Disposable
- Durable
- Commendable strength
- Less slippery & safer for user

STERILITY MANAGEMENT

1. JMI Autoclave



Features:

- Uses saturated steam under pressure to provide sterilization
- An anti-corrosion stainless-steel chamber that guarantees the steam sterilizer's longevity
- A touch-screen (HMI) LCD screen is provided
- A built-in printer is included
- Quality assured and approved by BUET and DGDA
- Available Chamber Sizes: 15 Liter, 50 Liter, 75 Liter, 100 Liter, and 300 Liter in both vertical and horizontal orientations

2. JEOSTER EO Gas Cartridge



Features:

- Single-use cartridges containing 100% ethylene oxide
- Deliver the proper amount of EO for each cycle, ensuring effective sterilization
- Free from chlorofluorocarbon or other banned diluents, minimizing environmental impact
- Manufactured in an ISO Certified & DGDA approved Plant, ensuring high quality and safety standards
- Available size: 100g & 170g


3. JMI Sterikit Chemical Indicator Tapes



Features:

- JMI Sterikit Chemical Indicators are designed for Steam, EO, and Plasma sterilization processes and safe solutions for closing all wrapping material

4. JMI Sterikit Heat-Sealing Flat Reel




Features:

- JMI Sterikit Heat-Sealing Flat Reels are constructed from medical grade paper and transparent PET/PP multi-layer co-polymer film
- Two water-based non-toxic process indicators for steam and ethylene oxide sterilization are imprinted on the paper

CRITICAL CARE


1. Javelin (Central Venous Catheter Set)



Features:

- Durable and safe high-quality medical-grade components
- Radiopaque multiple lumen catheter has a smooth inner and outer surface
- Even and Soft Tip reduces the risk of vessel trauma
- Kink-resistant and highly flexible of Nitinol Guidewire, ensuring smooth insertion
- Convenient Packaging Modes
- Available Spec: 24 G single lumen to 8.5 Fr Quad lumen

2. Jeducer (Blood Pressure Transducer Kit)



Features:

- Durable and safe high-quality medical-grade components
- Highly sensitive electronic component ensures accurate data measurement
- Transparent tubing enhances visualization, facilitating the easy identification and removal of air bubbles
- Needle-free blood sampling
- Different types of connectors are available
- Available type: Utah, BD, Edwards, Abbott & Philips

3. Jeplin (Pressure Monitoring Line)



Features:

- Safe high-quality medical-grade raw materials
- Transparent, Flexible and kink-resistant tube
- Lightweight
- Secure and leak-proof connection
- Non-pyrogenic and Latex-free
- Available size: 200 cm & 500 cm

Upcoming Products



Infusion Set for power driven pump




Colostomy Bag



Chest Drainage Catheter




Medical Garbage Bag



Hubber Needle




Antimicrobial Central Venous Catheter



PICC Line




Long Term Hemodialysis Catheter




Sayeba Condom Balloon Tamponade

Production Procedure













J-VAC

Vacuum Blood Collection Tube



Collects Blood with Confidence...

SERUM TUBE **ESR TUBE** **PLASMA TUBE**

EDTA TUBE **PT TUBE** **GLUCOSE TUBE**



JMI Hospital Requisite Manufacturing Ltd.

Financial Calendar

Q1
12 November 2024 Tuesday

Adoption of unaudited first quarter financial statements ended 30 September 2024

Q2
29 January 2025 Wednesday

Adoption of unaudited second quarter financial statements ended 31 December 2024

Q3
28 April 2025 Monday

Adoption of unaudited third quarter financial statements ended 31 March 2025

Annual
26 October 2025 Sunday

Adoption of audited financial statements for the year ended 30 June 2025

Record Date
26 November 2025 Wednesday

The cut-off date used to determine which shareholders are entitled to a corporate dividend.

AGM Notice
28 December 2025 Sunday

Notice of 17th Annual General Meeting

Annual Report
28 December 2025 Sunday

Issuance of Annual Report.

AGM Day
22 January 2026 Thursday

17th Annual General Meeting.

Dividend Payment
19 February 2026 Thursday

Payment of dividend to the shareholders whose name would appear in the register of the Company on Record Date 26.11.2025

Performance at a Glance

For the year 2024-2025

REVENUE

Tk. 1670.95 Million

COST OF GOODS SOLD

Tk. 1152.50 Million

GROSS PROFIT

Tk. 518.44 Million

OPERATING PROFIT

Tk. 382.96 Million

PROFIT BEFORE TAX

Tk. 317.65 Million

NET PROFIT AFTER TAX

Tk. 233.12 Million

EARNING PER SHARE

Tk. 1.86


NAV PER SHARE


Tk. 35.14


NOCFPS


Tk. 2.33


Graphical Presentation




















Current Asset
Millions
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
3,181
3,251
3,240
3,290
2,816
2024-2025
2023-2024
2022-2023
2021-2022
2020-2021
FINANCIAL YEAR


Current Liability
Millions
1,500
1,200
900
600
300
1,033
1,073
1,057
1,002
1,333
2024-2025
2023-2024
2022-2023
2021-2022
2020-2021
FINANCIAL YEAR


NAV
50
40
30
20
10
35.14
33.95
32.12
38.84
31.49
2024-2025
2023-2024
2022-2023
2021-2022
2020-2021
FINANCIAL YEAR


NOCFS
6
5
4
3
2
1
2.33
2.36
3.70
4.26
3.04
2024-2025
2023-2024
2022-2023
2021-2022
2020-2021
FINANCIAL YEAR


EPS
5
4
3
2
1
1.86
2.34
2.41
3.25
2.50
2024-2025
2023-2024
2022-2023
2021-2022
2020-2021
FINANCIAL YEAR

Directors' Report to the Shareholders

Bismillahir Rahmanir Rahim
Distinguished Shareholders,
Assalamu Alaikum Wa Rahmatullah,

On behalf of the Board of Directors of JMI Hospital Requisite Manufacturing Limited, I extend a cordial welcome to you at the 17th Annual General Meeting of the Company. It is my privilege to place before you the Audited Financial Statements for the year ended 30 June 2025, together with the Auditors' Report and this Directors' Report, for your review, consideration, and approval. We express our sincere gratitude to Almighty Allah for His blessings on the Company's performance during the financial year 2024–2025.

In compliance with Section 184 of the Companies Act, 1994 and the Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018, the Board of Directors is pleased to present this Directors' Report, which sets out the financial results and key developments of the Company for the year ended 30 June 2025. The Board has also provided such additional disclosures and explanations as deemed necessary to ensure transparency, accountability, and adherence to sound corporate governance practices.

Board Size

The Board of Directors is the highest governance body of the Company and represents the interests of all shareholders and stakeholders, irrespective of who elected its directors. The Board of the company comprises 06 (Six) Directors, of whom 3 (three) Directors are shareholder Directors, 1 (one) nominee Directors and 2 (two) Independent Directors.

Compliance with the Labor Laws

To maintain labor friendly atmosphere in all aspects, the Company duly comply with the Bangladesh Labor Act, 2006 (As amended 2018) and other laws and regulations applicable to the Company.

Pollution-Free Environment

To safeguard human health and the environment from the risks associated with man-made pollution, JMI Hospital Requisite Manufacturing Limited has taken necessary measures to maintain a pollution-free environment. The Company operates Effluent Treatment Plant (ETP) facilities and strictly adheres to the applicable laws, rules, and guidelines of the Directorate General of Drug Administration and the Department of Environment of the Government of Bangladesh, both within the factory premises and in the surrounding areas.


Financial Reporting and Accountability

The Board of Directors has duly discharged its responsibilities through the timely preparation and publication of the first quarter, half-yearly, third quarter, and annual financial statements for each reporting period of the year under review. The Audit Committee, a sub-committee of the Board, carefully examined these reports to ensure fairness, accuracy, transparency, and completeness before placing them before the Board for approval.

The Company published its Un-audited Financial Statements for the first quarter, half-yearly, and third quarter in compliance with the notification of the Bangladesh Securities and Exchange Commission (BSEC) and the Listing Rules 2015 of the Dhaka Stock Exchange PLC (DSE) and Chittagong Stock Exchange PLC (CSE). These statements were disseminated through the Company's website, national newspapers, and online news portals, and were also submitted in due time to BSEC, DSE, CSE, and other relevant regulatory authorities.

Company's Position in the Share Market

In the year under review, the shareholders had always been confident in JHRML shares. In the year 2024-2025, the company shares were traded in the Dhaka Stock Exchange at a minimum of Tk. 44.10 to a maximum of Tk. 77.50 and the Chittagong Stock Exchange at a minimum of Tk. 43.40 to a maximum of Tk. 75.40 as against the face value of Tk. 10.00.



	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25
Highest Price	75.00	77.50	73.30	64.00	58.70	55.60	53.20	54.20	53.90	53.20	50.80	48.00
Lowest Price	64.00	63.30	64.00	44.10	52.10	51.20	46.70	47.90	48.30	48.60	44.90	45.30
Closing Price	64.00	74.40	64.00	52.10	54.60	51.20	48.10	53.80	49.40	48.70	45.50	46.90

Directors' Code of Conduct

The board of the company has approved a separate Code of Conduct for its Directors in compliance with the requirement of Bangladesh Securities and Exchange Commission (BSEC) Corporate Governance Code issued on 03 June, 2018. This Code of Conduct was duly been uploaded in the Company's official website at the following link: ***https://jhrml-bd.com/index.php/Investors/?menu=Code%20of%20Conduct***

Appointment of Statutory Auditor

The existing statutory auditors of the company, G Kibria & Co., Chartered Accountants, shall retire at the 17th Annual General Meeting. The Board recommends the appointment of G. Kibria & Co., Chartered Accountants, as the statutory auditors of the Company for the year 30 June 2026 at a fee of BDT 350,000/- they will continue up to 18th Annual General Meeting.

Compliance Auditor Appointment

As per Corporate Governance Code issued by Bangladesh Securities and Exchange Commission (BSEC), Artisan, Chartered Accountants, compliance auditors of the company, audited the compliance status of the company for the year 2024-2025 and Artisan, Chartered Accountants, has given their expression of interest to be re-appointed as compliance auditors for the financial year 2025-2026.

The Board of Directors recommended for the appointment of Artisan, Chartered Accountants as the Compliance Auditors of the Company for the financial year 2025-2026.

Independent Scrutinizer Appointment

As per Bangladesh Securities and Exchange Commission's (BSEC's) directive No. BSEC/CMRRCD/2009-193/08 dated 10 March, 2021, the Board of Directors in its 160th meeting held on 26 October 2025 appointed Uttam & Associates, Chartered Secretaries as an Independent Scrutinizer to observe the 17th AGM of the company.

An industry outlook, peer industries and possible future developments.

Bangladesh medical device market size is estimated at around worth BDT 25,000 crore (≈USD 2.0 billion), growing at 15%+ annually. Part of a USD 14 billion healthcare sector, expected to reach USD 23 billion by 2030.There are more than four (4) thousand categories of medical devices including 400 types of high-end devices and surgical items used by caregivers such as syringe, infusion set, catheter, surgical mask, pulse oximeter and glucometer. More than 2,600 medical devices are registered with the DGDA of Govt. of Bangladesh. Almost 90 percent of these required items need to be imported every year. There are 10 manufacturers of medical devices and accessories including JMI Syringes Medical Devices Limited, Nipro JMI Company Ltd., JMI Hospital Requisite Mfg. Ltd., ANC Medical Device BD. Ltd., Getwell Ltd., Opso Saline Ltd., Techno Drugs Ltd., Incepta Hygiene & Hospicare Ltd., Libra Infusions, Bi=beat, DBL, Taiwan Bangla Medical and Promixco. Local manufacturing began in 1995s with operation of Opso Salaine, followed by JMI Syringes and others. All the manufacturers small and large have so far invested approximately BDT 100.00 billion in the last two and half decades.

JMI Group has so far invested around BDT 20.00 billion in the sector including BDT 8.00 billion of foreign investment from Japan and South Korea. The sector could become a crucial one for the country's economy if provided with required support by the Government. Though growing amid various limitations, local players are now exporting items to nearly 40 countries. The export trend is a testimony for the quality of locally manufactured goods. The need for updating the guideline for the sector, developing human resources and curbing uneven completion to strengthen the foothold in the sector.

Average Market Share/Position of the Peer Industries as follows:

Name of the Company	Market Share/Position
JMI Syringes & Medical Devices Ltd	1
Nipro JMI Company Ltd.	2
JMI Hospital Requisite Mfg. Ltd.	3
Incepta Hygiene and Hospicare Ltd.	4
ANC Medical Device BD. Ltd.	5
Gel well Ltd.	6
Opso Saline Ltd.	7
Others	8

Source: Newspaper, online Portal and website

Segment-wise or product-wise performance

The product-wise performance is given below:

SL No.	Product Name	Qty/Unit	UOM	Total Amount
1	IV Cannula (All Type)	52,076,650	Pcs	21,591,100
2	Urine Bag Set	8,651,740	Pcs	41,009,251
3	Catheter (All type)	328,337	Pcs	1,226,435
4	Feeding Tube (All type)	534,882	Pcs	2,353,480
5	Syringes & Other (All Type)	30,095,030	Pcs	76,692,369
6	Suture (All Type)	386,211	Pcs	67,490,101
7	Bulk Needle	304,384,824	Pcs	306,839,345
8	Infusion Set (All Type)	205,263,985	Pcs	505,047,718
9	Hand Gloves	3,878,412	Pcs	31,198,506
10	Renal items (All Type)	182,416	Pcs	34,386,425
11	Non Renal Items (All Type)	1,611,213	Pcs	220,763,029
12	Oxygen Mask, Face Mask	3,718,893	Pcs	20,807,596
13	Other Medical devices(All type)	120,590,499	Pcs	341,550,094
			Grand Total	**1,670,955,448**

Risks and Concerns

The medical device industry operates under several challenges, including power shortages, labor unrest, political instability, and strikes that disrupt production and increase financing costs. Shifts in national or global policies can bring both opportunities and risks. Shortages or price hikes of raw materials in the international market may hinder production and reduce profitability. Currency exchange fluctuations can also impact pricing and margins. In addition, political and economic instability, both in Bangladesh and abroad, may affect overall performance.

The company's management remains vigilant in identifying key business risks and taking timely measures to mitigate them. This includes maintaining stable production plans, securing raw material supply chains, setting appropriate pricing strategies, developing long-term plans, and addressing potential trade barriers to minimize adverse impacts on business operations.

Discussion on Cost of Goods Sold, Gross Profit Margin and Net Profit Margin

Cost of goods Sold:


The year's cost of goods sold was Tk. 1,152.50 million (68.97% of Sales) as compared to last year's cost of goods sold of Tk. 1,289.90 million (68.97% of Sales).

Gross Profit:

Gross profit earned during the year was Tk. 518.44 million as compared to last year's gross profit of Tk. 580.23 million.

Net Profit/ (Loss):

The company earned net profit during the year, amounting to Tk. 233.12 million as compared to last year's net profit of Tk. 293.10 million.



Subsidiary Company (JMI Specialized Hospital Limited)

The Company's representation on the Board of its subsidiary, JMI Specialized Hospital Limited, has been ensured in full compliance with the Corporate Governance Code. An Independent Director of JMI Hospital Requisite Manufacturing Limited has been nominated to serve on the Board of the subsidiary. The Minutes of the Board Meetings of the subsidiary are regularly placed before the Board of JMI Hospital Requisite Manufacturing Limited, duly reviewed, and formally recorded. The Board of Directors of the holding company also reviews the subsidiary's periodic as well as annual financial statements.

Extra-Ordinary Activities and their implication (gain or loss)

Extraordinary gains or losses refer to infrequent and unusual gain or loss and which is not part of the company's ordinary/day-to-day operations. No events of extra ordinary gain or loss occurred during the reporting period requiring adjustment or disclosure in the financial statements.

About the Related Party Transactions

The business related Party Transaction of the Company is being made based on the business principle and as per International Accounting Standard IAS-24. During the year under review, the standard, nature and the manner of related party transactions in the ordinary course of business carried out arm's length basis at commercial rates with related parties were reflected transparently in the financial statements, which is given in note no. 29.00 of the Financial Statements.

Credit Rating Report

Alpha Credit Rating Limited has assigned the credit rating to JMI Hospital Requisite Manufacturing Limited on the basis of financial and other relevant quantitative and qualitative information on 30 December 2024. The reaffirmed ratings are below:

Date of Declaration	Valid Till	Rating Action	Long Term Rating	Short Term Rating	Outlook
30 December 2024	25 December 2025	8th Surveillance	A+	ST-2	Stable

Significant Deviations from Last Year's Operating Results

No material deviations were observed between the quarterly financial performance and the annual financial statements.

Remuneration paid to the Directors including Independent Director

The Directors of the company did not take remuneration or any other benefit, which are mentioned in Notes 42 b and b (i) of the Financial Statements 30 June 2025.

Fairness of Financial Statements

The financial statements together with the notes thereon have been drawn up in conformity with the Companies Act 1994, Securities and Exchange Rules 1987. These statements present fairly the Company's state of affairs, the results of its operations, cash flows and changes in equity.

In Compliance with the requirement of the Bangladesh Securities and Exchange Commission (BSEC) notification dated June 3, 2018, the Chief Executive Officer and Chief Financial Officer have given the declaration about the fairness of the financial statement.

Proper Books of account

JMI Hospital Requisite Manufacturing Limited maintained proper books of account.

Accounting policies

Appropriate accounting policies were consistently applied in the preparation of the financial statements and the accounting estimates were based on reasonable and practical judgment.

Application of IAS and IFRS

The Board of Directors of the Company is entrusted to ensure the disclosure of the actual financial position and preparation and maintenance of all types of Statutory Statements as per the Bangladesh Securities and Exchange Commission (BSEC), the Companies Act-1994 and the Bangladesh Financial Reporting Act (FRA)-2015. The Board of Director's is absolutely responsible for preparing all types of financial reports in line with International Accounting Standards (IAS), International Financial Reporting Standards (IFRS) and other applicable rules and regulations.

Statement of Utilization of Proceeds raise through Public Issues

The company accorded the consent from Bangladesh Securities and Exchange Commission (BSEC) on 25 November 2021 for raising its capital through Initial Public Offering (IPO). The status of IPO proceeds as on 30 September 2025 are given below:

S.L	Purpose mentioned in the Prospectus	Time Line as per Prospectus	Revised Timeline as per 14th AGM 2023	Revised Timeline as per 15th AGM 2024	Cost Breakdown	Amount as per Prospectus	Amount (Revised as on 14th AGM 2023)	Amount (Revised as on 15th AGM 2024)	Total unutilized amount as on 30.09.2025
1	**Land & Land Development**	Within 03 months of receiving the IPO proceeds	Already purchased 34 decimal land	Within 31 March 2026	50 Decimal of Land Adjacent to the Project	78,700,000	42,500,000	42,500,000	-
2	**Building & Civil Construction**	Within 12 months of receiving the IPO proceeds	Within 2 Years i.e. 31 March 2024	Within 31 March 2026	Building Total Floor Space 24,000 sqf.	60,000,000	5,900,000	5,900,000	-
3	**Plant & Machineries for BMRE of the Project**	Within 12 months of receiving the IPO proceeds	Within 2 Years i.e. 31 March 2024	Within 31 March 2026	**(A)** Vacuum Blood Collection Tube, Mold for Vacuum Blood Collection Tube, Needle Grinding Machine, Injection Molding Machine, PET Blood Test Tube Mold With Hot Runner System & Controller, Auxiliary, Cap Mold With Hot runner System & Controller, Civil Modification, Epoxy, Duty & Others.	171,900,000	239,500,000	271,261,651	-
					(B) Machinery for Vacuum Blood Collection Line, 15RT Water Colling Chiller, Three in One Dehumidifying Dryer, Mold Dehumidifier, Auto Master Batch Doser, Meterila Reciver With Window Stand, Spring hose, High Frequency Plastic Welding Machine 3 Nos, Extuder Machine, Prefabricated Building Materials for Pharmaceuticals Industry, HVAC System for Pharmaceuticals Industry.	47,300,000	59,500,000	59,500,000	-
				-	**(C)** Cannula Grinding Machine Line.	44,700,000	59,300,000	27,538,349	-
	Sub Total					**263,900,000**	**358,300,000**	**358,300,000**	**-**
4	**Common Facilities (Utilities & Others)**	Within 12 months of receiving the IPO proceeds	Within 2 Years i.e. 31 March 2024	Within 31 March 2026		56,100,000	55,000,000	55,000,000	25,309
5	**Loan Repayment**	Within 03 months of receiving the IPO proceeds	Already Paid	-		250,000,000	250,000,000	250,000,000	-
6	**IPO Expenses**	As when required	Within 2 Years i.e. 31 March 2024	Within 31 March 2026		41,300,000	33,300,000	33,300,000	1,703,132
7	**Insurance, Duty and Inland Carriage Inward**		Within 2 Years i.e. 31 March 2024	Within 31 March 2026		-	5,000,000	5,000,000	-
	Total					**750,000,000**	**750,000,000**	**750,000,000**	**1,728,441**

System of Internal Control

The company maintains a sound internal control system, which gives reasonable assurance against any material misstatement. The internal audit, risk management, legal and compliance departments regularly monitor the internal control system.

Minority Shareholders Interest

In compliance with Condition No. 1(5) (xvi) of the Corporate Governance Code 2018 of BSEC, the Board hereby confirms that the interests of the minority shareholders have been duly protected in the Company.

Statement of going concerned

There are no significant doubts about the Company's ability to continue as a going concern. The Board of Directors has reviewed the Company's business plan and is satisfied that the Company has adequate resources to continue its operations in the future. Accordingly, the financial statements are prepared based on the going concern concept.

Five year's Financial Highlights

The key operating and financial data for the five years is given in Annexure II of the Directors' Report of this Annual Report.

Dividend

In view of the performance of the Company and considering the current liquidity position, the Board of Directors has recommended 5% Cash dividend to the general shareholders other than sponsors and directors for the year ended 30 June 2025 subject to approval by the shareholders in the 17th Annual General Meeting. The Board of Directors states that no stock dividend and interim dividend was considered during the year.

Bonus share or Stock Dividend:

During the period from July 2024 to June 2025 the company did not declared Bonus shares or stock dividend.

Unclaimed/ Unpaid Dividend

Unclaimed/ Unpaid Dividends are maintained according to the directives of the Bangladesh Securities and Exchange Commission and other regulatory authorities from time to time. Details of the Unclaimed/ Unpaid Dividends are shown in Notes no. 20.01 and 20.02 of the Financial Statements for the year 30 June 2025.

Board Meetings and Attendance during the year

During the period from 01.07.2024 to 30.06.2025, there were 09 (nine) Board Meetings were held. The attendance status of all the meetings is as follows:

Sl.	Name of Directors	Position	Meeting held	Attended
1	Md. Abdur Razzaq	Chairman	09	09
2	Mrs. Suriya Akther Rina	Managing Director	09	09
3	Hoi Kwan Kim	Director	09	07
4	Md. Mohiuddin Ahamed	Nominee director	09	06
5	Mr. Ranjit Chakraborty	Nominee director	09	03
6	Abdul Wahab Khan	Independent Director	09	08
7	Mrs. Jahanara Pervin	Independent Director	09	05
8	Md. Aminul Bar Chowdhury	Independent Director	09	05

Note: Mr. Md. Mohiuddin Ahamed, Nominee Director, was withdrawn from JMI Vaccine Limited on 25.03.2025. In his place, Mr. Ranjit Chakraborty has been appointed as the new Nominee Director.

The Pattern of Shareholding

The pattern of Shareholding is given in Annexure-III of the Directors' Report of this Annual Report.

Appointment or re-appointment of Director

During the upcoming 17th AGM, the following directors will retire from the office by rotation, but being eligible, they offer themselves for re-election. The retirement and re-appointment of the directors will be brought to shareholder's attention at this 17th AGM:

Sl.	Name of Shareholders	Position	Date of Appointment/Retire	Remarks
1	Mr. Md. Abdur Razzaq	Chairman	22nd January 2026	Retire and re-elected as Director
2	Mr. Hoi Kwan Kim	Director	22nd January 2026	Retire and re-elected as Director

The brief resume along with the required information of the directors is given under Annexure-I of the Directors' Profile in this Annual Report.

Appointment or Re-Appointment of Independent Director

During the period from July 2024 to June 2025, no Independent Director was appointed or re-appointed. Mr. Md. Aminul Bar Chowdhury, Independent Director of the Company, resigned on 17 August 2025.

Management's Discussion and Analysis

Detailed discussion on the operating and financial performance of the company, along with other disclosures as required under the Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) through Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated June 3, 2018, has been separately reported by the Managing Director in this Annual Report.

Declaration or Certification by the CEO and Chief Financial Officer

Declaration or Certification by the CEO and Chief Financial Officer to the Board of Director's as required by Annexure-A of the notification of BSEC, is disclosed in the Annual Report.

The report of compliance on the Corporate Governance Code

The report of compliance on the Corporate Governance Code, audited by Compliance Auditor has been incorporated as per preformats prescribed in Annexure-B and Annexure-C of the notification of BSEC has been disclosed in the Annual Report.

Recognition and Compliments

The Board of Directors extends its sincere appreciation to all employees, buyers, consumers, suppliers, patrons, well-wishers, and all others associated with the Company for their valuable contributions to its success. The board also expresses its gratitude to BSEC, DSE, CSE, CDBL, and, above all, to the esteemed shareholders for their continued trust and support.

On behalf of the Board of Directors,



Md. Abdur Razzaq
Chairman

Director's Profile

Annexure - I



Mr. Md. Abdur Razzaq
Chairman

Mr. Md. Abdur Razzaq was born in 1963 in Noakhali, Bangladesh. He completed both his graduation and post-graduation in Economics from the University of Chittagong. He is the founder of JMI Group, which today consists of 41 companies operating across diverse industries under Public Limited, Private Limited, and proprietorship structures. Mr. Razzaq currently serves as Chairman, or Managing Director, or Director of several concerns of the Group, including:
JMI Syringes & Medical Devices Ltd., JMI Hospital Requisite Manufacturing Ltd., JMI Industrial Gas Ltd., JMI Builders & Construction Ltd., JMI Printing & Packaging Ltd., JMI Export-Import Co. Ltd., JMI Safe Transportation Ltd., JMI CNG Dispensing Co. Ltd., JMI Hollow Block Co. Ltd., JMI Vaccine Ltd., Nipro JMI Pharma Ltd., Nipro JMI Medical Ltd., Nipro JMI Dialysis Centre Ltd., Nipro JMI Company Ltd., JMI Cylinders Ltd., JMI LPG & Petroleum Ltd., JMI Sankur Auto Tank Ltd., JMI Sankur Valve & Bung Ltd., JMI Industrial Research & Toxicology Ltd., Advance Travel Planner Ltd., JMI Engineering Ltd., JMI Sonlu Appliance Ltd., Sunrise Research & Consultancy Ltd., Cardiff International Ltd., Bangladesh Clinical Trials Ltd., 3i Securities Ltd., S.L. Karnafully LP Gas Ltd., Padma LPG Ltd.,Window Media Ltd., Takumi Ltd. and JMI Specialized Hospital Ltd.
He introduced exclusive, high-tech medical devices in Bangladesh for the first time, including Auto Disable (AD) Syringes, Blood Tubing Sets, Blood Transfusion Sets, and IV Cannulas. His business experience spans a wide range of sectors such as medical and surgical devices, medical equipment, pharmaceuticals, hospital, dialysis centers, industrial gases, LPG, gas cylinders, and CNG stations and conversion centers.
Mr. Razzaq is recognized as one of the country's most successful business entrepreneurs. For his contribution to national industry and healthcare, he received the prestigious CIP (Commercially Important Person) award three times, in 2015, 2017, and 2021.

Mrs. Suriya Akther Rina was born in 1971 in Noakhali, Bangladesh, and completed her graduation and post-graduation at the University of Chittagong. She is the founder of JMI Hospital Requisite Manufacturing Ltd. and has built more than two decades of experience across medical devices, pharmaceuticals, LPG, CNG, cylinders, and international trade.
Over the past 24 years, she has played a central role in expanding the JMI footprint in healthcare and related industries. Alongside her leadership as Managing Director of JMI Hospital Requisite Manufacturing Ltd., she also chairs JMI Specialized Hospital Ltd. and serves as Director in a number of other concerns, including JMI Builders & Construction, JMI Vaccine, JMI Printing & Packaging, JMI Safe Transportation, Nipro JMI Dialysis Centre, JMI Export & Import, JMI LPG & Petroleum, JMI Engineering, JMI Cylinders, JMI CNG Dispensing, JMI Hollow Block, JMI Sankur Auto Tank, JMI Valve & Bung, Bangladesh Clinical Trials, and Cardiff International Ltd.
Her career reflects a consistent focus on advancing healthcare solutions while driving business growth in multiple sectors.



Mrs. Suriya Akther Rina
Managing Director



Mr. Hoi Kwan Kim
Director

Mr. Hoi Kwan Kim was born in 1947 in South Korea. He is one of the founders of JMI Hospital Requisite Manufacturing Ltd. and has over 39 years of experience in the global syringes and medical devices industry.

Mr. Kim completed his MBA and has established a strong presence in the healthcare and manufacturing sectors, not only in Bangladesh but also through business ventures in Korea, China, Vietnam, Singapore, Taiwan, and several other countries.

He currently serves as Director of JMI Hospital Requisite Manufacturing Ltd., JMI Vaccine Ltd., JMI CNG Dispensing Ltd. JMI Safe Transportation Ltd., Nipro JMI Company Ltd., JMI Hollow Block Co. Ltd., and JMI Printing & Packaging Ltd.

Mr. Ranjit Chakraborty, FCMA was born in 1971 in Cumilla, Bangladesh. He is a seasoned finance professional with more than 22 years of experience in Finance and Accounts. He holds an M.Com in Accounting and is a Fellow Member of the Institute of Cost and Management Accountants of Bangladesh (ICMAB). He is also a member of the Tax Bar Council.
Over the course of his career, Mr. Chakraborty has gained extensive expertise through training programs, seminars, and workshops, both at home and abroad. He began his professional journey with Harvest Rich Group in 2003 and later served in leadership roles at well-known organizations including Al-Amin Group, Abdul Monem Group, and Ananda Group.
His career at JMI Group marked a significant chapter, where he rose through the ranks to become Executive Director.



Mr. Ranjit Chakraborty FCMA
Nominee Director of
JMI Vaccine Limited



Mr. Abdul Wahab Khan
Independent Director

Mr. Abdul Wahab Khan was born in 1961. He completed his LL.M. from the University of Dhaka in 1986 and began his career in law as an Advocate at the Judge Court.

In 1988, he joined the Bangladesh Civil Service (Administration) as Assistant Commissioner and Magistrate at the Dinajpur Collectorate. He later served as NDC at the Patuakhali DC Office and as Thana Magistrate in Barguna. In 1999, he was posted as Thana Nirbahi Officer (TNO) at Betagi, Barguna, and subsequently served as TNO/UNO in Khulna until 2004.

In May 2004, Mr. Khan was transferred to Cumilla as Additional Deputy Commissioner (ADC) and Additional District Magistrate (ADM, Revenue). He was promoted to Deputy Secretary in February 2006 and posted to the Ministry of Cultural Affairs in 2007. In 2010, he was transferred to the Ministry of Land, where he continued his service as Deputy Secretary. Four years later, in 2014, he joined the National Board of Revenue (NBR) as a Law Officer.

In 2016, he was transferred to the Ministry of Health & Family Welfare as Deputy Secretary. His career reached another milestone in 2018 when he was promoted to Joint Secretary. After more than three decades of dedicated public service across multiple key ministries and field administrations, Mr. Abdul Wahab Khan retired on 30 March 2021. He joined JMI Hospital Requisite Manufacturing Limited as Independent Director on 22 January 2024.

Mrs. Jahanara Pervin was born in 1962. After completing her bachelor's degree, she began her career in public service as Assistant Commissioner & Magistrate in 1987. Over the next three decades, she held a wide range of administrative and leadership roles, gaining extensive experience in governance, policy implementation, and public administration.

Her early postings included Upazila Magistrate of Sadar Upazila, Mymensingh (1990), Assistant Commissioner & Cognizance Magistrate (1994), and Metropolitan Magistrate at the Chief Metropolitan Magistrate Court in Dhaka (1994–1999). She then served as Upazila Nirbahi Officer (UNO) in Comilla Sadar Upazila (1999–2000) and Deputy Director at the Directorate of Non-Formal Education, Ministry of Primary and Mass Education (2000–2003).

Mrs. Pervin continued to advance through senior government positions, serving as Senior Assistant Secretary at the Ministry of Jute (2003–2005), Director and Deputy Director at the Anti-Corruption Commission (2005–2010), Deputy Secretary at the Ministry of Agriculture (2010–2012), Joint Secretary (2012–2014), and Additional Secretary (2014) in the same ministry. She further held executive-level roles as Executive Director of Jatio Mahila Sangstha (2014–2019) and Director General of the Department of Public Libraries (2019), before her final posting as Additional Secretary at the Ministry of Information and Broadcasting.

On 9 April 2021, Mrs. Pervin retired from government service after more than 30 years of distinguished contributions. She joined JMI Hospital Requisite Manufacturing Limited as an Independent Director on 22 January 2024, bringing her wealth of administrative experience and governance expertise to the Board.



Mrs. Jahanara Pervin
Independent Director

Profile of CFO, Company Secretary, and Head of Internal Audit & Compliance



Subas Chandra Banik
Chief Financial Officer

Mr. Subas Chandra Banik was born in 1980 in Munshiganj, Bangladesh. He holds an Hon's, M.Com in Accounting from Jagannath University and an LL.B from a reputed institution, and he is partially qualified as a Chartered Accountant (CA).

He began his career with Bashundhara Group as Assistant Manager – Accounts & Finance and later joined JMI Group as Manager – Accounts & Finance. He currently serves as Chief Financial Officer at JMI Hospital Requisite Manufacturing Limited & JMI Specialized Hospital Ltd a concern of JMI Group. He attended many training programs, workshops & Factory tests. He Visited China, India, Nepal, Malaysia, Dubai, Thailand, Maldives, Sri Lanka on Official assignments.

Since 2013, Mr. Banik has been an active member of the Dhaka Taxes Bar and has gained extensive practical expertise through trainings and seminars organized by NBR, BSEC, FBCCI, and other professional bodies. A seasoned finance professional and trainer in income tax, VAT management, and company affairs, his experience spans corporate finance, auditing, taxation, company law, capital market operations, customs, and regulatory compliance.



Md. Safiqur Rahaman, FCS
Company Secretary

Mr. Md. Safiqur Rahaman, FCS, is the Company Secretary of JMI Hospital Requisite Manufacturing Limited. He holds an M.Com and an LL.B from reputed universities and is a Fellow Chartered Secretary of the Institute of Chartered Secretaries of Bangladesh (ICSB). He is also a registered Income Tax Practitioner under the National Board of Revenue (NBR).

With over 25 years of experience, he has worked across the medical device industry, capital markets, banking, insurance, non-banking financial institutions, hospitals, and corporate affairs. His core expertise includes corporate governance, regulatory compliance, reporting, internal control systems, and board and stakeholder management.

In his current role, he supports the Board of Directors through timely disclosures, statutory compliance, and governance-driven processes that enhance transparency and accountability within the organization.

He has participated in various professional training programs and seminars organized by BSEC, DSE, CSE, NBR, IFC, BASM, and other CPD platforms, strengthening his knowledge in securities laws, corporate regulations, taxation, and governance best practices.



Md. Rakibul Haque Pradhan
Head of Internal Audit & Compliance

Mr. Md. Rakibul Haque Pradhan currently serves as the Head of Internal Audit at JMI Hospital Requisite Manufacturing Limited (JHRML). He is a CA (Partly Qualified) professional from the Institute of Chartered Accountants of Bangladesh (ICAB) with over 12 years of extensive experience in Internal Audit, Corporate Affairs, Audit Planning and Documentation, Internal Process Development, Investigation Procedures, and Strategic Business Planning & Execution.

Throughout his career, Mr. Pradhan has demonstrated strong analytical insight and a consistent ability to exceed organizational goals, achieve corporate objectives, and enhance stakeholder value in competitive business environments. He has played a key role in establishing and implementing effective internal control frameworks and risk management systems that reinforce corporate governance and regulatory compliance.

His professional expertise spans Compliance, Corporate Governance, Supply Chain Management, Accounts & Finance, VAT & Taxation, Financial Evaluation, Data Analysis, Strategic Decision-Making, and overall Business Operations Management. Under his leadership, the internal audit function at JHRML has seen notable improvements in operational efficiency, process integrity, and sustainable business growth.

5 Years Operational Result

Annexure - II

Particulars	Amount in BDT				
	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Sales Revenue	1,670,955,448	1,870,145,496	1,852,076,202	1,801,801,801	1,730,870,760
Cost of Sales	1,152,507,718	1,289,909,629	1,271,248,302	1,236,056,527	1,110,094,614
Operating Expenses	135,478,198	136,856,477	129,511,772	119,481,218	110,061,038
Financial Expenses	55,302,210	70,749,919	73,344,906	99,275,913	112,654,174
Gross profit	518,447,730	580,235,867	580,827,900	565,745,274	620,776,146
Operating Profit	382,969,532	443,379,390	451,316,128	446,264,056	510,715,108
Net Profit before tax	317,653,620	366,677,878	376,991,132	340,609,032	382,615,660
Net Profit after tax	233,127,043	293,108,261	302,286,195	325,019,973	225,004,371
Other comprehensive income	78,182	(168,975)	66,960	(71,676)	109,750
Shareholders' Equity	4,568,953,959	4,324,108,104	4,023,927,839	3,881,941,282	2,834,506,478
Total asset	5,913,543,679	5,683,413,120	5,464,917,493	5,320,846,042	4,850,205,480
Total liability	1,344,589,720	1,359,305,016	1,440,989,654	1,438,904,760	2,015,699,002
Current asset	3,413,473,527	3,433,058,592	3,240,474,905	3,289,840,792	2,815,685,237
Current liability	1,055,057,689	1,083,814,890	1,056,810,399	1,002,161,599	1,332,636,945
Non-Current asset	2,500,070,152	2,250,354,528	2,224,442,588	2,031,005,250	2,034,520,244
Non-Current liability	289,532,031	275,490,126	384,179,255	436,743,161	683,062,057
Gross profit margin %	31.03	31.03	31.36	31.40	35.86
Net profit margin %	13.95	15.67	16.32	18.04	12.99
Authorized Capital	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000
Paid-up Capital	1,252,941,200	1,252,941,200	1,252,941,200	1,252,941,200	900,000,000
Number of Share Outstanding	125,294,120	125,294,120	125,294,120	125,294,120	90,000,000
NAV	35.14	33.95	32.12	38.84	31.49
EPS	1.86	2.34	2.41	3.25	2.50
NOCFPS	2.33	2.36	3.70	4.26	3.04


Pattern of Shareholdings

Shareholding position as on 30 June 2025


Annexure - III



Sponsors & Directors



Institution



General Public

Sl.	Category	No. of Ordinary Shares	% of Holding
A	Sponsors and Directors	40,464,500	32.30%
B	Institution	54,898,650	43.82%
C	General Public	29,930,970	23.89%
	Total	**125,294,120**	**100.00%**

Sponsors & Directors:

Sl.	Name of Shareholders	Position	No. of Ordinary Shares Holding	Percentage of Holding
1	Md. Abdur Razzaq	Chairman	28,648,900	22.87%
2	Mrs. Suriya Akther Rina	Managing Director	2,600,030	2.08%
3	Hoi Kwan Kim	Director	4,626,080	3.69%
4	JMI Vaccine Ltd.	Director	4,464,490	3.56%
5	Mrs. Jae So Shim	Sponsor Shareholder	125,000	0.10%
6	Abdul Wahab Khan	Independent Director	-	0.00%
7.	Mrs.Jahanara Pervin	Independent Director	-	0.00%
8.	Md. Aminul Bar Chowdhury	Independent Director	-	0.00%
	Sub-Total (A):		**40,464,500**	**32.30%**

Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details)

Sl.	Name of Shareholders	Position	No. of Ordinary Shares Holding	Percentage of Holding
1	Md. Abdur Razzaq	Chairman	28,648,900	22.87%
2	Investment Corporation of Bangladesh (ICB)	Shareholder	22,500,000	17.96%

Surgical Suture

Stitch with Confidence





J-CRYL

Braided Coated Polyglactin 910

Synthetic Absorbable Surgical Suture

Size: USP 1 to USP 6/0, Metric: 4 to 0.7





J-LENE

Monofilament Polypropylene Blue

Synthetic Non-Absorbable Surgical Suture

Size: USP 1 to USP 6/0, Metric: 4 to 0.7





J-GUT

Catgut-Chromic

Natural Absorbable Surgical Suture

Size: USP 2 to USP 4/0, Metric: 6 to 1.5





J-SILK

Braided Silk Black

Natural Non-Absorbable Surgical Suture

Size: USP 1 to USP 4/0, Metric: 4 to 1.5





J-GUT

Catgut-Plain

Natural Absorbable Surgical Suture

Size: USP 3/0 to USP 5/0, Metric: 3 to 1.5



JMI Surgical Gloves

(Powdered & Powder Free)





Report of the
Audit Committee

For the year ended on 30th June 2025



Dear Shareholders

I am pleased to present the Report of the Audit Committee for the year ended on 30 June 2025. The Audit Committee Report presented under Condition No. 5 of the Bangladesh Securities and Exchange Commission (BSEC) Notification: **BSEC/ CMRRCD/ 2006-158/ 207/ Admin/ 80, dated 3 June, 2018.**

Meeting Attendance

The Audit Committee of JMI Hospital Requisite Manufacturing Limited was constituted by the Board of Directors as a sub-committee of the Board, in accordance with the terms of reference approved by the Board and as per the relevant notification of BSEC. The attendance of each member at the Audit Committee meetings held during the period from 1 July 2024 to 30 June 2025 is presented below:

Sl.	Members	Status with the Company	Status with the Committee	Meeting Attended	Remarks
1	Mr. Md. Aminul Bar Chowdhury	Independent Director	Chairman	4/4	
2	Mr. Md. Mohiuddin Ahamed	Nominee Director	Member	3/4	Retired on 25.03.2025
3	Mr. Hoi Kwan Kim	Director	Member	4/4	
4	Mr. Ranjit Chakraborty, FCMA	Nominee Director	Member	1/4	Appointed on 25.03.2025
5	Mr. Md. Safiqur Rahman, FCS	Company Secretary	Secretary	4/4	

Role of the Audit Committee

The Audit Committee is responsible for monitoring the integrity of the Company's financial statements and reviewing them as appropriate. It provides recommendations to the Board on matters relating to business risk, internal controls, compliance, and audit. The Committee ensures, through appropriate measures and information, that effective internal control systems are in place to identify and mitigate business risks, and that the Company operates in a proper and financially sound manner. The Audit Committee functions with consistency and in full compliance with the Corporate Governance Code issued by the Bangladesh Securities and Exchange Commission (BSEC).

Financial Reporting

The Audit Committee reviews the Company's quarterly and annual financial statements with particular focus on:

- Significant changes in accounting policies and practices
- Major adjustments arising from audits
- Compliance with applicable financial reporting standards, laws, and regulatory requirements

Internal Audit

The Audit Committee reviewed the Company's overall approach to risk management, internal control processes, outcomes, and related disclosures. It also examined the key activities undertaken by the Internal Control and Compliance Department during the period 2024–2025, which are summarized as follows:

- Reviewed and approved the internal audit plan of the company.
- Reviewed the report of the internal auditor.
- Reviewed the effectiveness of the internal control system of the company.
- Reviewed the report of the external auditor.
- Reviewed the quarterly, half-yearly and annual financial statements.
- Recommendation appointment and remuneration of the statutory auditor.

External Audit

The Audit Committee conducted a formal evaluation of the effectiveness of the external audit process. In this regard, the Committee reviewed the auditors' tenure, quality of service, and fees, and provided recommendations to the Board on the appointment and remuneration of the external auditors. G. Kibria & Company, Chartered Accountants, have been proposed for appointment for the year 2025–2026, subject to approval by the shareholders at the 17th Annual General Meeting.

Reporting to the authorities

The Audit Committee reports to the Board on issues that may have a material impact on the financial conditions and operations. The committee also discusses with the Board and the management if any rectification is necessary. If the committee finds that such rectification has been unreasonably ignored, it reports such findings to the BSEC upon reporting such matters to the Board three times or upon completion of a period of 6 months from the date of first reporting to the Board, whichever is earlier.

Conclusion

The Audit Committee noted no material deviations, non-compliance, or adverse audit findings requiring the attention of the Board or shareholders during the year under review. The Committee expresses its sincere appreciation to the members of the Board, Management, and Auditors for their continued support throughout the year.



Md. Aminul Bar Chowdhury
Chairman, Audit Committee

Report of the Nomination & Remuneration Committee

For The Year Ended On 30th June 2025

The Nomination & Remuneration Committee of JMI Hospital Requisite Manufacturing Limited being one of its Board Sub-committee assists the Board broadly in the formulation of policy with regard to determining qualifications, positive attributes, experiences and remuneration of the directors, top level executive of the company.

Meeting Attendance

The details of attendance of each member at the NRC meetings during the year 1st July 2024 to 30th June 2025 are given below:

Sl.	Members Name	Status with the Company	Status with the Committee	Meeting Attended	Remarks
1	Mr. Abdul Wahab Khan	Independent Director	Chairman	2/2	
2	Mr. Ranjit Chakraborty	Nominee Director	Member	1/2	Appointed on 25.03.2025
3	Mr. Md. Mohiuddin Ahamed	Nominee Director	Member	1/2	Retired on 25.03.2025
4	Mr. Hoi Kwan Kim	Director	Member	2/2	
5	Mr. Md. Safiqur Rahman	Company Secretary	Secretary	2/2	

The activities of the NRC during the year are as follows:

In the year 1st July 2024 to 30th June 2025 the Committee met twice. During the year under review, the Committee carried out the following activities:

i. Reviewed and ratified the uniform Code of Conduct for the Company, which is also applicable to members of the Board and Key Management Personnel and top-level executives as adopted by the Board.
ii. Reviewed the core human resources principles and philosophies of the Company including recruitment, and performance evaluation.
iii. Reviewed Employee Benefits policies to attract job seekers and retain internal talents.
iv. Overview of the Nomination and Remuneration policies.

Major Responsibilities of NRC

The purpose, authority, composition, duties and responsibilities of the Nomination and Remuneration Committee are delineated in its Charter. Some of the major responsibilities of the NRC are as follows:

1. Considering the terms of reference of NRC, as approved by the Board.
2. Formulated and recommended to the Board a set of corporate governance guidelines applicable to the Company.
3. Formulate the Board Performance Evaluation criteria and the committee shall conduct this evaluation in such manner as it deems appropriate.
4. Formulated the criteria for evaluation of independent directors and the Board and carry out the evaluation of every director's performance.
5. Formulated the policy relating to the remuneration of the Directors, top-level executives and all employees of the Company.
6. Formulated the criteria for evaluation of the performance of Independent Directors and Board Members
7. Identify the criteria for selection, transfer or placement and promotion at different levels of the company
8. Recommend a policy on the Board's diversity, taking into consideration age, gender, experience, education and nationality.

This Nomination and Remuneration Committee Report is made under the guidelines of the Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC).

On behalf of the Nomination and Remuneration Committee.



Abdul Wahab Khan
Chairman
Nomination and Remuneration Committee

Dividend Distribution Policy

1. Introduction

This Policy is called **"JMI Hospital Requisite Manufacturing Limited - Dividend Distribution Policy"** and has been framed by JMI Hospital Requisite Manufacturing Limited pursuant to Bangladesh Securities Exchange Commission's Directive No. BSEC/CMRRCD/2021-386/03 dated January 14, 2021.

The Board of Directors of JMI Hospital Requisite Manufacturing Limited has adopted this Dividend Distribution Policy for Shareholders of the Company for dividend distribution and management of unpaid and unclaimed dividend.

2. Definitions

"Act" shall mean the Companies Act, 1994.

"Applicable Laws" shall mean the Companies Act, 1994 and rules made thereunder, the Securities and Exchange Laws, the Stock Exchanges' Listing Regulations and such other Rules, Regulations, Directive, Circular and Order relating to declaration, entitlement, and distribution of Dividend.

"Company" shall mean JMI Hospital Requisite Manufacturing Ltd.

"Chairman" shall mean the Chairman of the Board of Directors of the Company.

"Board" or **"Board of Directors"** shall mean the Board of Directors of the Company.

"Dividend" means any sum payable or distributed to members/shareholders out of profits or reserves of the Company available for that purpose, for a particular period, against each share the member/shareholder owns.

"MD & CEO" shall mean Managing Director and Chief Executive Officer of the Company.

"Policy or this Policy" shall mean this Dividend Distribution Policy.

3. Objective

The objective of the Policy is to provide guidance to stakeholders on the dividend distribution framework adopted by the Company. The Board of Directors of the Company shall consider this Policy when resolving on dividends, always in compliance with the provisions of the Act, notifications/directives issued by the BSEC, Income Tax Ordinance, and other applicable legal provisions.

The Policy is not an alternative to the decision of the Board for declaring/recommending dividends, which takes into consideration all the relevant circumstances enumerated hereunder or other factors as may be decided by the Board.

4. Scope and Legal Basis

This Policy applies to the payment of interim and final dividends by the Company to its shareholders as per the Companies Act, 1994, the Securities & Exchange Commission and the Stock Exchanges' Listing Regulations and such other Rules, Regulations, Directive, Circular and Order relating to the declaration, entitlement, and distribution of Dividend.

5. Concept of Dividend

The concept of a Dividend is the payment of profit to shareholders, usually in the form of cash and/or stock (bonus). The profits earned by the Company can either be retained in the business or distributed among the shareholders as dividends.

6. Types of Dividend

The Act deals with two types of dividend - Interim and Final.

Interim dividend is the dividend declared by the Board between two AGMs as and when Considered appropriate. The Act authorizes the Board to declare interim dividend during any financial year out of the profits for the financial year in which the dividend is sought to be declared and/or out of the surplus in the profit and loss account.

Final Dividend is recommended for the financial year at the time of approval of the annual financial statements as well as appropriation of profit. The Board shall have the power to recommend final dividend to the shareholders for their approval at the AGM of the Company.

7. Declaration of Dividend

Subject to the provisions of the Act, dividend shall be declared and paid out of:

a. Profits of the Company for the year for which the dividend is to be paid after setting off carried over previous losses and depreciation not provided in the previous year(s).
b. Undistributed profits of the previous financial years after providing for depreciation in accordance with law and remaining undistributed.
c. Out of a & b both.

In the event of inadequacy or absence of profits in any financial year, the Company may declare dividend out of free reserves and/or from dividend equalization fund subject to the compliance with the Act and Rules.

The Board may declare Interim Dividend(s) for any financial year, (July to June), at its discretion, to be paid to the shareholders of the Company. Before declaring Interim Dividend, the Board shall consider the quarterly and/or half yearly financial position of the Company for the payment of such Dividend.

The payment of Interim Dividend(s) shall be made within 30 (thirty) days from the record date/book closure period.

The payment of annual or final dividend shall be made within 30 (thirty) days from the date of approval at the Annual General Meeting of the Company to the shareholders entitled to receive the dividend on the record date/book closure period as per the applicable law.

In case no final dividend is declared, interim dividend paid during the year, if any, will be regarded as final dividend in the AGM.

8. Parameters to be considered while recommending/ declaring dividend

The Board of Directors of the Company while declaring or recommending dividend will consider following factors, whereas, all these factors are of equal important and no single or group of factors supersedes any other factor or group of factors:

A) External Factors:

Though the dividend decision would be guided by current and prospective financial performance, it needs to be within the regulatory framework and also considering some other external factors.

- To retain a reasonable portion of profits to build up reserves, in case of adverse economic scenario.
- Considering the industry outlook and evaluating the market trends.
- The Board shall consider the restrictions, if any, imposed by the Act and other applicable laws with regard to declaration of dividend in order to ensure compliance with the applicable laws.
- Dividend distribution tax and/or any tax deduction at source as required by tax regulations, applicable at the time of declaration of dividend may impact the decision with regard to dividend declaration.
- Other factors beyond control of the Management like natural calamities, fire, etc. effecting operations of the Company may impact the decision with regard to dividend declaration.

B) Internal Factors:

- Profits earned during the financial year and the retained profits of the previous years or losses suffered in the past years.
- Accumulated reserves.
- Earnings per share.
- Cash flow position and treasury position of the Company keeping in view the total debt to equity ratio.
- Current and projected cash balance.
- Projections with regard to the performance of the Company.
- Future capital expenditure requirement of the Company.
- Working capital requirement of the Company.
- Cost of raising funds from alternate sources of capital.
- Corporate actions including mergers, acquisition of brands/business and additional investments including expansion plans and investment in subsidiaries/associates of the Company.
- Investment in technology and learning & development.
- Expenditure on Research & Development.
- Such other factors and/or material events, which the Company's Board may consider.

C) Shareholders of the Company may not except Dividend under the following circumstances:

- When the Company undertakes or proposes to undertake a significant expansion project requiring higher allocation of capital;
- Significantly, higher working capital requirements adversely impacting free cash flow;
- When the Company undertakes any acquisitions or joint ventures requiring significant allocation of capital;
- In the event of inadequacy of profits or the Company has incurred losses;
- Any rules, Directive or guidance issued by BSEC on declaration or distribution of dividend.

9. Utilization of retained earnings

The Board of Directors of the Company may retain its earnings in order to make better use of the funds available and increase the value of the stakeholders in the long run. The retained earnings of the Company may be used in any of the following ways:

- Capital expenditure;
- Declaration of dividend;
- Issue of bonus shares;
- Diversification of business;
- Capacity Expansion;
- Repayment of debts;
- Buy-back of shares/capital reduction;
- Other permissible usage as per Acts and regulations.

10. Procedure for Distribution of Dividend

The Company shall follow the guidelines regarding disbursement of dividend as prescribed by the regulatory authorities as under:

- Cash dividend shall be paid directly to the entitled shareholders' bank accounts as available in the BO accounts, or the bank accounts as provided by the shareholders in paper form, through BEFTN and/or any other electronic payment system within 30 days of final approval by the shareholders in the AGM;
- Upon receiving the detail information and claim on cash dividend from a stock broker or a merchant banker or a portfolio manager for the margin client or customer who has debit balance or margin loan, the cash dividend shall be paid to the Consolidated Customers' Bank Account of the stockbroker or to the separate bank account of the merchant banker or portfolio manager;
- Cash dividend shall be paid off to the non-resident sponsor, director, shareholder, or foreign portfolio investor (FPI) through the security custodian in compliance with the rules or regulations in this regard;
- In case of non-availability of a valid bank account or not possible to distribute cash dividend through BEFTN or any electronic payment system, cash dividend warrants and/or cheques shall be issued and sent by post/courier services to the respective shareholders' addresses;

- For the purpose of paying dividend, a separate bank account shall be maintained from which all the dividend payments are being made. Any unpaid/unclaimed cash dividend including accrued interest (after adjustment of bank charge and others, if any) thereon, if remains, shall be transferred to a separate bank account of the issuer as maintained for this purpose, within 01 (one) year from the date of declaration or approval, as the case may be;
- Stock dividend shall be directly credited to the BO accounts of respective shareholders within 30 days of AGM subject to clearance of the exchange(s) and Central Depository Bangladesh Limited (CDBL);
- The company shall inform its shareholders through publication in the newspaper after the dividend is being disbursed and/ or credited. Besides shareholders on record date shall be intimated through short message service (SMS) to the mobile numbers or email addresses as provided in the BO account;
- Company shall follow the directives/circulars in force of the securities regulator, related to dividend distribution from time to time.

11. Unclaimed/Unpaid/Undistributed Dividend

Pursuant to the Bangladesh Securities and Exchange Commission's Directive No. BSEC/CMRRCD/2021-386/03 dated 14 January 2021, the Company shall maintain a separate Bank Account for dividend, where unpaid or unclaimed dividend shall be kept for a period of 3 (three) years from the date of declaration or approval date or record date. After elapse of the aforesaid period, if any Dividend remains unpaid/unclaimed/ undistributed / unsettled, such Dividend along with accrued interest, if any, shall be transferred to a Fund maintained by Bangladesh Securities Exchange Commission.

12. Procedure for claiming unpaid Dividend

1. The Company has a policy in place for claiming unpaid or unclaimed Dividend which is as follows:

(a) Shareholders are required to make an "Application for Unpaid Dividend" in the format set out in this Policy. For the ease of shareholders, the Application Form is available on the Company website and at its office.

(b) Shareholders may apply in person at the Corporate Office of the Company or submit their application over email to cs@jhrml-bd.com

(c) Unpaid Dividends will be paid to the shareholders, upon verification of the relevant BO ID information, cell phone number and email address maintained with the Central Depository of Bangladesh Limited (CDBL)

(d) Unpaid Dividends will be paid through the issuance of Dividend warrant/BEFTN/other banking channels within 15(Fifteen) days.

2. For the avoidance of doubt, all Dividend payments from the Company shall be subject to applicable taxes and shall not bear any interest or whatsoever.

13. General

This Dividend Policy would be subject to revision/amendment in accordance with changes in applicable laws or the guidelines issued by BSEC or such other regulatory authority as may be authorized, from time to time, on the subject matter.

The Board shall review this Policy annually. Upon recommendation of the Board, the Company reserves its right to alter, modify, add, delete or amend any of the provisions of this Policy.

The policy will be available on the Company's website and will also be disclosed in the Company's Annual Report.

Management's Discussion & Analysis

Pursuant to the Corporate Governance Code 2018 [Condition # 1(5) (xxv)] of the Bangladesh Securities and Exchange Commission, the Management's Discussion & Analysis for the year ended 30 June 2025 has been depicted hereunder:

1. Accounting Policies and Estimation for preparation of Financial Statements

JMI Hospital Requisite Manufacturing Limited follows International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) and compliance with the Bangladesh Securities and Exchanges Commission Rules 1987, the Companies Act, 1994 and other applicable rules and regulations.

2. Changes in Accounting Policies and Estimation

JMI Hospital Requisite Manufacturing Limited follows consistency in accounting policies and estimation and there are no such changes in accounting policies or estimation which have a material impact on financial statements. However, the financial statements of the company are complied with the applicable standard (IFRS/IAS).

3. Comparative analysis of the company's performance over the years

Key operating and financial data over the last five years is given as follows:

Particulars	Amount in BDT				
	2024-2025	2023-2024	2022-2023	2021-2022	2020-2021
Sales Revenue	1,670,955,448	1,870,145,496	1,852,076,202	1,801,801,801	1,730,870,760
Cost of Sales	1,152,507,718	1,289,909,629	1,271,248,302	1,236,056,527	1,110,094,614
Gross profit	518,447,730	580,235,867	580,827,900	565,745,274	620,776,146
Net Profit after tax	233,127,043	293,108,261	302,286,195	325,019,973	225,004,371
Other comprehensive income	78,182	(168,975)	66,960	(71,676)	109,750
Gross profit margin %	31.03	31.03	31.36	31.40	35.86
Net profit margin %	13.95	15.67	16.32	18.04	12.99
Shareholders' Equity	4,568,953,959	4,324,108,104	4,023,927,839	3,881,941,282	2,834,506,478
Total asset	5,913,543,679	5,683,413,120	5,464,917,493	5,320,846,042	4,850,205,480
Total liability	1,344,589,720	1,359,305,016	1,440,989,654	1,438,904,760	2,015,699,002

4. Financial and Economic Scenario of Bangladesh and the Globe

With a current market size of USD 442 million and a Compound annual growth rate (CAGR) of 13%, this medical equipment & devices sector is expected to grow to USD 820 million by 2025. Bangladesh's medical sector witnessed an annual growth of 14.6% between FY 2016 and FY 2019, recording the fastest growth in the world. More than 4,000 types of medical devices & equipment are used in Bangladesh, 5-7% of which are manufactured locally. Import of medical equipment and devices increased with the CAGR of 10.2% during the last five years as per BIDA report.

5. Risks and concerns related to the financial statements

The company follows a number of accounting and financial reporting standards and practices for addressing financial reporting risks. The Chief Financial Officer and the Managing Director issued a certificate about the accuracy of the financial statements. Moreover, the annual and quarterly financial statements are thoroughly reviewed by the Audit Committee before circulation to the shareholders and regulators. Thus, the management has ensured sufficient internal control to mitigate addressing financial reporting risks.

6. Future Plan and Outlook

JHRML remains committed to delivering the highest quality products to its customers and brand partners. Looking ahead to 2024–2025 and beyond, the company aims to carry forward the same passion and dedication that have driven its growth over the past 17 years. JHRML's vision is to become the leading locally listed, socially responsible company in its sector. The management continues to focus on creating long-term value for shareholders while ensuring the well-being and benefit of all stakeholders.

Best wishes



Suriya Akther Rina
Managing Director

Declaration by CEO and CFO

October 20, 2025

The Board of Directors
JMI Hospital Requisite Manufacturing Ltd.
Unique Heights, Level-11,
117 Kazi Nazrul Islam Avenue, Ramna,
Dhaka -1217

Annexure - A

Subject: Declaration on Financial Statements for the year ended on June 30, 2025.

Dear Sirs,
According to the condition No. 1(5) (xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 Dated: 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

1. The Financial Statements of JMI Hospital Requisite Manufacturing Limited for the year ended on June 30, 2025 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh and any departure therefrom has been adequately disclosed;
2. The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, for the financial statements to reveal a true and fair view;
3. The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
4. To ensure the above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
5. Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
6. The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:-

i) We have reviewed the Financial Statements for the year ended on June 30, 2025, and to the best of our knowledge and belief:

a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

b) These statements collectively present a true and fair view of the Company's affairs and comply with existing accounting standards and applicable laws.

ii) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year, which is fraudulent, illegal, or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

Subas Chandra Banik
Chief Financial Officer

Mrs. Suriya Akther Rina
Managing Director

Statement of
Corporate Governance

At JMI Hospital Requisite Manufacturing Limited, we see corporate governance as more than just rules and regulations—it's the foundation for how we operate, make decisions, and uphold accountability. It shapes the way we protect and balance the interests of all our stakeholders, from shareholders and customers to suppliers, regulators, and our management team. Strong governance is central to our commitment to transparency, integrity, and sustainable growth.

Board Composition
The board of directors of the company is six including Chairman, Managing Director, Director, Nominee Director and Independent Directors.

Roles and Responsibilities of the Board
The board of directors ensures the company has sufficient, well-managed resources in its operation, helping it set broad goals and supporting the executive team's responsibilities.

Independent Directors
The Board has appointed two Independent Directors, including one female director, bringing diverse expertise and experience. Their presence strengthens the Board's balance and ensures transparency and objectivity in the company's decision-making process.

Qualification of Independent Director
The Independent Directors are knowledgeable and they can ensure compliance with financial laws, regulatory requirements and corporate laws.

Chairperson, Managing Director/ CEO
Md. Abdur Razzaq is the Chairman and Mrs. Suriya Akther Rina is the Managing Director of the Company.

The Directors reports to the shareholders
The Board of Directors of the Company disclosures in the Directors report under section 184 of the Companies Act. 1994.

Meeting of the Board of Directors
The Company conducted its Board Meeting and recorded the minutes of the meeting as well as keep required books and records as per provisions of Bangladesh Secretarial Standard (BSS).

Code of Conduct of the Chairperson, other Board member and CEO
The Board of Directors has established a code of conduct for the Chairperson, other Board members, and the CEO, in accordance with the relevant provisions.

Secretarial Standard
The company maintaining of the Secretarial Standard on meetings of the Board of Directors, Members (shareholders), Minutes and Dividend issued by the Institute of Chartered Secretaries of Bangladesh. A qualified Chartered Secretary is in charge of maintaining of the Secretarial Standard.

Compliances
The company has established procedures to ensure compliance with all applicable statutory and regulatory requirements. Respective officers are responsible for ensuring proper compliance with applicable laws and regulations.

MD/CEO, CFO, HIAC and CS.
The Board of Directors appointed Managing Director, Chief Financial Officer, Head of Internal Audit and Company Secretary. The Board also clearly defines respective roles, responsibilities and duties of them.

Audit Committee
For ensuring good governance in the Company, the company has an audit committee. The audit committee composed of four (4) member of the Board of Directors and Chairperson of the Audit Committee is Independent Director of the Company.

Nomination and Remuneration Committee (NRC)
The company has a Nomination and Remuneration Committee (NRC). The Committee comprised of four (4) members including an Independent Director.

External or Statutory Auditors
The Directors of the Company recommends G. Kibria & Co., Chartered Accountant as External Auditor of the Company as per provision of the Companies Act. 1994

Maintaining a website by the Company
www.jhrml-bd.com is the website of the Company.

Reporting and Compliance of Corporate Governance
The Company has obtained a certificate confirming compliance with the conditions of the Corporate Governance Code, which is disclosed in this Annual Report.



Certificate of Compliance

ARTISAN
Chartered Accountants

REPORT TO THE SHAREHOLDERS OF
JMI HOSPITAL REQUISITE MANUFACTURING LTD.
ON COMPLIANCE ON THE CORPORATE GOVERNANCE CODE

We have examined the compliance status to the Corporate Governance Code by **JMI HOSPITAL REQUISITE MANUFACTURING LTD.** for the year ended on June 30, 2025. This Code relates to the Notification No. BSEC/ CMRRCD/ 2006-158/ 207/Admin/ 80 dated 3 June 2018 of the Bangladesh Securities and Exchange Commission. Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above-mentioned Corporate Governance Code issued by the Commission, except the statement written in the remarks column;

b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;

c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws; and

d) The Governance of the company is satisfactory.

Dhaka, 15 November, 2025

Md. Selim Reza FCA FCS
Partner
ARTISAN
Chartered Accountants

Sonargaon Terrace (2nd floor), House # 52, Road # 13/C,
Block # E, Banani, Dhaka-1213, Bangladesh.

slm.reza@yahoo.com
src.ca2012@yahoo.com

Checklist on Corporate Governance Code

Status of compliance with the conditions imposed by the Commission's Notification No. SEC/CMRRC-D/2006-158/207/Admin/80 dated 03 June 2018 and Notification number BSEC/CMRRC-D/2009-193/66/PRD/148 dated 16th October, 2023 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9)

Condition No.	Title	Compliance status (Put √ in the appropriate column)		Remarks (if any)
		Complied	Not complied	
1.	**Board of Directors**			
1(1)	**Size of the Board of Directors:** The total number of members of the company's Board of Directors shall not be less than 5 (five) and more than 20 (twenty)	√		Board size 7 (Seven), including 03 (three) Independent Directors. Mr. Md. Aminul Bar Chowdhury- Independent Director resigned on 17 August 2025.
1(2)	**Independent Directors**			
1(2) (a)	At least 2(two) directors or one-fifth (1/5) of the total number of directors in the company's Board, whichever is higher, shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of independent director(s) The Board shall appoint at least 01 (one) female Independent Director in the Board of Directors of the Company	√		03 (three) Independent Directors, including one female.
1(2)(b)	**Without contravention of any provision of any other laws, for the purpose of this clause an "independent director" means a director-**			
1(2)(b)(i)	who either does not hold share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	√		The Independent Director has declared his compliance
1(2)(b)(ii)	who is not a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company;	√		

1(2)(b)(iii)	who has not been an executive of the company in immediately preceding 2 (two) financial years;	√		
1(2)(b)(iv)	who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	√		
1(2)(b)(v)	who is not a member of TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange;	√		
1(2)(b)(vi)	who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	√		
1(2)(b)(vii)	who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this code;	√		
1(2)(b)(viii)	who is not independent director in more than 5 (five) listed companies;	√		
1(2)(b)(ix)	who has not been reported as a defaulter in the latest Credit Information Bureau (CIB) report of Bangladesh Bank for nonpayment of any loan or advance or obligation to a bank or a financial institution; and	√		
1(2)(b)(x)	who has not been convicted for a criminal offence involving moral turpitude;	√		
1(2)(c)	The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM): Provided that the Board shall appoint the independent director, subject to prior consent of the Commission, after due consideration of recommendation of the Nomination and Remuneration Committee (NRC) of the company,	√		In practice
1(2)(d)	The post of independent director(s) cannot remain vacant for the more than 90 (ninety) days; and	√		There was no vacancy in the position of Independent Director
1(2)(e)	The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only;	√		
1(3)	**Qualification of Independent Director**			
1(3)(a)	Independent director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to the business;	√		All qualifications and backgrounds of Independent Directors are justified by the Board and BSEC
1(3)(b)	**Independent Director shall have following Qualifications:**			
1(3)(b)(i)	Business Leader who is or was a promoter or director of an unlisted company having minimum paid-up capital of Tk.100.00 million or any listed company or a member of any national or international chamber of commerce or registered business association; or			N/A

1(3)(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director of Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company; or			N/A
1(3)(b)(iii)	Former or existing official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or Law: Provided that in case of appointment of existing official as independent director, it requires clearance from the organization where he or she is in service; or	√		
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law; or			N/A
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;			N/A
1(3)(c)	The independent director shall have at least 10 (ten) years of experiences in any filed mentioned in clause (b);	√		
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission,			N/A
1(4)	**Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer**			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and /or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	√		CEO and CFO are separate individual person.
1(4)(b)	The Managing Directors (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	√		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	√		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/or Chief Executive Officer;	√		
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as chairperson for that particular Board meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		No such case occurred in the year
1(5)	**The Directors' Report to Shareholders**			
1(5)(i)	An industry outlook and possible future developments in the industry;	√		The Directors' report complies with the guidelines.
1(5)(ii)	The segment-wise or product-wise performance;	√		

1(5)(iii)	Risk and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	√		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	√		
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	√		
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	√		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	√		
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc.;	√		
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial performance and Annual Financial Statements;	√		
1(5)(x)	A statement of remuneration paid to the directors including independent director;	√		
1(5)(xi)	A statement that the Financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	√		
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	√		
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	√		
1(5)(xiv)	A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	√		
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	√		
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√		
1(5)(xvii)	A statement that there is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	√		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	√		
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	√		
1(5)(xx)	An explanation of the reasons if the issuer company has not declared dividend (cash or stock) for the years;			N/A

1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	√		No interim dividend declared
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	√		
1(5)(xxiii)	**A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:**			
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	√		
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details);	√		
1(5)(xxiii)(c)	Executives; and	√		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details);	√		
1(5)(xxiv)	**In case of the appointment or reappointment of a director, a disclosure on the following information of the shareholders:**			
1(5)(xxiv)(a)	A brief resume of the director;	√		
1(5)(xxiv)(b)	Nature of his or her expertise in specific functional areas; and	√		Directors have expertise on the activities of the Company's business
1(5)(xxiv)(c)	Names of companies in which the person also holds the directorship and the membership of committees of the Board;	√		
1(5)(xxv)	**A Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with brief discussion of changes in the financial statements, among others, focusing on:**			
1(5)(xxv)(a)	Accounting policies and estimation for preparation of financial statements;	√		
1(5)(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	√		
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	√		
1(5)(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	√		
1(5)(xxv)(e)	Briefly explain the financial and economic scenario of the country and the globe;	√		
1(5)(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and	√		

1(5)(xxv)(g)	Future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	√		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No.3(3) shall be disclosed as per Annexure-A;	√		CEO and CFO certified to the Board regarding financial statements.
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C;	√		Certified by ARTISAN-Chartered Accountants
1(5)(xxviii)	The Directors' report to the shareholders does not require to include the business strategy or technical specification related to products or services, which have business confidentiality.	√		
1(6)	**Meetings of the Board of Directors**			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	√		
1(7)	**Code of Conduct for the Chairperson, other Board members and Chief Executive Officer**			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	√		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	√		Posted on the website of the Company.
2.	**GOVERANCE OF BOARD OF DIRECTORS OF SUBSIDIARY COMPANY:**			
2(a)	Provisions relating to the compositions of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;	√		
2(b)	At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company;	√		
2(c)	The minutes of the board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;	√		
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	√		
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	√		

3.	**MANAGING DIRECTOR (MD) OR CHIEF EXECUTIVE OFFICER (CEO), CHIEF FINANCIAL OFFICER (CFO), HEAD OF INTERNAL AUDIT AND COMPLIANCE (HIAC) AND COMPANY SECRETARY (CS):**			
3(1)	Appointment			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	√		
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	√		
3(1)(c)	The MD or CEO, CS, CFO, and HIAC of a listed company shall not hold any executive position in any other company at the same time: Provided that CFO or CS of any listed company may be appointed for the same position in any other listed or non-listed company under the same group for reduction of cost or for technical expertise, with prior approval of the Commission: Provided further that the remuneration and perquisites of the said CFO or CS shall be shared by appointing companies proportionately;	√		No such case occurred in the year
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	√		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	√		HIAC resigned, and a new one was appointed on October 12, 2025, with the Board's approval and subsequent disclosure to the Commission and the stock exchanges.
3(2)	**Requirement to attend Board of Directors' Meetings**			
	The MD or CEO, CS, CFO, HIAC of the company shall attend the meetings of the Board: Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	√		In practice
3(3)	**Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)**			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:			
3(3)(a)(i)	these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	√		
3(3)(a)(ii)	these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	√		

3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members;	√		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	√		
4.	**BOARD OF DIRECTORS' COMMITTEE :**			
4(i)	Audit Committee; and	√		
4(ii)	Nomination and Remuneration Committee (NRC).	√		
5.	**AUDIT COMMITTEE :**			
5(1)	Responsibility to the Board of Directors			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	√		
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	√		
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	√		
5(2)	**Constitution of the Audit Committee**			
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	√		The audit committee is composed of 4 (four) members
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be nonexecutive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	√		The members of the Audit Committee are appointed by the Board, who are which includes 01 (one) Independent Director
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	√		Complied
5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 60 (sixty) days from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	√		The Board Appointed audit committee member in due time
5(2)(e)	The Company Secretary shall act as the secretary of the Committee;	√		Do

5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director;	√		One Independent Director is the Chairperson of the Audit Committee
5(3)	**Chairperson of the Audit Committee**			
5(3)(a)	The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	√		In practice
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		In practice
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM)	√		In practice
5(4)	**Meeting of the Audit Committee**			
5(4)(a)	The Audit Committee shall conduct at least its four meeting in financial year	√		In practice
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	√		In practice
5(5)	**Role of Audit Committee**			
5(5)(a)	Oversee the financial reporting process;	√		In practice
5(5)(b)	monitor choice of accounting policies and principles;	√		
5(5)(c)	monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	√		
5(5)(d)	oversee hiring and performance of external auditors;	√		
5(5)(e)	hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval of adoption;	√		
5(5)(f)	review along with the management, the annual financial statements before submission to the Board for approval;	√		
5(5)(g)	review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	√		
5(5)(h)	review the adequacy of internal audit function;	√		
5(5)(i)	review the Management's Discussion and Analysis before disclosing in the Annual Report;	√		
5(5)(j)	review statement of all related party transactions submitted by the management;	√		
5(5)(k)	review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	√		
5(5)(l)	oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and	√		

5(5)(m)	oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Right Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission			N/A
5(6)	**Reporting of the Audit Committee**			
5(6)(a)	**Reporting to the Board of Directors**			
5(6)(a)(i)	The Audit Committee shall report on its activities to the board.	√		
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board on the following findings, if any :-			
5(6)(a)(ii)(a)	report on conflicts of interest;			There is no reportable case of conflict of interest in the year 2024-2025
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularly or material defect identified in the internal audit and compliance process or in the financial statements;			N/A
5(6)(a)(ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations; and			N/A
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately.			N/A
5(6)(b)	**Reporting to the Authorities** If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.	√		
5(7)	**Reporting to the Shareholders and General Investors** Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	√		The audit committee report is disclosed in the Annual Report and signed by the Chairperson of Audit Committee.
6.	**NOMINATION AND REMUNERATION COMMITTEE (NRC):**			
6(1)	**Responsibility to the Board of Directors**			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a subcommittee of the Board,	√		
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	√		

6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b),	√		
6(2)	**Constitution of the NRC**			
6(2)(a)	The Committee shall comprise of at least three members including an independent director,	√		The NRC is composed of 4 (Four) members.
6(2)(b)	At least 02 (two) members of the Committee shall be non-executive directors;	√		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	√		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	√		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;	√		Mr. Abdul Wahab Khan, Independent director and Chairperson of NRC
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	√		
6(2)(g)	The Company Secretary shall act as the secretary of the Committee;	√		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an Independent Director;	√		
6(2)(i)	No member of the NRC receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	√		
6(3)	**Chairperson of the NRC**			
6(3)(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	√		Mr. Abdul Wahab Khan, Independent director and Chairperson of NRC
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for the particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	√		No such case in the year
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders;	√		
6(4)	**Meeting of the NRC**			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	√		
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	√		No such case in the year

6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	√		
6(5)	**Role of the NRC**			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	√		
6(5)(b)	**NRC shall oversee, among others, the following matters and make report with recommendation to the Board**			
6(5)(b)(i)	Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:			
6(5)(b)(i)(a)	the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	√		
6(5)(b)(i)(b)	the relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	√		
6(5)(b)(i)(c)	remuneration to the directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	√		
6(5)(b)(ii)	devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	√		
6(5)(b)(iii)	identifying persons who are qualified to become directors and who may be appointed in top level executives position in accordance with the criteria laid down, recommended their appointment and removal to the board;	√		
6(5)(b)(iv)	formulating the criteria for evaluation of performance of independent directors and the Board;	√		
6(5)(b)(v)	identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; and	√		
6(5)(b)(vi)	developing, recommending and reviewing annually the company's human resources and training policies;	√		
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	√		The NRC report is disclosed in the Annual Report and signed by the Chairperson of the NRC

7.	**EXTERNAL OR STATUTORY AUDITORS:**			
7(1)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:			
7(1)(i)	appraisal or valuation services or fairness opinions,	√		In practice
7(1)(ii)	financial information systems design and implementation;	√		
7(1)(iii)	book-keeping or other services related to the accounting records or financial statements;	√		
7(1)(iv)	broker-dealer services;	√		
7(1)(v)	actuarial services;	√		
7(1)(vi)	internal audit services or special audit services;	√		
7(1)(vii)	audit or certification services on compliance of corporate governance as required under condition No. 9(1); and	√		
7(1)(ix)	any other service that creates conflict of interest.	√		
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company	√		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General Meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	√		
8.	**MAINTAINING A WEBSITE BY THE COMPANY:**			
8(1)	The company shall have an official website linked with the website of the stock exchange.	√		
8(2)	The company shall keep the website functional from the date of listing.	√		
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchanges(s).	√		
9.	**REPORTING AND COMPLIANCE OF CORPORATE GOVERNANCE:**			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in Annual Report.	√		Certified by ARTISAN-Chartered Accountants
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	√		A separate agenda to be provided for the 17th AGM
9(3)	The directors of the company shall state, in accordance with the **Annexure-C** attached, in the directors' report whether the company has complied with these conditions or not.	√		



Audited Financial Statements of

JMI Hospital Requisite Manufacturing Ltd. and its Subsidiary

For the year ended
on 30 June 2025

G. KIBRIA & CO.
CHARTERED ACCOUNTANTS

gmni member
an association of legallyindependent accounting firms
partnering for success

Independent Auditor's Report

To the Shareholders of JMI Hospital Requisite Manufacturing Ltd. and its subsidiary

Report on the Audit of the Consolidated and Separate Financial Statements

Qualified Opinion

We have audited the consolidated and separate financial statements of JMI HOSPITAL REQUISITE MANUFACTURING LTD. and its subsidiary (the "Group"), which comprise the consolidated and separate statement of financial position as at June 30, 2025 and the consolidated and separate statement of profit or loss and other comprehensive income, consolidated and separate statement of changes in equity and consolidated and separate statement of cash flows for the year then ended, and notes to the consolidated and separate financial statements, including material accounting Policy Information.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying consolidated and separate financial statements give a true and fair view of the consolidated and separate financial position of the Company as at June 30, 2025 and of its consolidated and separate financial performance and its consolidated and separate cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). The Companies Act 1994, The Securities and Exchange Rules 2020 and other applicable laws and regulations.

Basis for Qualified Opinion

The Group's consolidated financial statements include the financial information of its subsidiary, JMI Specialized Hospital Limited, which has recognized Start-up Cost of BDT 88,202,738 under Capital Work-in-Progress (CWIP), which do not meet the definition of Directly Attributable Cost incompliance with IAS 16 Property, Plant and Equipment. Moreover, certain rental expenses have not been recognized incompliance with the IFRS 16 Leases. This matter was the subject of a qualified opinion in the auditor's report on the financial statements of JMI Specialized Hospital Limited. As the amount involved is material to the consolidated financial statements, our opinion on the Group's consolidated financial statements is also qualified on the same basis.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the consolidated and separate Financial Statements section of our report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Head Office : Sadharan Bima Sadan (5th Floor) 24-25, Dilkusha Commercial Area, Dhaka-1000, Bangladesh
Branch Office : Plot 51, Floor-2, Road 14, Block-G, Niketon, Gulshan-1, Dhaka-1212
TEL OFF : 02-223388071, 02-223355324, 48812331, 48812332
E-mail : gkibria@gkibriaandco.com, kibria03@hotmail.com, Web: http://gkibriaandco.com

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated and separate financial statements of the current period. These matters were addressed in the context of our audit of the consolidated and separate financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the Opinion section we have determined the matters described below to be the key audit matters to be communicated in our report

KEY AUDIT MATTERS	How our audit addresses the Key Audit Matter
Property, Plant & Equipment	
The Company's PPE balance as at 30 June 2025 was BDT 174.06 Crore (BDT 184.11 (consolidation basic) Crore as at 30 June 2024). This represents 29% of Total Assets of the Company (32% of the Company as at 30 June 2024). There is estimation performed by management in regards to Asset useful life. Based on the requirement of estimates and the fact that this is a major asset category, this was determined to be a key audit matter.	Our audit procedures included: ▸ Obtain an understanding of Company's internal controls, systems and processes around PPE. ▸ We performed PPE additions procedures by obtaining supporting documentation, invoices and payments support. ▸ We performed reasonability of depreciation expenses charged by management to ensure accuracy and occurrence. ▸ Reviewed management's calculations to ensure it is free from no clerical errors.
Detailed notes regarding Property, Plant & Equipment has been included in Note 04A in the Financial Statements	

Other Matters

The Document Verification Code (DVC) had been taken for separate financial statements of JMI HOSPITAL REQUISITE MANUFACTURING LTD. by us the "group auditor" and the DVC of subsidiary JMI SPECIALIZED HOSPITAL LIMITED has been also taken by us the component auditors based on the separate Financial Statements of JSHL.

Information Other than the consolidated and separate Financial Statements and Auditor's Report Thereon

Management is responsible for information other than consolidated and separate financial statements and auditor's report. The other information comprises of the Director's Report, Corporate Governance Compliance Report, Business Responsibility & Sustainability Report and Management Discussion and Analysis. We expect to receive this other information after the date of our auditor's report.

Our opinion on the consolidated and separate financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
In connection with our audit of the consolidated and separate financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed on the other information obtained prior to the date of the auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Head Office : Sadharan Bima Sadan (5th Floor) 24-25, Dilkusha Commercial Area, Dhaka-1000, Bangladesh
Branch Office : Plot 51, Floor-2, Road 14, Block-G, Niketon, Gulshan-1, Dhaka-1212
TEL OFF : 02-223388071, 02-223355324, 48812331, 48812332
E-mail : gkibria@gkibriaandco.com, kibria03@hotmail.com, Web: http://gkibriaandco.com

Responsibilities of Management and Those Charged with Governance for the consolidated and separate Financial Statements

Management is responsible for the preparation of consolidated and separate financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB), the Companies Act 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of consolidated and separate financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated and separate financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company's or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the consolidated and separate Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated and separate financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Head Office : Sadharan Bima Sadan (5th Floor) 24-25, Dilkusha Commercial Area, Dhaka-1000, Bangladesh
Branch Office : Plot 51, Floor-2, Road 14, Block-G, Niketon, Gulshan-1, Dhaka-1212
TEL OFF : 02-223388071, 02-223355324, 48812331, 48812332
E-mail : gkibria@gkibriaandco.com, kibria03@hotmail.com, Web: http://gkibriaandco.com

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, the Securities and Exchange Rules 2020 and relevant notifications issues by Bangladesh Securities and Exchange Commission, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, we also report the following:

- we have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books; and
- the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account.
- The expenditures incurred were for the purpose of the group's business.

Place: Dhaka
Date: 26 October 2025
DVC No. 2510260392AS831630

For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

A.K. Gulam Kibria, FCA, (#392)
Partner

Head Office : Sadharan Bima Sadan (5th Floor) 24-25, Dilkusha Commercial Area, Dhaka-1000, Bangladesh
Branch Office : Plot 51, Floor-2, Road 14, Block-G, Niketon, Gulshan-1, Dhaka-1212
TEL OFF : 02-223388071, 02-223355324, 48812331, 48812332
E-mail : gkibria@gkibriaandco.com, kibria03@hotmail.com, Web: http://gkibriaandco.com

JMI HOSPITAL REQUISITE MANUFACTURING LTD. and its Subsidiary

Consolidated Statement of Financial Position

As at 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
ASSETS			
Non-Current Assets			
Property, Plant & Equipment	04A	1,740,681,529	1,841,128,359
Right of Use Assets	4.00	2,553,062	385,984
Capital Work in Progress(CWIP)	4.02A	756,835,561	408,840,185
		2,500,070,152	**2,250,354,528**
Current Assets			
Inventories	05A	748,246,525	719,461,927
Inter Company Loan	06A	745,212,197	705,499,345
Advance, Deposit & Prepayments	07A	806,985,519	692,610,074
Accounts & Other Receivables	08A	790,152,908	748,657,012
Investment in Shares & Others	09A	156,719,814	244,014,160
Cash & Cash Equivalents	10A	166,156,564	322,816,074
		3,413,473,527	**3,433,058,592**
Total Assets		**5,913,543,679**	**5,683,413,120**
EQUITY & LIABILITIES			
Equity			
Share Capital	11A	1,252,941,200	1,252,941,200
Share Premium	11.01A	1,205,506,932	1,205,789,432
Reserve & Surplus	12A	310,107,867	312,199,137
Retained Earnings	13A	1,633,884,725	1,483,198,516
		4,402,440,724	**4,254,128,285**
Non - Controlling Interests	13.01A	166,513,235	69,979,819
		4,568,953,959	**4,324,108,104**
Non-Current Liabilities			
Term Loan (Non Current maturity)	14A	153,573,581	147,653,053
Deferred Tax Liability	15A	129,841,178	127,351,046
Lease Finance (Non-current maturity)	16A	3,411,968	-
Rental Lease Liability	17A	2,705,304	486,027
		289,532,031	**275,490,126**
Current Liabilities			
Lease Finance (Current maturity)	16.01A	1,443,600	-
Term Loan (Current maturity)	14.01A	78,224,259	135,979,778
Working Capital Loan	18A	816,604,426	822,434,240
Liability Against Import	19A	22,817,655	25,563,257
Account & Other Payables	20A	65,746,924	70,980,334
Unclaimed Dividend	20.1A	10,793,931	5,115,003
Loan from Director's & Others	21A	7,756,976	7,756,976
Income Tax Liability	22A	51,669,918	15,985,302
		1,055,057,689	**1,083,814,890**
Total Equity & Liabilities		**5,913,543,679**	**5,683,413,120**
Net Asset Value Per Share (NAV)	31A	**35.14**	**33.95**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Dhaka.
Date: 26 October 2025
DVC:

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI HOSPITAL REQUISITE MANUFACTURING LTD. and its Subsidiary

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Sales Revenue	23A	1,670,955,448	1,870,145,496
Cost of Goods Sold	24A	(1,152,507,718)	(1,289,909,629)
Gross Profit/(Loss)		**518,447,730**	**580,235,867**
Operating Expenses			
Administrative Expenses	25A	(80,849,356)	(79,295,089)
Selling & Distribution Expenses	26A	(54,628,842)	(57,561,388)
Total Operating Expenses		**(135,478,198)**	**(136,856,477)**
Operating Profit		**382,969,532**	**443,379,390**
Financial Expense	27A	(55,302,210)	(70,749,919)
Net Profit After Financial Expenses		**327,667,322**	**372,629,471**
Income From Others Sources	28A	5,875,982	12,384,488
Net Income before adjustment of WPPF		**333,543,304**	**385,013,959**
Workers' Profit Participation Fund		(15,889,684)	(18,336,081)
Net Profit Before Taxation		**317,653,620**	**366,677,878**
Provision for Income Tax Expense			
Current Tax		(82,067,042)	(82,526,288)
Deferred Tax		(2,459,535)	8,956,671
Profit after Tax for the year		**233,127,043**	**293,108,261**
Attributable to:			
Owners of the parent		233,177,401	293,128,442
Non - controlling interests		(50,359)	(20,181)
Profit after Tax for the year		**233,127,042**	**293,108,261**
Other Comprehensive Income:			
Unrealized Gain: Fair value gain/(loss) of investment		108,780	(197,195)
Deferred Tax		(30,598)	28,220
		78,182	**(168,975)**
Total Comprehensive Income for the year		**233,205,225**	**292,939,286**
Basic Earning Per Share (EPS)	32A	**1.86**	**2.34**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Dhaka.
Date: 26 October 2025
DVC:

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI HOSPITAL REQUISITE MANUFACTURING LTD. and its Subsidiary

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2025

Particulars	Share Capital	Share Premium	Tax Holiday Reserve.	Revaluation Surplus	Fair Value Gain /(Loss)	Retained Earnings	Non - Controlling Interests	Total amount in Taka
Balance as on 01.07.2024	**1,252,941,200**	**1,205,789,432**	**124,185,213**	**188,182,899**	**(168,975)**	**1,483,198,516**	**69,979,819**	**4,324,108,104**
Share Issued/Equity portion	-	-	-	-	-	-	96,583,775	**96,583,775**
Revaluation Surplus	-	-	-	(2,338,427)	-	2,338,427		**-**
Adjustment of Other Comprehensive Income	-	-	-	-	168,975	-		**168,975**
Other Comprehensive Income	-	-	-	-	78,182	-		**78,182**
IPO Expenses	-	(282,500)	-	-	-	-		**(282,500)**
Dividend For the year 2023-2024 10% Cash (Other than Sponsors & Directors Share Holder)		**-**				(84,829,620)		**(84,829,620)**
Net Profit during the Year	-	-	-	-	-	233,177,401	(50,359)	**233,127,042**
Balance as on 30.06.2025	**1,252,941,200**	**1,205,506,932**	**124,185,213**	**185,844,472**	**78,182**	**1,633,884,725**	**166,513,235**	**4,568,953,959**

For the year ended 30 June 2024

Particulars	Share Capital	Share Premium	Tax Holiday Reserve.	Revaluation Surplus	Fair Value Gain /(Loss)	Retained Earnings	Non - Controlling Interests	Total amount in Taka
Balance as on 01.07.2023	**1,252,941,200**	**1,205,834,432**	**124,185,213**	**190,644,401**	**66,960**	**1,250,255,631**	**-**	**4,023,927,839**
Share Issued/Equity portion	-	-	-	-	-	-	70,000,000	**70,000,000**
Revaluation Surplus	-	**-**	-	(2,461,502)	-	2,461,502		**-**
Adjustment of Other Comprehensive Income	-	**-**	-	-	(66,960)	-		**(66,960)**
Other Comprehensive Income	-	-	-	-	(168,975)	-		**(168,975)**
IPO Expenses	-	(45,000)	-	-	-	-		**(45,000)**
Dividend For the year 2022-2023 @05.00 % Cash		-				(62,647,060)		**(62,647,060)**
Net Profit during the Year	-	-	-	-	-	293,128,442	(20,181)	**293,108,261**
Balance as on 30.06.2024	**1,252,941,200**	**1,205,789,432**	**124,185,213**	**188,182,899**	**(168,975)**	**1,483,198,516**	**69,979,819**	**4,324,108,104**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Dhaka.
Date: 26 October 2025

JMI HOSPITAL REQUISITE MANUFACTURING LTD. and its Subsidiary

Consolidated Statement of Cash Flows

For the year ended 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Cash flow from operating activities			
Cash Receipts from customers and others		1,635,289,990	1,832,326,107
Paid to suppliers and others		(1,297,077,735)	(1,461,730,734)
Income tax paid		(46,382,426)	(75,453,031)
Net cash generated from operating activities		**291,829,829**	**295,142,342**
Cash flow from investing activities			
Investment in Shares & Others		87,572,101	(87,780,539)
Dividend Received		1,360	-
Balance with inter company		(39,712,852)	(104,443,490)
Investment in subsidiary		(169,900,000)	(130,000,000)
Capital Work in Progress(CWIP)		(347,995,376)	(101,775,069)
Acquisition of Non-current Assets		(41,647,168)	(69,261,698)
Net cash generated from investing activities		**(511,681,935)**	**(493,260,796)**
Cash flow from financing activities			
Financing cost paid		(73,312,210)	(70,749,919)
Term Loan received/(paid)		(51,834,991)	(91,050,570)
Lease Finance received/(paid)-net off payment		4,855,568	(962,790)
Working capital loan received/(paid)		(5,829,814)	44,973,522
IPO Expenses		(282,500)	(45,000)
Share Money Deposit		143,483,775	-
Received from Share Capital		125,000,000	198,000,000
Dividend Paid		(79,150,692)	(69,412,164)
Rental Lease Liability Payment		2,219,277	(1,073,890)
Net cash generated from financing activities		**65,148,413**	**9,679,189**
Net cash Surplus/(Deficit) for the year		**(154,703,693)**	**(188,439,265)**
Cash & Cash Equivalents at the Beginning of the year		320,816,074	509,255,339
Effect of exchanges rate changes on cash and cash equivalents		44,184	-
Cash & Cash Equivalents at the End of the year		**166,156,564**	**320,816,074**
Net Operating Cash Flow Per Share (NOCFPS)	33A	**2.33**	**2.36**
Cash & Cash Equivalents as Statement of Cash Flows			320,816,074
Cheque in transit *			2,000,000
Total			**322,816,074**

* Details of this cheque in transit are mentioned in the relevant note 10.2A(iii)
Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Dhaka.
Date: 26 October 2025

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

Statement of Financial Position

As at 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
ASSETS			
Non-Current Assets			
Property, Plant & Equipment	4.00	1,740,681,529	1,841,128,359
Right of Use Assets	4.00	2,553,062	385,984
Capital Work in Progress(CWIP)	4.02	501,077,062	379,796,944
Investment in Subsidiary	4.04	299,900,000	130,000,000
		2,544,211,653	**2,351,311,287**
Current Assets			
Inventories	5.00	748,246,525	719,461,927
Inter Company Loan	6.00	745,212,197	705,499,345
Advance, Deposit & Prepayments	7.00	582,686,774	564,640,169
Accounts & Other Receivables	8.00	790,152,908	748,657,012
Investment in Shares & Others	9.00	156,719,814	244,014,160
Cash & Cash Equivalents	10.00	157,653,226	269,222,010
		3,180,671,444	**3,251,494,623**
Total Assets		**5,724,883,097**	**5,602,805,910**
EQUITY & LIABILITIES			
Equity			
Share Capital	11.00	1,252,941,200	1,252,941,200
Share Premium	11.01	1,205,506,932	1,205,789,432
Reserve & Surplus	12.00	310,107,867	312,199,137
Retained Earnings	13.00	1,634,015,727	1,483,235,995
		4,402,571,726	**4,254,165,764**
Non-Current Liabilities			
Term Loan (Non Current maturity)	14.00	153,573,581	147,653,053
Deferred Tax Liability	15.00	129,841,178	127,351,046
Lease Finance (Non-current maturity)	16.00	3,411,968	-
Rental Lease Liability	17.00	2,705,304	486,027
		289,532,031	**275,490,126**
Current Liabilities			
Lease Finance (Current maturity)	16.01	1,443,600	-
Term Loan (Current maturity)	14.01	78,224,259	135,979,778
Working Capital Loan	18.00	816,604,426	822,434,240
Liability Against Import	19.00	22,817,655	25,563,257
Account & Other Payables	20.00	43,468,575	60,315,464
Unclaimed Dividend	20.01	10,793,931	5,115,003
Loan from Director's & Others	21.00	7,756,976	7,756,976
Income Tax Liability	22.00	51,669,918	15,985,302
		1,032,779,340	**1,073,150,020**
Total Equity & Liabilities		**5,724,883,097**	**5,602,805,910**
Net Asset Value Per Share (NAV)	31.00	**35.14**	**33.95**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co. Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Dhaka.
Date: 26 October 2025
DVC: 2510260392AS831630

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Sales Revenue	23.01	1,670,955,448	1,870,145,496
Cost of Goods Sold	24.01	(1,152,507,718)	(1,289,909,629)
Gross Profit/(Loss)		**518,447,730**	**580,235,867**
Operating Expenses			
Administrative Expenses	25.01	(80,696,521)	(79,204,937)
Selling & Distribution Expenses	26.01	(54,628,842)	(57,561,388)
Total Operating Expenses		**(135,325,363)**	**(136,766,325)**
Operating Profit		**383,122,367**	**443,469,542**
Financial Expense	27.01	(55,302,210)	(70,749,919)
Net Profit After Financial Expenses		**327,820,157**	**372,719,623**
Income From Others Sources	28.01	5,863,192	12,338,071
Net Income before adjustment of WPPF		**333,683,349**	**385,057,694**
Workers' Profit Participation Fund		(15,889,684)	(18,336,081)
Net Profit Before Taxation		**317,793,665**	**366,721,613**
Provision for Income Tax Expense			
Current Tax		(82,063,205)	(82,512,363)
Deferred Tax		(2,459,535)	8,956,671
		(84,522,740)	**(73,555,692)**
Profit after Tax for the year		**233,270,925**	**293,165,921**
Other Comprehensive Income:			
Unrealized Gain: Fair value gain/(loss) of investment		108,780	(197,195)
Deferred Tax		(30,598)	28,220
		78,182	**(168,975)**
Total Comprehensive Income for the year		**233,349,107**	**292,996,946**
Basic Earning Per Share (EPS)	32.00	**1.86**	**2.34**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Dhaka.
Date: 26 October 2025
DVC: 2510260392AS831630

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

Statement of Profit or Loss and Other Comprehensive Income (Production)

For the year ended 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Sales Revenue	23.01	875,213,576	973,204,682
Cost of Goods Sold	24.01	(590,335,660)	(654,604,163)
Gross Profit/(Loss)		**284,877,916**	**318,600,519**
Operating Expenses			
Administrative Expenses	25.01	(40,986,777)	(41,500,772)
Selling & Distribution Expenses	26.01	(5,946,987)	(7,135,667)
Total Operating Expenses		**(46,933,764)**	**(48,636,439)**
Operating Profit		**237,944,152**	**269,964,080**
Financial Expense	27.01	(30,447,080)	(33,410,998)
Net Profit after financial Expenses		**207,497,072**	**236,553,082**
Income From Others Sources/(Loss)	28.01	2,805,886	9,064,043
Net Income before adjustment of WPPF		**210,302,958**	**245,617,125**
Workers Profit Participation Fund		(10,014,427)	(11,696,054)
Net Profit Before Taxation		**200,288,531**	**233,921,071**
Provision for Income Tax Expense			
Current Tax		(42,983,092)	(52,632,241)
Deferred Tax		(2,428,316)	8,829,012
		(45,411,408)	**(43,803,229)**
Profit after Tax for the year		**154,877,123**	**190,117,842**
Other Comprehensive Income:			
Unrealized Gain: Fair value gain/(loss) of investment		-	-
Deferred Tax		-	-
		-	**-**
Total Comprehensive Income for the year		**154,877,123**	**190,117,842**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Dhaka.
Date: 26 October 2025
DVC: 2510260392AS831630

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI HOSPITAL REQUISITE MANUFACTURING LTD.
Statement of Profit or Loss and Other Comprehensive Income (Trading)
For the year ended 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Sales Revenue	23.01	795,741,872	896,940,814
Cost of Goods Sold	24.01	(562,172,058)	(635,305,466)
Gross Profit/(Loss)		**233,569,814**	**261,635,348**
Operating Expenses			
Administrative Expenses	25.01	(39,709,744)	(37,704,165)
Selling & Distribution Expenses	26.01	(48,681,855)	(50,425,721)
Total Operating Expenses		**(88,391,599)**	**(88,129,886)**
Operating Profit		**145,178,215**	**173,505,462**
Financial Expense	27.01	(24,855,130)	(37,338,921)
Net Profit After Financial Expenses		**120,323,085**	**136,166,541**
Income From Others Sources	28.01	3,057,306	3,274,028
Net Income before adjustment of WPPF		**123,380,391**	**139,440,569**
Workers Profit Participation Fund		(5,875,257)	(6,640,027)
Net Profit Before Taxation		**117,505,134**	**132,800,542**
Provision for Income Tax Expense			
Current Tax		(39,080,113)	(29,880,122)
Deferred Tax		(31,219)	127,659
		(39,111,332)	**(29,752,463)**
Profit after Tax for the year		**78,393,802**	**103,048,079**
Other Comprehensive Income:			
Unrealized Gain: Fair value gain/(loss) of investment		108,780	(197,195)
Deferred Tax		(30,598)	28,220
		78,182	**(168,975)**
Total Comprehensive Income for the period		**78,471,984**	**102,879,104**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co. Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Dhaka.
Date: 26 October 2025
DVC: 2510260392AS831630

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2025

Particulars	Share Capital	Share Premium	Tax Holiday Reserve.	Revaluation Surplus	Fair Value Gain /(Loss)	Retained Earnings	Total amount in Taka
Balance as on 01.07.2024	**1,252,941,200**	**1,205,789,432**	**124,185,213**	**188,182,899**	**(168,975)**	**1,483,235,995**	**4,254,165,764**
Revaluation Surplus	-	-	-	(2,338,427)	-	2,338,427	**-**
Adjustment of Other Comprehensive Income	-	-	-	-	168,975	-	**168,975**
Other Comprehensive Income	-	-	-	-	78,182	-	**78,182**
IPO Expenses	-	(282,500)	-	-	-	-	**(282,500)**
Dividend For the year 2023-2024 10% Cash (Other than Sponsors & Directors Share Holder)		**-**				(84,829,620)	**(84,829,620)**
Net Profit during the Year	-	-	-	-	-	233,270,925	**233,270,925**
Balance as on 30.06.2025	**1,252,941,200**	**1,205,506,932**	**124,185,213**	**185,844,472**	**78,182**	**1,634,015,727**	**4,402,571,726**

For the year ended 30 June 2024

Particulars	Share Capital	Share Premium	Tax Holiday Reserve.	Revaluation Surplus	Fair Value Gain /(Loss)	Retained Earnings	Total amount in Taka
Balance as on 01.07.2023	**1,252,941,200**	**1,205,834,432**	**124,185,213**	**190,644,401**	**66,960**	**1,250,255,631**	**4,023,927,839**
Revaluation Surplus	-	**-**	-	(2,461,502)	-	2,461,502	**-**
Adjustment of Other Comprehensive Income	-	**-**	-	-	(66,960)	-	**(66,960)**
Other Comprehensive Income	-	-	-	-	(168,975)	-	**(168,975)**
IPO Expenses	-	(45,000)	-	-	-	-	**(45,000)**
Dividend For the year 2022-2023 @5% Cash		-				(62,647,060)	**(62,647,060)**
Net Profit during the Year	-	-	-	-	-	293,165,921	**293,165,921**
Balance as on 30.06.2024	**1,252,941,200**	**1,205,789,432**	**124,185,213**	**188,182,899**	**(168,975)**	**1,483,235,995**	**4,254,165,764**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Dhaka.
Date: 26 October 2025

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

Statement of Cash Flows

For the year ended 30 June 2025

Particulars	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Cash flow from operating activities			
Cash Receipts from customers and others		1,635,277,200	1,832,279,690
Paid to suppliers and others		(1,212,209,539)	(1,344,335,547)
Income tax paid		(46,378,589)	(75,439,106)
Net cash generated from operating activities		**376,689,072**	**412,505,037**
Cash flow from investing activities			
Investment in Shares & Others		87,572,101	(87,780,539)
Dividend Received		1,360	-
Balance with inter company		(39,712,852)	(104,443,490)
Investment in subsidiary		(169,900,000)	(130,000,000)
Capital Work in Progress(CWIP)		(121,280,118)	(72,731,828)
Acquisition of Non-current Assets		(41,647,168)	(69,261,698)
Net cash generated from investing activities		**(284,966,677)**	**(464,217,555)**
Cash flow from financing activities			
Financing cost paid		(73,312,210)	(70,749,919)
Term Loan received/(paid)		(51,834,991)	(91,050,570)
Lease Finance received/(paid)-net off payment		4,855,568	(962,790)
Working capital loan received/(paid)		(5,829,814)	44,973,522
IPO Expenses		(282,500)	(45,000)
Dividend Paid		(79,150,692)	(69,412,164)
Rental Lease Liability Payment		2,219,277	(1,073,890)
Net cash generated from financing activities		**(203,335,362)**	**(188,320,811)**
Net cash Surplus/(Deficit) for the year		**(111,612,967)**	**(240,033,329)**
Cash & Cash Equivalents at the Beginning of the year		269,222,010	509,255,339
Effect of exchanges rate changes on cash and cash equivalents		44,184	-
Cash & Cash Equivalents at the End of the year		**157,653,226**	**269,222,010**
Net Operating Cash Flow Per Share (NOCFPS)	**33.00**	**3.01**	**3.29**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Dhaka.

Date: 26 October 2025

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

Notes to the Financial Statements

for the year ended 30 June 2025

1.00 The Company and its Activities:

1.01 About the Company

JMI Hospital Requisite Mfg. Ltd. (JHRML) (herein after reffered to as JHRML or the Company) incorporated [C-72728(770)/08] as Private Limited Company as on 20 August 2008 under the Companies Act 1994. It is a joint venture company with Republic of South Korea and has set up its plant at Vitikandi, Gazaria, under Munshigonj district. It is a modern medical instruments and hospital equipments manufacturing plant in Bangladesh.

The company was converted to Public Limited Company as on 30 November 2014.

The consolidated financial statements of the Company as at and for the year ended 30 June 2025 comprise the Company's and its subsidiaries (together referred to as the "Group" and individually as "Group entities") and the Group's interest in associates and jointly controlled entities.

1.02 Nature of the Business

It is a modern medical instruments and hospital equipment's manufacturer in Bangladesh and besides that it has trading & distribution business of other medical instruments.

a) **Manufacturing products:** Autoclave, JMI Respirator (KN-95), IV cannula, Face Mask ,scalp vein set, Blood transfusion set, Bulk Needle, IV infusion set, Urine Drainage Bag, Drain Bag, Priming Set, Film Making , Plunger, Catheter.

b) **Trading Products:** Latex Surgical Gloves, Latex examination gloves, Latex Foley Catheter, Male External Catheter, True Result Meter, True Result Twist Meter, True Balance 25's Strips, True Result 25's Strips, Plastic Vacuum Blood Collection Tube, Glass Vacuum Blood Collection Tube, Blood Collection Needle, NIPRO Dialyzer Sureflux, NIPRO Dialyzer Elisio, NIPRO Blood Tubing Set, AVF Fistula Needle, NIPRO Dialysis Machine, Heart Stent:- Coronary Stent- BMS, Coronary Stent-DES, PTCA Ballonne Catheter- NC, PTCA Ballonne Catheter- CTO, PTCA Ballonne Catheter SC etc.

1.03 Registered Office

The registered office of the company is situated at 72/C, Progoti Shoroni, Middle Badda, Dhaka-1212.

1.04 Factory:

The factory of the Company is situated at Vitikandi, Gazaria, Munshigonj, Bangladesh.

1.05 Number of Employees

The number of employee at the end of the year was 650.

1.06 Description of subsidiaries

The company, a 65.00% owned subsidiary of JMI Specialized Hospital Limited (JSHL), was incorporated on 6 August 2023 as a private limited company under the Companies Act 1994. The principal activities of the company are the business of General medical services and JSHL operates through the following business segments: Hospital, Medical Services, Diagnostics, Pharmacy, and Others. It offers internal medicine, neurology, diabetes, endocrinology, and nephrology services etc.

2.00 Basis for the Preparation of Financial Statements:

2.01 Basis of Accounting

The elements of the consolidated financial statements have been prepared on Historical Cost concept except Land and Building which is stated at revalued amount, and on accrual basis in compliance with the Companies Act 1994, the Securities and Exchange Rules, 1987, The International Accounting Standards (IAS) and The International Financial Reporting Standards (IFRS).

2.02 Statement of Compliance

The consolidated financial statements have been prepared in compliance with the requirements of the Companies Act 1994, The Securities & Exchange Rules 1987, the listing regulation of Dhaka and Chittagong stock exchange and other relevant local laws as applicable and in accordance with the International Financial Reporting Standards (IFRSs).

2.03 Applicable Accounting Standards & Financial Reporting standards

The following IASs and IFRSs are applicable for the financial statements for the year under review:

IAS 1	Presentation of financial statements
IAS 2	Inventories
IAS 7	Statement of cash flows
IAS 8	Accounting policies, changes in accounting estimates and errors
IAS 10	Events after the reporting period
IAS 12	Income taxes
IAS 16	Property, plant and equipment
IAS 19	Employee benefits
IAS 21	The effects of changes in foreign exchange rates
IAS 23	Borrowing costs
IAS 24	Related party disclosures
IAS 32	Financial instruments: Presentation
IAS 33	Earnings per share
IAS 36	Impairment of assets
IAS 37	Provisions, contingent liabilities and contingent assets
IFRS 7	Financial instruments: disclosures
IFRS 8	Operating Segments
IFRS 9	Financial instruments
IFRS 13	Fair value measurement
IFRS 15	Revenue from contracts with customers
IFRS 16	Leases

2.04 Use of Estimates and Judgments

The preparation of consolidated financial statements in conformity with the IFRSs including IASs require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure during and at the date of the consolidated financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates are recognized in the period in which the estimates is revised and in any future periods affected as required by IAS 8: Accounting Policies, Changes in Accounting Estimates and Errors.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include depreciation, inventory valuation, accrued expenses, reserves, contingencies and other payable.

2.05 Going Concern

The Company has adequate resources to continue in operation for foreseeable future. For this reason, the board of directors continues to adopt going concern basis in preparing the consolidated financial statements. The current credit facilities and resources of the company provide sufficient funds to meet the present requirements of its existing businesses and operations.

3.00 Significant Accounting Policies

The accounting principles and policies in respect of material items of financial statements set out below have been applied consistently to all periods presented in these financial statements.

3.01 Revenue Recognition

In compliance with the requirements of IFRS 15-Revenue from contracts with customers, The company recognizes revenue when performance obligations in relation to sales has been transferred by the company. Revenue from sales is exclusive of VAT. Rental income is recognized when accrued on a time proportion basis.

3.02 Property, Plant & Equipment

3.2.1 Recognition and Measurement

Property, Plant and Equipment are recognized, when and only when the necessary recognitions criteria set out in IAS 16: Property, Plant & Equipment are met, means it is probable that future economic benefits associated with the asset will be flow to the Company, controlled by the company and the cost of the asset can be measured reliably. Items of property, plant and equipment are measured at cost/revaluation less accumulated depreciation and accumulated impairment losses.

Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the asset to a working condition for its intended use and the present value of dismantling and removing the items and restoring the site on which they are located if any.

3.2.2 Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

3.2.3 Depreciation

Depreciation is the systematic allocation of depreciable amount of an asset over it's useful life, In accordance with the provisions of IAS 16: Property, Plant and Equipment. depreciation has been charged from date of purchase or ready to use for addition of fixed assets. Depreciation is charged on all fixed assets except land and land development on reducing balance method at the following rates:

Sl No.	Name of Assets	% of Depreciation	
		Production Unit	Trading Unit
01	Land and Land Development	0%	0%
02	Factory Building	5%	0%
03	Machineries	10%	20%
04	Furniture and Fixture	10%	10%
05	Office Equipment	15%	15%
06	Electrical Installation and Equipment	10%	10%
07	Computer and Other Equipment	10%	10%
08	Motor Vehicles	20%	20%

The company's policy is to transfer excess depreciation of revalued assets from revaluation surplus to retained earnings through the Statement of Change in Equity.

3.2.4 Retirements and Disposal

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain loss on such disposal is reflected in Statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets at disposal date and net sales proceeds. When revalued assets are sold or disposed, the balance of revaluation reserve is transferred to retained earnings.

3.2.5 Revaluation of Property, Plant and Equipment

The Revaluation surplus, difference between revalued amount and carrying value of assets at revaluation date, is recognized as revaluation reserve after recognizing necessary deferred tax arisen on revaluation reserve. The excess deprecation difference between deprecation at revalued amount and depreciation at cost value is being transferred from revaluation reserve to retained earrings through statement of changes in equity.

3.03 IFRS 16 : Leases

IFRS 16 introduces new requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance lease and requiring the recognition of a right-of-use asset and a lease liability at commencement for all leases, except for short-term leases and leases of low value assets when such recognition exemptions are adopted. In contrast to lessee accounting, the requirements for lessor accounting have remained largely unchanged. Details of these new requirements and impact of the adoption of IFRS 16 on the Company's financial statements is described below.

The date of initial application of IFRS 16 for the Company is 01 July 2019. The Company has applied IFRS 16 using the cumulative catch-up approach. The Company utilized the option to measure the right-of-use asset at an amount equal to the lease liability in accordance with para C8 of IFRS 16 at the date of initial application. This approach does not require restatement of comparatives, which continue to be presented under IAS 17 and IFRIC 4.

IFRS 16 changes how the Company accounts for leases previously classified as operating leases under IAS 17, which were off balance sheet. Applying IFRS 16, for all leases (except as noted below), the Company:

- Recognises right-of-use assets and lease liabilities in the separate statement of financial position, initially measured at the present value of the future lease payments, with the right-of-use asset adjusted by the amount of any prepaid or accrued lease payments in accordance with IFRS 16:C8(b)(ii);
- Recognises depreciation of right-of-use assets and interest on lease liabilities in the consolidated statement of profit or loss;
- Separates the total amount of cash paid into a principal portion (presented within financing activities) and interest (presented within financing activities) in the consolidated statement of Cash flows.

Under IFRS 16, right-of-use assets are tested for impairment in accordance with IAS 36.

For short-term leases (lease term of 12 months or less) and leases of low-value assets, the Company has opted to recognize a lease expense on a straight-line basis as permitted by IFRS 16. This expense is presented in profit or loss. The Company has used the following practical expedients when applying the cumulative catch-up approach to leases previously classified as operating leases applying IAS 17.

- The Company has applied a single discount rate to a portfolio of leases with reasonably similar characteristics.
- The Company has elected not to recognize right-of-use assets and lease liabilities to leases for which the lease term ends within 12 months of the date of initial application.
- The Company has excluded initial direct costs from the measurement of the right-of-use asset at the date of initial application.
- The Company has used hindsight when determining the lease term when the contract contains options to extend or terminate the lease.

3.04 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. The company is recognising financial instrument in its financial statements when it becomes a party under the instrument.

3.4.1 Financial Assets

Financial assets of the company include cash and cash equivalents, accounts receivable and other receivables. The company initially recognizes receivable on the date they are originated. All others financial assets are recognized initially on the date at which the company becomes a party to the contractual provisions of the transaction. The company derecognizes a financial asset when and only when the contractual rights or probabilities of receiving the cash flows from the asset expire or it transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risk and rewards of ownership of the financial asset are transferred.

3.4.1(a) Investment in Shares

Investment in shares of listed companies are carried in the statement of financial position at fair value based on DSE quoted price at the year end and the gain/loss thereon were accounted for through other comprehensive income considering it as “Available – for – Sale” financial assets.
Investment in other shares is carried in the statement of financial position at cost.

3.4.1(b) Accounts Receivable

Accounts receivable are created at original invoice amount less any provisions for doubtful debts. Provisions are made where there is evidence of a risk of non-payment, taking into account aging, previous experience and general economic conditions. When an accounts receivable is determined to be uncollected it is written off, firstly against any provision available and then to the statement of profit or loss and other comprehensive income.

3.4.1(c) Cash and Cash Equivalents

Cash and Cash Equivalents are comprised of cash in hand and cash at bank that are readily convertible to known amount of cash and that are subject to an insignificant risk of change in value.

3.4.2 Financial Liability

Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. Financial liabilities include payable for expenses, liability for capital expenditure and other current liabilities.

3.05 Impairment

(a) Financial Assets

Accounts receivable and other receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effects on the estimated future cash flows of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy etc.

(b) Non-Financial Assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impairment loss if, and only if, the recoverable amount of the asset is less than its carrying amount. Impairment loss is recognized immediately in profit or loss, unless the asset is carried at revalued amount. Any impairment loss of a revalued asset shall be treated as a revaluation decrease. WIP are valued on the basis of stage of completion and finished goods are valued at cost of material plus standard conversion

3.06 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present condition and realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale. WIP are valued on the basis of stage of complication and finished goods are valued at cost of material plus standard conversion cost.

3.07 Provisions

Provisions and accrued expenses are recognozed in the financial statements in line with the International Accounting Standards (IAS) 37 "Provisions, Contingent Liabilities and Contingent Assets" when:

- The company has a legal or constructive obligation as a result of past events.
- It is probable that an outflow of economic benefit will be required to settle the obligations.
- A reliable estimate can be made of the amount of the obligations.

3.08 Income Tax Expenses:

Income tax expenses comprises of current and deferred tax. Income tax expenses is recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted for in accordance with the requirements of IAS 12: Income Tax.

Current Tax

Current tax is the expected tax payable on the taxable income for the period/year and any adjustment to tax payable in respect of previous years.

Deferred Tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and are accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognized for all taxable temporary difference. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which such differences can be utilized. Deferred tax is charged or credited to the Statement of Profit or Loss and Other Comprehensive Income.

3.09 Interest Income

Interest income is recognized when accrued on a time proportion basis.

3.10 Borrowing Cost

Interest and other cost incurred by the company in connection with the borrowings of funds are recognized as expenses in the year in which they are incurred unless such borrowing cost related to acquisition/construction of assets in progress that are capitalized as per IAS 23: 'Borrowing Costs'.

3.11 Employee Benefits

The company maintains defined contribution plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective agreements/trust deeds.

The company has accounted for and disclosed employee benefits in compliance with the provision of IAS 19: Employee Benefits.

Confirmed employees of the company are entitled to get provident fund where both the employee's and employer's contribution is respectively 7% which is recognized.

The company provides 5% of its profit before tax after charging contribution to WPPF in accordance with the Bangladesh Labor Act 2006 as amended in 2013.

3.12 Foreign Currency Transaction

The financial records of the company are maintained and the financial statements are stated in Bangladesh Taka. Any foreign currency transactions are recorded at Bangladeshi taka after converting into Taka by the exchange rate ruling on the date of transaction and the year balance at foreign currency are converted into Bangladeshi taka at the exchange rate prevailing on the reporting date as per IAS-21: The effects of exchanges in foreign currency rate.

3.13 Payable and Accruals

Liabilities are recognized for amounts to be paid in future date for the goods and services received by the Company up to 30 June 2025 and incorporated in the Financial Statements.

3.14 Contingent Liability

There was no claim against the company not acknowledge as debt as on 30 June 2025.

3.15 Events after the Reporting Period

Even after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

3.16 Financial Risk Management

The Board of Directors has overall responsibility for the establishment and oversight of the Company's financial risk management. The responsibility also includes developing and monitoring the Company's risk management policies. To assist the Board in discharging its oversight responsibility, management has been made responsible for identifying, monitoring and managing the Company's financial risk exposures.

3.17 Market Risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters while optimizing returns.

3.18 Price Risk

Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market price (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The company does not have any financial instrument that expose the price risk.

3.19 Components of Financial Statements

The presentation of Financial Statements is in accordance with guidelines provided by IAS 1: Presentation of Financial Statements.

The Financial Statements comprises :

a) a Statement of Financial Position as at June 30, 2025;
b) a Statement of Profit or Loss and Other Comprehensive Income for the year ended June 30, 2025;
c) a Statement of Changes in Equity for the year ended June 30, 2025;
d) a Statement of Cash Flows for the year ended June 30, 2025;
e) Notes, comprising summary of significant accounting policies and explanatory information.

3.20 Reporting Period

The financial statements cover the accounting year from 01 July 2024 to 30 June 2025.

3.21 Comparative Information

Comparative Information has been disclosed in respect of the year June 30, 2025 for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period financial statements.

JMI HOSPITAL REQUISITE MANUFACTURING LTD.
Notes to the Financial Statements - As at 30 June 2025

			Amount in BDT	
			30 June 2025	30 June 2024
04A	**Consolidated Property, Plant & Equipment**			
JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**4.00**	1,740,681,529	1,841,128,359
JMI SPECIALIZED HOSPITAL LIMITED	**Note :**	**4.01**	-	-
			1,740,681,529	**1,841,128,359**
4.00	**JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Property, Plant & Equipment**			
A .Factory :				
Balance as per last account			1,815,267,282	1,891,259,844
Add : Addition during the year			42,003,168	64,433,528
			1,857,270,450	**1,955,693,372**
Less : Depreciation During the Year			136,162,828	140,426,090
Sub Total:			**1,721,107,622**	**1,815,267,282**
The details of Fixed Assets Schedule has been shown in Annexure- 1				
B .Trading :				
Balance as per last account			26,247,061	26,117,628
Add : Addition during the year			-	5,177,089
			26,247,061	**31,294,717**
Less : Depreciation During the Year			4,120,092	5,047,656
Sub Total:			**22,126,969**	**26,247,061**
The details of Fixed Assets Schedule has been shown in Annexure- 2				
Total (A+B): Written Down Value			1,743,234,591	1,841,514,343
Less :Right of Use Assets			**2,553,062**	**385,984**
Written Down Value			**1,740,681,529**	**1,841,128,359**

Right of Use Assets (The details of Fixed Assets Schedule has been shown in Annexure- 1 & 2)

1. The land and building & other construction of the company was pledged as security for long term loan.
2. The Land and building are carried at revaluation. An Independent valuer named Malek Siddiqui Wali, Chartered Accountants an enlisted valuer of BSEC revalued land and Factory Building of the company as on 30 June 2014, following current cost method. Such revaluation in to a revaluation surplus aggregating an amount of Tk. 220,452,087.

4.01	**JMI SPECIALIZED HOSPITAL LIMITED.:Property, Plant & Equipment**			
Balance as per last account			-	-
Add : Addition during the year			-	-
			-	**-**
Less : Depreciation During the Year			-	-
Written Down Value			**-**	**-**
4.02A	**Consolidated Capital Work in Progress(CWIP)**			
JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**4.02**	501,077,062	379,796,944
JMI SPECIALIZED HOSPITAL LIMITED	**Note :**	**4.03A**	255,758,499	29,043,241
			756,835,561	**408,840,185**
4.02	**JMI HOSPITAL REQUISITE MANUFACTURING LTD.: Capital Work in Progress(CWIP)**			
The above balances are made up as follows:				
Balance as per last account			379,796,944	307,065,116
Add : Addition During the year	**Note :**	**4.03**	121,280,118	72,731,828
			501,077,062	**379,796,944**
4.03	**Addition During the period**			
Factory Buildings BCT Project			1,663,168	6,381,121
Furniture & Fixture BCT Project			13,700	252,185
Machinery (Not ready to use) BCT Project			119,603,250	66,098,522
			121,280,118	**72,731,828**

			Amount in BDT	
			30 June 2025	30 June 2024
4.03A	**JMI SPECIALIZED HOSPITAL LIMITED.: Capital Work in Progress(CWIP)**			
	The above balances are made up as follows:			
	Balance as per last account		29,043,241	-
	Add : Addition During the year	**Note : 4.03B**	226,715,258	29,043,241
			255,758,499	**29,043,241**
4.03B	**Addition During the period**			
	Interior Decoration-Civil CWIP		226,698,202	27,611,511
	Network Installation-CWIP		17,056	1,431,730
			226,715,258	**29,043,241**
4.04	**Investment in Subsidiary**			
	JMI SPECIALIZED HOSPITAL LIMITED		299,900,000	130,000,000
			299,900,000	**130,000,000**

JMI Hospital Requisite Manufacturing Ltd. invested in JMI Specialized Hospital Limited to purchase 21,000,000 ordinary share of Tk 10 each as its 65% share holding as well as invested as share money deposit Tk.89,900,000. JMI Specialized Hospital Ltd(JSHL) will carry out the business of General medical services and JSHL operates through the following business segments: Hospital, Medical Services, Diagnostics, Pharmacy, and Others. It offers internal medicine, neurology, diabetes, endocrinology, and nephrology services etc.

05A	**Consolidated Inventories**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**5.00**	748,246,525	719,461,927
	JMI SPECIALIZED HOSPITAL LIMITED			-	-
				748,246,525	**719,461,927**
5.00	**Inventories**				
	The above balances are made up as follows:				
	Raw & Packing Materials			227,504,797	219,708,478
	Work-in-Process			93,940,893	103,687,567
	Finished Goods			426,800,835	396,065,882
				748,246,525	**719,461,927**

Year end inventory counting were taken place by the management team as well as in the presence of auditors and appropriate adjustment were made, where applicable.

06A	**Consolidated Inter Company Loan**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**6.00**	745,212,197	705,499,345
	JMI SPECIALIZED HOSPITAL LIMITED			-	-
				745,212,197	**705,499,345**
6.00	**Inter Company Loan**				
	The above balance are made up as follows:				
	JMI Industrial Gas Ltd.			87,269,882	118,497,816
	JMI Export-Import Company Ltd.			124,482,204	109,492,527
	JMI LPG & Petroleum Ltd.			9,454,733	8,316,230
	JMI Vaccine Ltd.			447,298,079	393,436,131
	JMI Printing & Packaging Ltd.			76,707,300	75,756,641
				745,212,197	**705,499,345**

Note: The above amount is unsecured but considered good & bears interest consider the commercial bank's interest rate.
The Inter Company Loan to Related Parties have been approved through Board Resolution during the meeting held on October 26, 2025, and subject to approval of up-coming Annual General Meeting.

07A	**Consolidated Advance, Deposit & Prepayments**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**7.00**	582,686,774	564,640,169
	JMI SPECIALIZED HOSPITAL LIMITED	**Note :**	**7.04**	224,298,745	127,969,905
				806,985,519	**692,610,074**

			Amount in BDT	
			30 June 2025	30 June 2024

7.00 JMI HOSPITAL REQUISITE MANUFACTURING LTD. :Advance, Deposit & Prepayments

The above balances are made up as follows:

Advance against Others :

Advance Against Construction Materials			21,099,460	21,455,460
Advance Against Others			80,196,126	80,419,383
Advance Against Security Deposit			27,219,850	21,414,771
Comilla Palli Biddut Samity			3,163,500	3,163,500
LC Margin & Immatured LC			171,441,664	174,275,543
Advance Income Tax	**Note :**	**7.01**	-	-
Advance Against Purchase			279,566,174	263,911,512
			582,686,774	**564,640,169**

7.01 Advance Income Tax

Opening			-	-
Add: Addition During the year	**Note :**	**7.02**	46,378,589	75,439,106
Less: Transferred to Provison of income tax	**Note :**	**22.00**	(46,378,589)	(75,439,106)
Total			-	-

7.02 Advance Income Tax

Production Unit				
Source Tax			20,096,330	25,677,663
Tax Paid at Import Stage			15,548,031	18,693,990
Sub Total			**35,644,361**	**44,371,653**
Trading Unit				
Tax paid at Import stage			1,000,392	4,494,044
TDS from Interest on FDR and Source			265,738	7,742,766
TDS from Interest on Bank Deposit			9,880	30,561
Income tax paid			9,458,218	18,800,082
Sub Total			**10,734,228**	**31,067,453**
Total			**46,378,589**	**75,439,106**

7.03 Maturity Analysis

Realisable/ Adjustable within 1 year	579,523,274	561,476,669
Realisable/Adjustable after 1 year	3,163,500	3,163,500
	582,686,774	**564,640,169**

Disclosure for Advance, Deposit and Prepayment to related party must be mentioned in following way:

Balance with the directors	**-**	**-**
Balance with the sister concern	-	-
Balance with the others	582,686,774	564,640,169
	582,686,774	**564,640,169**

As per assessment of directors, above balances are considered good and realisable/adjustable within the due course of operation.

7.04 JMI SPECIALIZED HOSPITAL LIMITED. :Advance, Deposit & Prepayments

The above balances are made up as follows:

Advance against Others :

Advance Against Construction Materials			172,013,274	91,318,217
Advance Against Security Deposit			50,479,500	36,000,000
Advance Against Others			1,805,971	651,688
Advance Income Tax	**Note :**	**7.05**	-	-
			224,298,745	**127,969,905**

7.05 Advance Income Tax

Opening			-	-
Add: Addition During the year	**Note :**	**7.06**	3,837	13,925
Less: Transferred to Provision of income tax			(3,837)	(13,925)
Total			-	-

		Amount in BDT	
		30 June 2025	30 June 2024
7.06	**Advance Income Tax**		
	Source Tax	3,837	13,925
	Sub Total	**3,837**	**13,925**
08A	**Consolidated Accounts & Other Receivable**		
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	790,152,908	748,657,012
	JMI SPECIALIZED HOSPITAL LIMITED	-	-
		790,152,908	**748,657,012**
8.00	**Accounts & Other Receivable**		
	Accounts Receivable **	789,816,650	748,621,732
	Receivable from PF Accounts for Forfeited Amount	336,258	35,280
		790,152,908	**748,657,012**
	**** Accounts Receivable Balances are made up as follows:**		
	Opening Balance	748,621,732	697,763,901
	Add: Sales during the period	1,670,955,448	1,870,145,496
	Balance after addition	**2,419,577,180**	**2,567,909,397**
	Less: Realisation during the period	1,629,760,530	1,819,287,665
	Closing Balance	**789,816,650**	**748,621,732**
	Subsequently the receivables have been realized and ageing are as follows:		
	Receivable Ageing:		
	Invoiced 0-30 Days	101,254,495	269,428,961
	Invoiced 31-60 Days	275,646,011	359,413,293
	Invoiced 61-90 Days	213,250,496	68,274,302
	Invoiced 91-180 Days	199,665,649	51,505,176
	Invoiced 181-365 Days	-	-
	Invoiced over 365 Days	-	-
	Total Receivable Amount	**789,816,650**	**748,621,732**
	Trade receivables disclosure as per Schedule-XI, Part-I, of the Companies Act, 1994		
	Receivable Ageing:		
	Debts less than 06 months	789,816,650	748,621,732
	Other debts less provision	-	-
	Total Receivable Amount	**789,816,650**	**748,621,732**
	Debts considered good and secured	789,816,650	748,621,732
	Debts considered good without debtors personal security	-	-
	Debts considered doubtful or bad	-	-
	Debts due from companies same management	-	-
	Maximum debt due by director or officers at any time	-	-
		789,816,650	**748,621,732**
	Balance with the directors	-	-
	Balance with the sister concern	522,143,420	501,507,695
	Balance with the others	267,673,230	247,114,037
		789,816,650	**748,621,732**
09A	**Consolidated Investment in Shares & Others**		
	JMI HOSPITAL REQUISITE MANUFACTURING LTD. Note : 9.00	156,719,814	244,014,160
	JMI SPECIALIZED HOSPITAL LIMITED	-	-
		156,719,814	**244,014,160**

		Amount in BDT	
		30 June 2025	30 June 2024

9.00 Investment in Shares & Others

The above balances are made up as follows:

Other Investment

i) In 1,360 Shares of JMI Syringes & Medical Devices Ltd.(Face value of Tk. 10.00) (Listed company, Market value Tk. 130.50 per share & Average Cost Tk. 265.90 on 30 June 2025)	9.01	177,480	153,700
ii) In 8,150 Shares of Tk. 10 each of JMI Sonlu Electric Appliance Co. Ltd		81,500	81,500
iii) Investment in FDR	9.02	2,685,834	90,003,960
iv) Advance against share money-JMI Sonlu Electric Appliance Co.		153,775,000	153,775,000
		156,719,814	**244,014,160**

The Investment in JMI Sonlu Electric Appliance Co. Ltd a non-quoted share is stated at cost as determine the fair value of non-quoted share is cumbersome. However, difference between the fair value of investment and cost of investment are not material.

9.01 Details of Investment in shares of listed securities are as below:

Particulars	Cost Price	Market Price	Considerable Value 30 June 2025	Considerable Value 30 June 2024
JMI Syringes & Medical Devices Ltd.	265,895	177,480	177,480	153,700

The difference between Market price and Cost price is recognized as unrealized gain and accounted for in the Statement of Profit or Loss and Other Comprehensive Income.

9.02 Details of Investment in FDR are as below:

Bank Name	FDR Number	30.06.2025	30.06.2024
Janata Bank Ltd	0888003031962	2,685,834	2,509,472
Pubali Bank Ltd	0939104066269	-	51,886,266
Pubali Bank Ltd	0939104066273	-	35,608,222
	Total	**2,685,834**	**90,003,960**

10A Consolidated Cash & Cash Equivalents

Consolidated Cash in hand	**Note : 10.1A**	90,081,067	91,345,230
Consolidated Cash at Bank	**Note : 10.2A**	76,075,497	229,470,844
		166,156,564	**320,816,074**

10.1A Consolidated Cash in hand

Cash in Hand (Factory)	7,903,097	3,549,423
Cash in Hand (Sales Center)	36,191,969	45,601,863
Cash in Hand (Head Office)	45,986,001	42,193,944
	90,081,067	**91,345,230**

10.2A Consolidated Cash at Bank

BANK ACCOUNTS OF JMI HOSPITAL REQUISITE MANUFACTURING LTD.

DBBL, A/C # 1011100033914	2,231,921	40,991,057
Janata Bank Ltd., CD # 001020283	1,647,477	30,257,723
Janata Bank Ltd., CD # 0100153872486	982,560	950,891
Janata Bank Ltd., CD # 010240402330	2,620,231	2,633,668

	Amount in BDT	
	30 June 2025	30 June 2024
Janata Bank Ltd., CD # 0100253429130	1,131,774	2,730,690
Janata Bank Ltd., CD # 0100267047868	7,328,748	-
Pubali Bank Ltd, A/C# 0106102001260/0939102001259	493	14,072,375
Pubali Bank Ltd, Factory A/c # 3452901008490	68,644	62,317
Pubali Bank Ltd. CD A/C # 2905901043904	2,020,022	26,194,209
Pubali Bank Ltd. STD A/C No. # 2905102001064	1,681,139	3,209,623
Pubali Bank Ltd, A/C# 0106102001467/0939102001466	17,891	1,241,051
Pubali Bank Ltd, A/C# 40131301714-134046/01711-401315(held in USD)	476,487	1,246,042
DBBL , A/C # 101.110.42246	31,228,057	33,126,962
DBBL , A/C # 101.110.56995	10,151,794	1,882,139
DBBL , A/C # 108.120000.5976	3,211,057	3,271,690
Standard Bank Ltd, CD A/C # 00233012209	32,521	154,235
Brac Bank Ltd, A/C# 1501204394979001	2,414,659	16,593,625
Uttara Bank Ltd, A/C# 142012200215080	507,787	29,213
HSBC , A/C # 007-027691-011	99,655	99,655
Mutual Trust Bank Ltd, A/C # 00460210008905	187,230	188,070
	68,040,146	**178,935,235**
BANK ACCOUNTS OF SUBSIDIARY:		
Janata Bank Ltd., CD # 0100248987132	3,760,100	5,081,652
Pubali Bank Ltd, A/C# 3478102001960	3,896,469	45,453,957
Pubali Bank A/C # 0939901049779	2,328	-
Pubali Bank A/C NO: 3478901023844	167,314	-
DBBL A/C# 1711100164718	209,141	-
	8,035,351	**50,535,609**
Cheque in Transit *	-	2,000,000
Cheque in Transit *	**-**	**2,000,000**
Consolidated Cash at Bank	**76,075,497**	**231,470,844**

i) The bank balances reconciliation has been performed with respective bank statements and found in order.

ii) All Cash & Cash Equivalents are readily available for use.

* iii) This amount represented a cheque in transit at the end of previous year in the financial statement of JMI SPECIALIZED HOSPITAL LIMITED, which has been realized during the current year. In the prior year's financial statements, It was presented under Call In Arrear. For the fair Presentation, the comparative figure has been reclassified to Cash & Cash Equivalents in accordance with paragraph 41 of IAS 1.

10.00 Cash & Cash Equivalents

The above balance are made up as follows:

Cash in Hand :		
Cash in Hand (Factory)	7,903,097	3,549,423
Cash in Hand (Sales Center)	36,191,969	45,601,863
Cash in Hand (Head Office)	45,518,014	41,135,489
	89,613,080	**90,286,775**
Cash at Bank:		
DBBL, A/C # 1011100033914	2,231,921	40,991,057
Janata Bank Ltd., CD # 001020283	1,647,477	30,257,723
Janata Bank Ltd., CD # 0100153872486	982,560	950,891
Janata Bank Ltd., CD # 010240402330	2,620,231	2,633,668
Janata Bank Ltd., CD # 0100253429130	1,131,774	2,730,690
Janata Bank Ltd., CD # 0100267047868	7,328,748	-
Pubali Bank Ltd, A/C# 0106102001260/0939102001259	493	14,072,375
Pubali Bank Ltd, Factory A/c # 3452901008490	68,644	62,317
Pubali Bank Ltd. CD A/C # 2905901043904	2,020,022	26,194,209
Pubali Bank Ltd. STD A/C No. # 2905102001064	1,681,139	3,209,623
Pubali Bank Ltd, A/C# 0106102001467/0939102001466	17,891	1,241,051
Pubali Bank Ltd, A/C# 40131301714-134046/01711-401315(held in USD)	476,487	1,246,042
DBBL , A/C # 101.110.42246	31,228,057	33,126,962
DBBL , A/C # 101.110.56995	10,151,794	1,882,139
DBBL , A/C # 108.120000.5976	3,211,057	3,271,690

	Amount in BDT	
	30 June 2025	30 June 2024
Standard Bank Ltd, CD A/C # 00233012209	32,521	154,235
Brac Bank Ltd, A/C# 1501204394979001	2,414,659	16,593,625
Uttara Bank Ltd, A/C# 142012200215080	507,787	29,213
HSBC , A/C # 007-027691-011	99,655	99,655
Mutual Trust Bank Ltd, A/C # 00460210008905	187,230	188,070
	68,040,146	**178,935,235**
	157,653,226	**269,222,010**

i) Physical cash counting were taken place by the management team as well as in the presence of auditors.
ii) The bank balances reconciliation has been performed with respective bank statements and found in order.
iii) All Cash & Cash Equivalents are readily available for use.

11A Consolidated Share Capital

a) **Issued, Subscribed & Paid up Share Capital**

125,294,120 Ordinary Shares of BDT. 10/- each fully paid up in each	1,252,941,200	1,252,941,200

11.00 Share Capital

a) **Authorized Capital**

300,000,000 Ordinary Shares of BDT. 10/- each	3,000,000,000	3,000,000,000

b) **Issued, Subscribed & Paid up Share Capital**

125,294,120 Ordinary Shares of BDT. 10/- each fully paid up in each	1,252,941,200	1,252,941,200

c) **Composition of Shareholdings:**

Particulars	As of 30 June 2025		As of 30 June 2024	
	No. of Shares	%	No. of Shares	%
Sponsors & Directors :				
Bangladeshi	35,713,420	28.50%	35,713,420	28.50%
Foreign	4,751,080	3.79%	4,751,080	3.79%
Sub-Total	**40,464,500**	**32.30%**	**40,464,500**	**32.30%**
Institution	54,898,650	43.82%	54,274,744	43.32%
General Public	29,930,970	23.89%	30,554,876	24.39%
Total	**125,294,120**	**100.00%**	**125,294,120**	**100.00%**

d) **Classification of Shareholders by Holding (as per Folio & BO ID):**

Name of Shareholders	As at 30.06.2025			As at 30.06.2024		
	No. of Holders	No. of Shares	%	No. of Holders	No. of Shares	%
Upto 500 Shares	35,839	2,707,396	2.16%	42,350	3,153,309	2.52%
From 501 to 5,000 Shares	4,161	7,291,771	5.82%	4,324	7,312,075	5.84%
From 5,001 to 10,000 Shares	540	3,997,497	3.19%	526	3,941,290	3.15%
From 10,001 to 20,000 Shares	261	3,859,277	3.08%	243	3,544,031	2.83%
From 20,001 to 30,000 Shares	95	2,374,173	1.89%	92	2,377,678	1.90%
From 30,001 to 40,000 Shares	38	1,338,988	1.07%	41	1,451,244	1.16%
From 40,001 to 50,000 Shares	30	1,390,689	1.11%	34	1,591,648	1.27%
From 50,001 to 1,00,000 Shares	51	3,786,326	3.02%	57	4,200,970	3.35%
From 1,00,001 to 10,00,000 Shares	40	10,370,275	8.28%	44	10,441,063	8.33%
From 10,00,001 and above Shares	12	88,177,728	70.38%	12	87,280,812	69.66%
Total	**41,067**	**125,294,120**	**100%**	**47,723**	**125,294,120**	**100.00%**

11.01A Consolidated Share Premium

JMI HOSPITAL REQUISITE MANUFACTURING LTD.	1,205,506,932	1,205,789,432
JMI SPECIALIZED HOSPITAL LIMITED	-	-
Total	**1,205,506,932**	**1,205,789,432**

		Amount in BDT	
		30 June 2025	30 June 2024
11.01	**Share Premium**		
	The above balance are made up as follows:		
	Opening Share Premium	1,205,789,432	1,205,834,432
	Add: New Share Issue at premium	-	-
	Less: IPO Expenses	282,500	45,000
	Total	**1,205,506,932**	**1,205,789,432**

The IPO expenses deducted from the Share Premium in line with the IAS 32 paragraph 37 and the Companies Act 1994 section 57.

12A	**Consolidated Reserve & Surplus**		
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	310,107,867	312,199,137
	JMI SPECIALIZED HOSPITAL LIMITED	-	-
	Total	**310,107,867**	**312,199,137**
12.00	**Reserve & Surplus**		
	The above balance are made up as follows:		
	A) Tax Holiday Reserve:		
	This has been provided for as per of the Income Tax ordinance		
	Opening Balance	124,185,213	124,185,213
	Add: Addition during the year	-	-
		124,185,213	**124,185,213**

As per section 46 B of the Income Tax Ordinance, 1984 the tax holiday reserve has been made @ 40% on net profit earned by the Company from 2013 to 2017.

B) Revaluation Reserve:		
Opening Balance	188,182,899	190,644,401
Less: Adjustment for depreciation on revalued assets	(2,338,427)	(2,461,502)
	185,844,472	**188,182,899**
C) Fair value reserve	**78,182**	**(168,975)**
Total (A+B+C)	**310,107,867**	**312,199,137**

The land & Land Building Development and Factory Building being carried at revalued amount. The detail of revaluation is as follow:

i. Class of assets revaluation: Land and Building
ii. Name of revaluer: Malek Siddique Wali, Chartered Accountants (A Pannel of valuer of BSEC)
iii. Relationship with company : Independent from the company
iv. Date of revaluation: 30.06.2014
v. The revaluation surplus cannot be distributed in form of dividend or any other form to the shareholders

13A	**Consolidated Retained Earnings**		
	JMI HOSPITAL REQUISITE MANUFACTURING LTD. Note 13.00	1,634,015,727	1,483,235,995
	JMI SPECIALIZED HOSPITAL LIMITED.:		
	65% of opening retained earnings	(37,479)	-
	65% of current profit attributable to owner	(93,523)	(37,479)
	Closing balance	**1,633,884,725**	**1,483,198,516**
13.00	**Retained Earnings**		
	The above balance are made up as follows:		
	Opening Balance	1,483,235,995	1,250,255,632
	Net Profit during the year	233,270,925	293,165,921
	Dividend for the FY 2023-2024 @ 10.00% Cash/FY 2022-2023 @ 05.00% Cash	(84,829,620)	(62,647,060)
	Adjustment for Revaluation Reserve	2,338,427	2,461,502
		1,634,015,727	**1,483,235,995**

			Amount in BDT	
			30 June 2025	30 June 2024
13.01A	**Non controlling interest**			
	Opening Equity portion		70,000,000	70,000,000
	Add: Share Issued, Subscribed & Paid up/Share Money Deposit during the year		96,583,775	
	Retained earnings of NCI			
	35% of opening retained earnings		(20,181)	-
	35% of current profit attributable to owner		(50,359)	(20,181)
	Closing balance		166,513,235	69,979,819
14A	**Consolidated Term Loan (Non Current Maturity)**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note : 14.00**	153,573,581	147,653,053
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**153,573,581**	**147,653,053**
14.00	**Term Loan (Non Current Maturity)**			
	The above balance are made up as follows:			
	Non-Current year maturity (payable 2 to 5 years)		153,573,581	147,653,053
	Non-Current year maturity (payable above 5 years)		-	-
	Total Non-Current year maturity		**153,573,581**	**147,653,053**
14.01A	**Consolidated Current year maturity (Payable within 1 year)**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.		78,224,259	135,979,778
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**78,224,259**	**135,979,778**
14.01	**Current year maturity (Payable within 1 year)**		**78,224,259**	**135,979,778**
			231,797,840	**283,632,831**
	A) Term Loan-12390/12391			
	The above balance are made up as follows:			
	Opening Balance		69,979,778	124,247,406
	Add: Loan Received during the year		-	-
			69,979,778	**124,247,406**
	Add: Interest Charged during the year		6,044,781	10,082,372
			76,024,559	**134,329,778**
	Less: Loan Paid During the Year		63,850,300	64,400,000
			12,174,259	**69,929,778**
	Add: Bank Charge		50,000	50,000
			12,224,259	**69,979,778**

A.01) Terms and conditions on the above facility including security details are as follows:

Lender Name	:	Pubali Bank Limited. Dhaka Stadium Corporate Branch
	:	684,400,000
Interest Rate	:	12.25% (As per new schedule)
Installment Size	:	60,00,000/=
Validity	:	2017 to 2025
Loan Type	:	Term Loan
Nature of Security	:	Land & Buildings

A.02) Maturity Analysis of Loan:

Current year maturity (payable within 1 year) N-14.01	12,224,259	69,979,778
Non-Current year maturity (payable 2 to 5 years) N-14.00	-	-
Non-Current year maturity (payable over 5 years)	-	-
	12,224,259	**69,979,778**

	Amount in BDT	
	30 June 2025	30 June 2024
B) Term Loan-12399/12400		
The above balance are made up as follows:		
Opening Balance	213,653,053	250,435,995
Add: Loan Received during the year	-	-
	213,653,053	250,435,995
Add: Interest Charged during the year	24,865,988	24,067,058
	238,519,041	274,503,053
Less: Loan Paid During the Year	55,000,000	60,900,000
	183,519,041	213,603,053
Add: Bank Charge	50,000	50,000
	183,569,041	**213,653,053**

B.01) Terms and conditions on the above facility including security details are as follows:

Lender Name	:	Pubali Bank Limited. Dhaka Stadium Corporate Branch
Sanction Limit	:	415,600,000
Interest Rate	:	12.25% (As per revised schedule)
Installment Size	:	55,00,000/=
Validity	:	2017 to 2028
Loan Type	:	Term Loan
Nature of Security	:	Land & Buildings

B.02) Maturity Analysis of Loan:

Current year maturity (payable within 1 year) N-14.01	66,000,000	66,000,000
Non-Current year maturity (payable 2 to 5 years) N-14.00	117,569,041	147,653,053
Non-Current year maturity (payable over 5 years)	-	-
	183,569,041	**213,653,053**

C) Term Loan-07550		
The above balance are made up as follows:		
Opening Balance	-	-
Add: Loan Received during the period	35,000,000	-
	35,000,000	-
Add: Interest Charged during the period	2,049,540	-
	37,049,540	-
Less: Loan Paid During the period	1,045,000	-
	36,004,540	-
Add: Bank Charge	-	-
	36,004,540	**-**

C.01) Terms and conditions on the above facility including security details are as follows:

Lender Name	:	Pubali Bank Limited. Dhaka Stadium
Sanction Limit	:	35,000,000
Interest Rate	:	12.25% p.a with quarterly rest.
Installment Size	:	6,71,000/=
Validity	:	31.12.2032
Loan Type	:	Term Loan

Monthly installment will be started from 31.01.2026 as per sanction letter due to 01 (One) year moratorium period from the date of disbursement.

C.02) Maturity Analysis of Loan:

Current period maturity (payable within 1 period) N-14.01	-	-
Non-Current period maturity (payable 2 to 5 periods) N-14.00	36,004,540	-
Non-Current period maturity (payable over 5 periods)	-	-
	36,004,540	**-**

			Amount in BDT	
			30 June 2025	30 June 2024
15A	**Consolidated Deferred Tax Liability**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note : 15.00**	129,841,178	127,351,046
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**129,841,178**	**127,351,046**
15.00	**Deferred Tax Liability**			
	The above balance are made up as follows:			
	Deferred tax (recognised in profit or Loss statement) on temporary difference on PPE except land value and its revaluation:			
	WDV of PPE (excluding land) at Accounting Base		1,365,003,608	1,463,283,360
	WDV of PPE (excluding land) at Tax Base		(830,487,873)	(939,698,891)
	Temporary Difference		**534,515,734**	**523,584,469**
	Tax rate		22.50%	22.50%
	Deferred Tax		**120,266,040**	**117,806,506**
	Deferred tax (expenses)/income during the year in P/L		(2,459,535)	8,956,671
	Deferred tax on OCI:			
	Deferred tax on revaluation of Land		9,564,260	9,564,260
	Deferred tax on OCI: Fair value gain/(loss) @10%		10,878	(19,720)
	Deferred tax		**9,575,138**	**9,544,540**
	Deferred tax (expenses)/income during the year in OCI		(30,598)	28,220
	Closing liability of deferred tax: Required		**129,841,178**	**127,351,046**
16A	**Consolidated Lease Finance (Non-current Maturity)**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.		3,411,968	-
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**3,411,968**	**-**
16.01A	**Consolidated Current year maturity (payable within 1 year)**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.		1,443,600	-
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**1,443,600**	**-**
16.00	**Lease Finance (Non-current Maturity)**			
	Non-Current year maturity (payable 2 to 5 years)		3,411,968	-
16.01	**Current year maturity (payable within 1 year)**		1,443,600	-
			4,855,568	**-**
a)	**Pubali Bank Limited. A/C# 3033**			
	Cost of Car (in BDT)		2,978,000	-
	Initial Deposit		(297,800)	-
	Leasing company's investment (in BDT)		2,680,200	-
	Interest rate		12.00	-
	No. of monthly installment		60	-
	Installment size (in BDT)		60,150	-
	Loan Received/BD		2,680,200	-
	Interest charged		225,741	-
	Bank Charge		3,000	-
	Repayment		(481,200)	-
			2,427,741	**-**
	Maturity Analysis of Loan:			
	Current year maturity (payable within 1 year) N-16.01		721,800	-
	Non-Current year maturity (payable 2 to 5 years) N-16.00		1,705,941	-
	Non-Current year maturity (payable over 5 years)		-	-
			2,427,741	**-**

		Amount in BDT	
		30 June 2025	30 June 2024
b)	**Pubali Bank Limited A/C# 3041**		
	Cost of Car (in BDT)	2,978,000	-
	Initial Deposit (PBL)	(297,800)	-
	Leasing company's investment (in BDT)	2,680,200	-
	Interest rate	12.00	-
	No. of monthly installment	60	-
	Installment size (in BDT)	60,150	-
	Loan Received/BD	2,680,200	-
	Interest charged	225,827	-
	Bank Charge	3,000	-
	Repayment	(481,200)	-
		2,427,827	**-**
	Maturity Analysis of Loan:		
	Current year maturity (payable within 1 year) N-16.01	721,800	-
	Non-Current year maturity (payable 2 to 5 years) N-16.00	1,706,027	-
	Non-Current year maturity (payable over 5 years)	-	-
		2,427,827	**-**
c)	**Pubali Bank Limited A/C# 2540/2539**		
	Cost of Motorbike (in BDT)	-	1,872,000
	Initial Deposit (PBL)	-	-
	Leasing company's investment (in BDT)	-	1,872,000
	Interest rate	-	7.00%
	No. of monthly installment	-	60
	Installment size (in BDT)	-	40,500
	Loan Received/BD	-	425,697
	Interest charged	-	20,824
	Bank Charge	-	650
	Repayment	-	(447,171)
		-	**-**
	Maturity Analysis of Loan:		
	Current year maturity (payable within 1 year) N-16.01	-	-
	Non-Current year maturity (payable 2 to 5 years) N-16.00	-	-
	Non-Current year maturity (payable over 5 years)		
		-	**-**
e)	**Pubali Bank Limited A/C# 2519/2518**		
	Cost of Motorbike (in BDT)	-	2,340,000
	Initial Deposit (PBL)	-	-
	Leasing company's investment (in BDT)	-	2,340,000
	Interest rate	-	7.00%
	No. of monthly installment	-	60
	Installment size (in BDT)	-	50,500
	Loan Received/BD	-	537,093
	Interest charged	-	26,564
	Bank Charge	-	650
	Repayment	-	(564,307)
		-	**-**
	Maturity Analysis of Loan:		
	Current year maturity (payable within 1 year) N-16.01	-	-
	Non-Current year maturity (payable 2 to 5 years) N-16.00	-	-
	Non-Current year maturity (payable over 5 years)	-	-
		-	**-**

The amounts of current maturity of long term lease finance obtained from different Leasing companies and Bank. which are payable within next 12 (Twelve) months from the date of statement of Financial Position.

			Amount in BDT	
			30 June 2025	30 June 2024
17A	**Consolidated Rental Lease Liability**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note : 17.00**	2,705,304	486,027
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**2,705,304**	**486,027**
17.00	**Rental Lease Liability**			
	The above balance are made up as follows:			
	Opening Balance		486,027	1,559,917
	Add: During the year		5,106,124	-
	Less: Adjustment during the year		2,886,847	1,073,891
	Closing balance		**2,705,304**	**486,027**
18A	**Consolidated Working Capital Loan**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note : 18.00**	816,604,426	822,434,240
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**816,604,426**	**822,434,240**
18.00	**Working Capital Loan**			
	The above balance are made up as follows:			
	Uttara Bank Ltd.-Revolving Short Term Loan		59,074,965	56,540,208
	Pubali Bank Ltd.-Overdraft		618,562,964	614,209,578
	Uttara Bank Ltd.-Overdraft		69,688,610	82,447,437
	Pubali Bank Ltd.-Overdraft.		69,277,887	69,237,017
			816,604,426	**822,434,240**

Particulars	Uttara Bank Ltd.	Pubali Bank Ltd.
Sanction Facility	55,000,000	600,000,000
Repayment term	12 months	12 months
Types of loan	Revolving Short Term Loan	Overdraft
Interest Rate	14.00%	12.25%

Excess outstanding balance of Uttara Bank Ltd. is due to interest charged as on 30th June, 2025 which was subsequently paid.

19A	**Consolidated Liability Against Import**			
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note : 19.00**	22,817,655	25,563,257
	JMI SPECIALIZED HOSPITAL LIMITED		-	-
	Total		**22,817,655**	**25,563,257**
19.00	**Liability Against Import**			
	The above balance are made up as follows:			
	019925010056		3,929,938	
	019925010048		4,667,649	
	019925010097		769,994	
	019925010123		3,840,495	
	019925010132		8,573,860	
	019925010170		1,035,719	

	Amount in BDT	
	30 June 2025	30 June 2024
019623010284		2,938,144
019623010269		3,124,904
019623010222		896,532
019924010057		1,410,298
019924010034		1,994,978
019924010101		701,589
019924010056		3,827,420
019924010054		842,808
019924010048		4,364,513
019924010055		858,823
019924010052		1,102,021
019924010123		3,501,227
	22,817,655	**25,563,257**

A)	Lender	:	Pubali Bank Limited, Dhaka Stadium Corporate Branch, Dhaka.
	Sanction Facility		Tk 60.00 crore
	Types of loan		OD (Working Capital)
	Interest Rate		12.25% p.a. with quarterly rest.
B)	Lender	:	Pubali Bank Limited, Dhaka Stadium Corporate Branch, Dhaka.
	Sanction Facility		Tk 50.00 crore including UPAS facility (if required)
	Repayment Term		Sight/upto 180-days deferred payment
	Types of loan		L/C Limit (Sight/Deferred) (Revolving)
	Margin		5%
	Interest Rate		12.25% p.a. with quarterly rest.
	Commission		0.15% for per quarter
C)	Lender	:	Pubali Bank Limited, Dhaka Stadium Corporate Branch, Dhaka.
	Sanction Facility		Tk. 35 Crore
	Repayment Term		180 days from the date of creation
	Types of loan		LATR
	Interest Rate		12.25% p.a. with quarterly rest
D)	Lender	:	Pubali Bank Limited, Dhaka Stadium Corporate Branch, Dhaka.
	Sanction Facility		Tk. 02 Crore
	Repayment Term		180 days from the date of creation
	Types of loan		Bank Guarantee(BG)
	Margin		5% in cash/FDR & 15% cash for open ended BG.
	Commission		0.20% per quarter
E)	Lender	:	Standard Bank Ltd, Principal Branch, Dhaka.
	Sanction Facility		Tk. 20.00 Crore along with JMI Export Import Company Ltd, JMI Syringes & Medical Devices Ltd, and JMI Printing & Packing Ltd
	Repayment Term		For sight L/C- By creating LTR, For Deferred L/C- By way of Acceptance
	Types of loan		L/C Limit (Sigh/Deferred) (Revolving)
	Interest Rate		12.25 % p.a.
	Commission		0.25% per quarter
F)	Lender	:	Standard Bank Ltd, Principal Branch, Dhaka.
	Sanction Facility		Tk. 12.00 Crore along with JMI Export Import Company Ltd, JMI Syringes & Medical Devices Ltd, and JMI Printing & Packing Ltd
	Repayment Term		180 days or as per guideline of Bangladesh bank
	Types of loan		Loan against Trust Receipt (LTR) (revolving)
	Interest Rate		15.25 % p.a.

				Amount in BDT	
				30 June 2025	30 June 2024
20A	**Consolidated Accounts & Other Payable**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**20.00**	43,468,575	60,315,464
	JMI SPECIALIZED HOSPITAL LIMITED	**Note :**	**20.1A**	22,278,349	10,664,870
	Total			**65,746,924**	**70,980,334**
20.00	**JMI HOSPITAL REQUISITE MANUFACTURING LTD. :Accounts & Other Payable**				
	The above balance are made up as follows:				
	Payable to Suppliers			7,438,025	7,367,004
	Contributory provident Fund			916,062	398,709
	Salary & Allowance Payable			16,556,375	12,526,200
	Vat Payable Account			286,584	1,317,098
	Salary Tax Payable			290,510	205,082
	Interest Payable			-	18,010,000
	Sales Commission Payable			278,190	264,149
	Audit Fee Payable			460,000	460,000
	AIT Payable on Sales Commission			30,910	29,351
	WPPF			15,889,684	18,336,081
	Payable to Others			1,322,235	1,401,790
				43,468,575	**60,315,464**
	Balance with the sister concern			-	-
	Balance with the others			43,468,575	60,315,464
				43,468,575	**60,315,464**
20.01A	**JMI SPECIALIZED HOSPITAL LIMITED. :Accounts & Other Payable**				
	The above balance are made up as follows:				
	Payable to Suppliers			12,334,539	2,474,006
	Audit Fee Payable			57,500	57,500
	Salary & Allowance Payable			4,746,981	533,316
	Salary Tax Payable			36,494	2,817
	VAT Payable Account			2,372,143	199,096
	Payable to Others			2,730,692	7,398,135
				22,278,349	**10,664,870**
20.1A	**Consolidated Unclaimed Dividend**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.			10,793,931	5,115,003
	JMI SPECIALIZED HOSPITAL LIMITED			-	-
	Total			**10,793,931**	**5,115,003**
20.01	**Unclaimed Dividend**				
	Opening Balance			5,115,003	11,880,107
	Add: Addition During the Year			84,829,620	62,647,060
	Less: Dividend Paid during the Year			79,150,692	69,412,164
	Closing Balance		**20.02**	**10,793,931**	**5,115,003**
20.02	**Details of Closing balance of Unclaimed Dividend(30.06.2025) are as below:**				
	TDS on Dividend			1,701,000	1,562,447
	Dividend payable			9,092,931	3,552,556
				10,793,931	**5,115,003**
	The above balance are made up as follows:				
	For the year ended June 30, 2024			5,580,443	-
	For the year ended June 30, 2023			890,513	921,063
	For the year ended June 30, 2022			2,621,975	2,631,493
				9,092,931	**3,552,556**

				Amount in BDT	
				30 June 2025	30 June 2024
21A	**Consolidated Loan from Directors & Others**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**21.00**	7,756,976	7,756,976
	JMI SPECIALIZED HOSPITAL LIMITED			-	-
	Total			**7,756,976**	**7,756,976**
21.00	**Loan from Directors & Others**				
	The above balance are made up as follows:				
	Foreign Sponsor				
	Hoi Kwan Kim			**7,756,976**	**7,756,976**
	Lender	:	Hoi Kiwan Kim		
	Sanction Facility	:	N/A		
	Repayment Term	:	Repayment obligation will be settled within competent time.		
	Interest Rate	:	Nill		
	Security	:	N/A		
22A	**Consolidated Income Tax Liability**				
	JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note :**	**22.00**	51,669,918	15,985,302
	JMI SPECIALIZED HOSPITAL LIMITED			-	-
	Total			**51,669,918**	**15,985,302**
22.00	**JMI HOSPITAL REQUISITE MANUFACTURING LTD : Income Tax Liability**				
	Opening			15,985,302	8,912,045
	Add: Addition During the year			82,063,205	82,512,363
	Less: Adjustment with AIT (Note 7.01)			46,378,589	75,439,106
	Total			**51,669,918**	**15,985,302**
22.01	**JMI HOSPITAL REQUISITE MANUFACTURING LTD : Income Tax Liability**				
	Production Unit				
	This has been made up as under:				
	Balance as per Account			15,050,745	6,790,157
	Add: Provision for the year			42,983,092	52,632,241
				58,033,837	**59,422,398**
	Less: Source Tax			20,096,330	25,677,663
	Less: Tax Paid at Import Stage			15,548,031	18,693,990
	Tax Payable(A)			**22,389,476**	**15,050,745**
	Trading Unit				
	This has been made up as under:				
	Balance as per Account			934,557	2,121,888
	Add: Provision for the year			39,080,113	29,880,122
				40,014,670	**32,002,010**
	Less: Tax paid at Import stage			1,000,392	4,494,044
	Less:TDS from Interest on FDR and Source			265,738	7,742,766
	Less:TDS from Interest on Bank Deposit			9,880	30,561
	Less: Income tax paid			9,458,218	18,800,082
	Tax Payable(B)			**29,280,442**	**934,557**
	Total Tax Payable C=(A+B)			**51,669,918**	**15,985,302**
22.02	**JMI SPECIALIZED HOSPITAL LIMITED : Income Tax Liability**				
	This has been made up as under:				
	Balance as per Account			-	-
	Add: Provision for the year			3,837	13,925
				3,837	**13,925**
	Less: Source Tax			3,837	13,925
	Less: Advance income tax			-	-
	Tax Payable			**-**	**-**

Notes to the Financial Statement for the year ended 30 June 2025

			Amount in BDT	
			30 June 2025	30 June 2024
	Trading	Production	Total	Total
23A Consolidated Revenue				
JMI HOSPITAL REQUISITE MANUFACTURING LTD.		**Note : 23.01**	**1,670,955,448**	**1,870,145,496**
JMI SPECIALIZED HOSPITAL LIMITED		**Note : 23.02**	**-**	**-**
Net Sales			**1,670,955,448**	**1,870,145,496**

23.01 JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Revenue

The above balance are made up as follows:

Gross Sales	872,270,963	931,408,024	1,803,678,987	2,018,294,613
Less: VAT	76,529,091	56,194,448	132,723,539	148,149,117
Net Sales	**795,741,872**	**875,213,576**	**1,670,955,448**	**1,870,145,496**
	795,741,872	**875,213,576**	**1,670,955,448**	**1,870,145,496**

23.02 JMI SPECIALIZED HOSPITAL LIMITED.:Revenue

The above balance are made up as follows:

Revenue			-	-
			-	**-**

24A Consolidated cost of goods sold/Direct Expenses

JMI HOSPITAL REQUISITE MANUFACTURING LTD.		**Note : 24.01**	**1,152,507,718**	**1,289,909,629**
JMI SPECIALIZED HOSPITAL LIMITED		**Note : 24.03**	**-**	**-**
			1,152,507,718	**1,289,909,629**

24.01 JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Cost of Goods Sold

The above balance are made up as follows:

Opening Stock of Raw Material & Packaging	-	219,708,478	219,708,478	207,696,190
Purchase	570,086,249	297,664,339	867,750,588	999,097,569
Less: Closing Stock of Raw Material & Packaging	-	227,504,797	227,504,797	219,708,478
Raw Material & Packaging Consumed	**570,086,249**	**289,868,020**	**859,954,269**	**987,085,281**
Factory Overhead (Note: 24.02)	-	313,541,728	313,541,728	298,927,092
Cost of Goods Manufactured	**570,086,249**	**603,409,748**	**1,173,495,997**	**1,286,012,373**
Add: Work-in-process (Beginning Inventory)	-	103,687,567	103,687,567	116,694,229
Less: Work-in-process (Ending Inventory)	-	93,940,893	93,940,893	103,687,567
Cost of Production	**570,086,249**	**613,156,422**	**1,183,242,671**	**1,299,019,035**
Add: Finished Goods (Beginning Inventory)	99,068,191	296,997,691	396,065,882	386,956,476
Less: Finished Goods (Ending Inventory)	106,982,382	319,818,453	426,800,835	396,065,882
Cost of Goods Sold	**562,172,058**	**590,335,660**	**1,152,507,718**	**1,289,909,629**

24.02 Factory Overhead

The above balances are made up as follows:

Freight Charge /Carriage Inward	-	23,300	23,300	75,385
Salary & Allowance	-	99,385,511	99,385,511	87,308,610
Salary & Wages	-	5,557,734	5,557,734	4,921,527
Festival Bonus	-	9,973,190	9,973,190	9,389,515
Gas & Fuel	-	104,275	104,275	134,811
Medical Expense	-	70,181	70,181	73,928
Laundry Exp	-	352,067	352,067	583,775
Sanitation & Cleaning Exp	-	469,979	469,979	312,285
Fooding Expenses	-	5,224,040	5,224,040	5,186,619
Attendance Bonus	-	1,043,611	1,043,611	924,147
Staff uniform	-	123,182	123,182	837,890
Overtime Expenses	-	7,865,280	7,865,280	7,664,922
Supplies Expenses	-	467,954	467,954	316,997
Entertainment	-	775,865	775,865	1,178,014
Travelling & Conveyance	-	1,329,410	1,329,410	1,319,895
Vehicle Repair & Maintenance	-	716,553	716,553	677,086
Spare Parts & Others	-	1,072,575	1,072,575	982,244
Research & Development Expense	-	-	-	27,066

	Amount in BDT			
			30 June 2025	30 June 2024
	Trading	Production	Total	Total
Diesel Expenses	-	5,701,500	5,701,500	5,564,000
Internet & Dish Bill	-	63,000	63,000	63,000
Mobile Bill	-	452,231	452,231	516,061
Electricity Bill	-	40,742,408	40,742,408	35,542,416
Registration & Renewal	-	325,069	325,069	389,921
Printing & Stationery	-	704,609	704,609	1,046,213
Contributory Providend Fund	-	3,693,889	3,693,889	3,253,904
Repair & Maintanence of Machinery	-	4,879,933	4,879,933	4,938,297
Repair & Maintenance-Building	-	1,033,686	1,033,686	507,122
Depreciation	-	121,390,696	121,390,696	125,191,443
	-	**313,541,728**	**313,541,728**	**298,927,092**

24.03 JMI SPECIALIZED HOSPITAL LIMITED.:Cost of Goods Sold/Direct Expenses

The above balance are made up as follows:

Direct Expenses		-	-
		-	**-**

25A Consolidated administrative Expenses

JMI HOSPITAL REQUISITE MANUFACTURING LTD.	**Note: 25.01**	**80,696,521**	**79,204,937**
JMI SPECIALIZED HOSPITAL LIMITED	**Note: 25.02**	**152,835**	**90,152**
		80,849,356	**79,295,089**

25.01 JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Administrative Expenses

The above balances are made up as follows:

Electricity Bill	-	647,551	647,551	568,498
Entertainment	498,238	569,607	1,067,845	916,831
Travelling & Conveyance	442,334	269,700	712,034	917,312
Postage & Courier	14,957	15,035	29,992	13,270
Gas & Fuel	325,614	476,194	801,808	773,889
Fooding Expenses	412,538	643,888	1,056,426	921,538
Miscellaneous	49,048	133,056	182,104	188,845
Office Expenses	5,550	117,717	123,267	101,923
Printing & Stationary	392,718	799,518	1,192,236	1,133,682
Repair & Maintenance	153,783	233,860	387,643	593,430
Travelling -Overseas & Inland	515,426	592,505	1,107,931	953,426
Legal fee	-	86,000	86,000	178,000
VAT on Office Rent	-	509,004	509,004	473,697
Supplies Expense	185,261	215,726	400,987	212,014
Professional Fee	-	28,750	28,750	115,000
Insurance Premiun-Employee Life	-	291,936	291,936	305,642
Internet Bill	36,000	122,232	158,232	165,232
Telephone/Mobile Bill	-	557,967	557,967	493,768
Licence & Renewal Fee	550,588	706,589	1,257,177	1,341,176
Contributory Provident Fund	224,400	759,886	984,286	889,964
Company Secretarial & AGM Expenses	95,375	260,000	355,375	217,750
Salary & Allowance	28,752,220	14,400,929	43,153,149	40,869,886
Festival Bonus	1,650,751	1,752,165	3,402,916	3,387,899
Vehicle Repair & Maintenance	798,363	433,154	1,231,517	1,401,073
Water & Sewerage Bill	-	135,624	135,624	132,182
Audit fee	-	460,000	460,000	460,000
Bank Charges	400,988	813,178	1,214,166	835,001
Medical Expense	85,500	139,236	224,736	229,066
Security Bill	-	43,639	43,639	132,640
Depreciation	4,120,092	14,772,132	18,892,224	20,282,304
Total :	**39,709,744**	**40,986,777**	**80,696,521**	**79,204,937**

			Amount in BDT	
			30 June 2025	30 June 2024
	Trading	Production	Total	Total
25.02 JMI SPECIALIZED HOSPITAL LIMITED.:Administrative Expenses				
The above balances are made up as follows:				
Audit Fee			57,500	57,500
Bank Charge			95,335	32,652
Total :			**152,835**	**90,152**
26A Consolidated Selling & Distribution				
JMI HOSPITAL REQUISITE MANUFACTURING LTD.		**Note: 26.01**	**54,628,842**	**57,561,388**
JMI SPECIALIZED HOSPITAL LIMITED		**Note: 26.02**	**-**	**-**
			54,628,842	**57,561,388**
26.01 JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Selling & distribution expenses				
The above balances are made up as follows:				
Advertisement	328,553	-	328,553	630,081
Tour Bill-Local	430,194	-	430,194	1,407,680
Mobile Bill	245,287	-	245,287	125,184
VAT on Showroom Rent	125,905	-	125,905	423,362
Marketing Salary with Bonus	31,268,197	-	31,268,197	29,459,906
Postage & Courier	76,160	-	76,160	5,765
Utilities Expenses	511,615	-	511,615	307,839
Promotional Expenses	3,178,100	3,697,031	6,875,131	8,762,481
Sales Commission/Incentive	949,346	930,186	1,879,532	1,702,691
TA/DA Allowance (Marketing)	5,742,898	-	5,742,898	6,053,145
Sample Expenses	1,019,856	529,860	1,549,716	3,113,537
Product Enlisted /Inclusion Fee	573,550	-	573,550	237,750
Tender Expense	104,788	-	104,788	66,950
Cover Van Expenses	1,671,333	-	1,671,333	2,179,072
Contributory Providend Fund	594,555	-	594,555	497,531
Security Guard Bill	177,660	-	177,660	177,660
Training & Development Expenses	20,053	-	20,053	110,116
Fooding Expenses	652,548	-	652,548	588,664
Delivery Expense	1,011,257	789,910	1,801,167	1,711,974
Total :	**48,681,855**	**5,946,987**	**54,628,842**	**57,561,388**
26.02 JMI SPECIALIZED HOSPITAL LIMITED.: Selling & distribution expenses			**-**	**-**
27A Consolidated Financial expense				
JMI HOSPITAL REQUISITE MANUFACTURING LTD.		**Note: 27.01**	**55,302,210**	**70,749,919**
JMI SPECIALIZED HOSPITAL LIMITED		**Note: 27.03**	**-**	**-**
			55,302,210	**70,749,919**
27.01 JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Financial expense				
The above balances are made up as follows:				
Interest on PAD Liability	7,062,910	12,442,429	19,505,339	24,676,014
Interest on Lease Finance	-	451,568	451,568	47,388
Interest Expense (Term Loan)	16,480,154	16,480,155	32,960,309	34,149,430
Finance Charge for Rental Lease	12,066	483,536	495,602	107,053
Interest on Short term & OD Loan (Note:27.02)	1,300,000	589,392	1,889,392	11,770,033
Total :	**24,855,130**	**30,447,080**	**55,302,210**	**70,749,919**
27.02 Interest On Short Term & OD Loan				
A. Interest Paid During the Year:				
Uttara Bank Ltd			18,291,162	14,767,023
Pubali Bank Ltd-SOD			77,811,082	68,932,295
			96,102,244	**83,699,318**

			Amount in BDT	
			30 June 2025	30 June 2024
	Trading	Production	Total	Total
B. Interest Income from Sister Concern:				
JMI Industrial Gas Ltd.			14,272,066	12,757,018
JMI Export Import Co. Ltd.			14,989,677	11,005,219
JMI LPG & Petrolium Ltd.			1,138,503	835,874
JMI Vaccine Ltd.			53,861,947	39,716,788
JMI Printing & Packaging Ltd.			9,950,659	7,614,387
			94,212,852	**71,929,285**
Interest On Short Term & OD Loan (A-B):			**1,889,392**	**11,770,033**
27.03 JMI SPECIALIZED HOSPITAL LIMITED.:Financial expense			-	-
28A Consolidated Income From Others Sources				
JMI HOSPITAL REQUISITE MANUFACTURING LTD.		**Note: 28.01**	5,863,192	12,338,071
JMI SPECIALIZED HOSPITAL LIMITED		**Note: 28.02**	12,790	46,417
			5,875,982	**12,384,488**

28.01 JMI HOSPITAL REQUISITE MANUFACTURING LTD.:Income From Others Sources

The above balances are made up as follows:

Interest on FDR/ Bank Interest	49,402	2,167,268	2,216,670	8,492,169
House Rent-Sub Rental Income (NJCL)	2,400,000	-	2,400,000	2,400,000
Dividend Income	-	1,360	1,360	-
Foreign Exchange Gain/(Loss)	22,092	22,092	44,184	510,622
Forfeited Amount of Provident Fund (PF)	135,812	165,166	300,978	35,280
Others Income	450,000	450,000	900,000	900,000
Total :	**3,057,306**	**2,805,886**	**5,863,192**	**12,338,071**

28.02 JMI SPECIALIZED HOSPITAL LIMITED.:Income From Others Sources

The above balances are made up as follows:

Bank Interest and Others	12,790	46,417
Total :	**12,790**	**46,417**

29.00 Related Party-Disclosures under IAS 24 " Related Party Disclosure"

The Company Carried out a number of transactions with related parties/associates undertaking in the normal course of business and on arms length basis. The nature of transaction and their total value are in below:

Name	Nature of Transaction	Net transaction for the year	Balance as on 30.06.2025
A. Advance & Short term Loan Paid			
JMI Industrial Gas Ltd.	Short Term Loan	31,227,934	87,269,882
JMI Export-Import Company Ltd.	Short Term Loan	14,989,677	124,482,204
JMI LPG & Petroleum Ltd.	Short Term Loan	1,138,503	9,454,733
JMI Vaccine Ltd.	Short Term Loan	53,861,947	447,298,079
JMI Printing & Packaging Ltd.	Short Term Loan	950,659	76,707,300
Total		**102,168,720**	**745,212,197**
B. Supplier/ Creditors (Payable)			
JMI Printing & Packaging Ltd	Supplier	1,684,720	3,116,881
Total		**1,684,720**	**3,116,881**
C. Sundry Debtors (Product Sales, Receivable)			
JMI Syringes & Medical Devices Ltd.	Debtors	15,120,194	224,416,968
Nipro JMI Medical Ltd	Debtors	(12,468,716)	183,590,927
Nipro JMI Company Limited	Debtors	20,984,247	111,707,873
Nipro JMI Dialysis Center	Debtors	(3,000,000)	2,427,652
Total		**20,635,725**	**522,143,420**
D. Loan from Director's			
Hoi Kwan Kim		-	7,756,976
		-	**7,756,976**

Name	Nature of Transaction	Net transaction for the year	Balance as on 30.06.2025
E. Advance, Deposit & Prepayments			
JMI Sonlu Electric Appliance Co. Ltd	Advance Against Share Money Deposit	-	153,775,000
Total		**-**	**153,775,000**
F. Investment in Subsidiary			
JMI Specialized Hospital Limited	Investment in Subsidiary	169,900,000	299,900,000
Total		**169,900,000**	**299,900,000**
Grand Total		**294,389,165**	**1,731,904,474**

	Amount in BDT	
Key Management Personnel Compensation	**30 June 2025**	**30 June 2024**
Compensation to Key Management personnel	**15,749,280**	**14,533,220**
	15,749,280	**14,533,220**

In accordance with IAS 24 Paragraph 17, the Company has disclosed Compensation to Key Management Personnel. Key Management Personnel includes Directors and Executive employees up to AGM of the Company.

30.00 Contribution to WPPF:

This represents statutory contribution by the company as per Bangladesh Labour (amendment) Act, 2013. The amount is computed @ 5% of net profit before tax (but after charging such contribution).

31A Consolidated net asset value per share (NAV)

Share Holders Equity	4,402,440,724	4,254,128,285
Weighted average No. of share	125,294,120	125,294,120
Net Asset Value Per Share (NAV):	**35.14**	**33.95**

31.00 Net Asset Value Per Share (NAV)

Share Holders Equity	4,402,571,726	4,254,165,764
Weighted average No. of share	125,294,120	125,294,120
Net Asset Value Per Share (NAV):	**35.14**	**33.95**

32A Consolidated basic earning per share (EPS)

Profit attributable for distribution to Ordinary Shareholders	233,177,401	293,128,442
Weighted average No. of share	125,294,120	125,294,120
Consolidated earning per share (EPS):	**1.86**	**2.34**

32.00 Basic Earning Per Share (EPS)

Profit attributable for distribution to Ordinary Shareholders	233,270,925	293,165,921
Weighted average No. of share	125,294,120	125,294,120
Earning Per Share (EPS):	**1.86**	**2.34**

33A Consolidated Net Operating Cash Flow Per Share (NOCFPS)

Net cash generated from operating activities	291,829,829	295,142,342
Weighted average No. of share	125,294,120	125,294,120
Net Operating Cash Flow Per Share -(NOCFPS):	**2.33**	**2.36**

33.00 Net Operating Cash Flow Per Share (NOCFPS)

Net cash generated from operating activities	376,689,072	412,505,037
Weighted average No. of share	125,294,120	125,294,120
Net Operating Cash Flow Per Share -(NOCFPS):	**3.01**	**3.29**

JMI HOSPITAL REQUISITE MANUFACTURING LTD.

Notes to the Financial Statement - as at 30 June 2025

		Amount in BDT	
		30 June 2025	30 June 2024
34A	**Consolidated Reconciliation between net profit to operating cash flow:**		
	Profit/(loss) before tax	317,653,620	366,677,878
	Finance cost	55,302,210	70,749,919
	Operating profit	**372,955,830**	**437,427,797**
	Adjustment:		
	Depreciation	140,282,920	145,473,746
	Dividend Income	(1,360)	-
	Effect of exchanges rate changes on cash and cash equivalents	(44,184)	-
	Changes in Working capital:		
	(Increase)/Decrease of Inventory	(28,784,598)	(8,115,032)
	(Increase)/Decrease of Trade debt	(41,495,896)	(50,203,877)
	(Increase)/Decrease of Advance, Deposit & Prepayment expect AIT, Advance against non-current assets	(114,731,445)	(129,093,089)
	Increase/(Decrease) Accounts & Other Payable except interest payable	12,776,590	10,581,033
	Increase/(Decrease) Liability Against Import	(2,745,602)	(35,475,205)
		338,212,255	**370,595,373**
	Tax paid	(46,382,426)	(75,453,031)
	Net cash generated from operating activities	**291,829,829**	**295,142,342**

34.00	**Reconciliation between net profit to operating cash flow:**		
	Profit/(loss) before tax	317,793,665	366,721,613
	Finance cost	55,302,210	70,749,919
	Operating profit	**373,095,875**	**437,471,532**
	Adjustment:		
	Depreciation	140,282,920	145,473,746
	Dividend Income	(1,360)	-
	Effect of exchanges rate changes on cash and cash equivalents	(44,184)	-
	Changes in Working capital:		
	(Increase)/Decrease of Inventory	(28,784,598)	(8,115,032)
	(Increase)/Decrease of Trade debt	(41,495,896)	(50,203,877)
	(Increase)/Decrease of Advance, Deposit & Prepayment expect AIT, Advance against non-current assets	(18,402,605)	(1,123,184)
	Increase/(Decrease) Accounts & Other Payable except interest payable	1,163,111	(83,837)
	Increase/(Decrease) Liability Against Import	(2,745,602)	(35,475,205)
		423,067,661	**487,944,143**
	Tax paid	(46,378,589)	(75,439,106)
	Net cash generated from operating activities	**376,689,072**	**412,505,037**

35.00 Capital Expenditure Commitment

There was no contingent liabilities as on 30.06.2025 except L/C liabilities.

There was no credit facility available to the company under any contract, other than trade credit available in the ordinary course of business and not availed of as on 30.06.2025.

36.00 Payment of Foreign Currency

Import of Machinery & spare parts of the machinery. Import of Raw Materials.

No other expense included consultancy fee, royalty, technical expert and professional advisory fee, interest, etc. was incurred or paid in foreign currencies except as stated above.

37.00 Foreign Exchange Earned

No other income included consultancy fee, royalty, technical expert and professional advisory fee, interest, etc. was incurred or paid in foreign currencies except as stated above.

38.00 Commission, Brokerage or Discount against sales

No commission was incurred or paid to distributors, agents nor any brokerage or discount was incurred or paid against sales.

39.00 Credit Facility Not Availed

There was no credit facility available to the company under any contract, but not availed as on 30th June 2025 other than trade credit available in the ordinary course of business.

40.00 Segment Reporting

As there is single business and geographic segment within the company operates as such no segment reporting is felt necessary.

41.00 Attendance Status of Board Meeting of Directors

During the period from 01.07.2024 to 30.06.2025 there were 09 (Nine) Board Meetings were held. The attendance status of all the meetings is as follows:

Name of Directors	Position	Meeting Held	Attended
Md. Abdur Razzaq	Chairman	09	09
Mrs. Suriya Akther Rina	Managing Director	09	09
Hoi Kwan Kim	Director	09	07
Md. Mohiuddin Ahmed	Nominee Director	09	06
Mr. Ranjit Chakraborty	Nominee Director	09	03
Abdul Wahab Khan	Independent Director	09	08
Mrs.Jahanara Pervin	Independent Director	09	05
Md. Aminul Bar Chowdhury	Independent Director	09	05

Note:

Mr. Md. Mohiuddin Ahamed, Nominee Director, was withdrawn from JMI Vaccine Limited on 25.03.2025. In his place, Mr. Ranjit Chakraborty has been appointed as the new Nominee Director.

42.00 Disclosure as per requirement of Schedule XI, Part II of the Company Act. 1994

a **Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3**

a(i) **Employee Position** **(As at 30th June 2025)**

Salary Range (Monthly)	Officer & Staff		Total Employee
	Head Office	Factory	
Below Tk. 5,000/-	Nil	Nil	Nil
Above Tk. 5,000/-	106	544	650
Total	**106**	**544**	**650**

b **Disclosure as per requirement of Schedule XI, Part II, Para 4**

Name of Directors	Designation	Remuneration	Festival Bonus	Total Payment
Md. Abdur Razzaq	Chairman	-	-	-
Mrs. Suriya Akther Rina	Managing Director	-	-	-
Mr. Hoi Kwan Kim	Director	-	-	-
Total		**-**	**-**	**-**

b(i) The above Directors of the company did not take any other benefit

a. Expense reimbursed to the managing agent -Nil

b. Commission or other remuneration payable separately to a managing agent or his associate -Nil

c. Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into such concerns with the company - Nil.

d. The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year. N/A.

e. Any other perquisites or benefit in cash or in kind stating - Nil

f. Other allowances and commission including guarantee commission - Nil.

g. Pensions, etc.-

1) Pensions - Nil
2) Gratuities - Nil
3) Payment from Provident Fund - Nil
4) Compensation for loss of office - Nil
5) Consideration in connection with retirement from office - Nil.

c **Disclosure as per requirement of Schedule XI, Part II, Para 7**

Capacity of the Industrial Unit, actual production, shortfall and achievement are as follows:

Particulars	2025		2024	
	Pcs	%	Pcs	%
Installed Capacity	1,573,040,560	100.00	1,573,040,560	100.00
Actual Production	1,212,185,056	77.06	1,290,050,563	82.01
Deficit/(excess)	**360,855,504**	**22.94**	**282,989,997**	**17.99**

d **Disclosure as per requirement of Schedule XI, Part II, Para 8**

Items	Purchase in Taka			Consumption in Taka	% of Consumption of total purchase
	Import	Local	Total		
Raw Materials	370,734,101	479,374,445	850,108,546	866,737,796	98.85
Spare Parts	4,865,358	-	4,865,358	-	-
Packing Materials	-	29,636,684	29,636,684	10,076,473	1.15
Total	**375,599,459**	**509,011,129**	**884,610,588**	**876,814,269**	**100.00**

The value of imported raw materials is calculated on CIF basis.

i) The Company has not incurred any expenditure in foreign currency for the period from 1st July 2024 to 30th June 2025 on account of royalty, know-how, professional fee, consultancy fees and interest.
ii) The Company has not earned any foreign exchanges for royalty, know-how, professional fees and consultancy fees.
iii) The value of export from the period from 1st July 2024 to 30th June 2025. N/A.

e **Disclosure as per requirement of Schedule XI, Part II, Para 3**

Requirements under condition No.	Compliance status of Disclosure of Schedule XI, Part II, Para 3
3(i)(a) The turnover	1,670,955,448
3(i)(b) Commission paid to selling agents	1,879,532
3(i)(c) Brokerage and discount of sales, other than the usual trade discount	N/A
3(i)(d)(i) The value of the raw materials consumed, giving item-wise	Notes: 24A
3(i) (d)(ii) The opening and closing stocks of goods produced	Notes: 24A
3(i)(e)For trading companies, the purchase made, opening and closing stocks	Notes: 24A
3(i)(f) In the case of Companies rendering or supplying services, the gross income derived from services rendered or supplied	N/A
3(i)(g) Opening and closing stocks, purchases, sales and consumption of raw materials with value and quantity breakup for the Company, which falls under one or more categories i.e. manufacturing and/or trading	Notes: 24A
3(i)(h) In the case of other companies, the gross income derived under different heads	N/A
3(i)(i) Work-in-progress, which have been completed at the commencement and at the end of the accounting period	Notes: 24A
3(i)(j) Provision for depreciation, renewals or diminution in value of fixed assets	As per Fixed Asset Schedule
3(i)(k) Interest on the debenture paid or payable to the Managing Director, Managing Agent and the Manager	N/A
3(i)(l) Charge for income tax and other taxation on profits	As per Income Statement
3(i)(m) Reserved for repayment of share capital and repayment of loans	N/A
3(i)(n)(i) Amount set aside or proposed to be set aside, to reserves, but not including provisions made to meet any specific liability, contingency or commitment, know to exist at the date as at which the balance sheet is made up.	N/A
3(i)(n)(ii) Amount withdrawn from above mentioned reserve	N/A
3(i)(o)(i) Amount set aside to provisions made for meeting specific liabilities, contingencies of commitments.	N/A
3(i)(o)(ii) Amount withdrawn from above mentioned provisions, as no longer required.	N/A
3(i)(p) Expenditure incurred on each of the following items, separately for each item: (i) Consumption of stores and spare parts (ii) Power and Fuel (iii) Rent (iv) Repairs of Buildings (v) Repairs of Machinery (vi)(1) Salaries, wages and bonus (2) Contribution to provident and other funds (3) Workmen and staff welfare expenses to the extent not adjusted from any previous provision or reserve.	Notes: 24.02

43.00 Subsequent Disclosure of Events after the Balance Sheet Date - Under IAS 10

There is no non-adjusting post balance sheet event of such importance, non disclosure of which would affect the ability to the users of the financial statements to proper evaluation and decision.

44.00 Details of Lease Agreement:

There is lease assets. So lease agreement was required or signed.

45.00 Disclosure as per requirement of schedule XI, Part - I (A. Horizontal Form) of Companies Act. 1994

Accounts Receivable Balance are made up against sales from more than 3500 (Three Thousand Five Hundred) Customer's all over the country.

46.00 (I) Debt considered good in respect of which the company is fully secured :

The debtors occurred in the ordinary course of business are considered good and secured.

(II) Debt considered good for which the company hold no security other than the debtors personal security

There is no such debt in this respect as on 30 June 2025.

(III) Debt considered doubtful or bad

The company does not make any provision for doubtful debts as on 30 June 2025, because of the fact that local sales are being made on regular basis with fixed maturity dates.

(IV) Debt due by directors or other officers of the company

There is no such debt in this respect as on 30 June 2025.

(V) Debt due by Common Management

The company has Tk.522,143,420 receivable from sister companies under common management. For more details related to this receivable, refer to 'Note: 29 ' "Related Party Disclosures"

(VI) The maximum amount due by directors or other officers of the company

There is no such debt in this respect as on 30 June 2025.

47.00 Approval of the financial statements:

These financial statements were authorized for issue in accordance with a resolution of the company's Board of Directors on 26.10.2025.

48.00 General

a Comparative amounts

Wherever considered necessary previous year's figures have been restated, in order to confirm to current year's presentation

b Presentation currency

The annexed financial statements are presented in Bangladeshi currency (Taka), which have been rounded off to the nearest Taka.

49.00 Events after the Reporting Period:

The Board of Directors recommended 5% cash dividend for the year ended on 30 June 2025. The dividend proposal is subject to shareholders' approval in the forthcoming 17th Annual General Meeting. Except the fact stated above no circumstance have arisen that to be disclosed as note or adjusted in the financial statements.

50.00 Proposed Dividend

In the Board Meeting held on 26.10.2025 the management proposed 5% cash dividend for the year ended June 30, 2025 subject to the approval by the shareholders in the 17th Annual General Meeting.

51.00 Internal Control

The following steps have been taken for implementation of an effective internal control procedure of the Company:

A strong internal control and compliance division has been formed with a view to establish a well designated system of internal control.
Regular review of internal audit reports with a view to implement the suggestion of internal auditors in respect of internal control technique.
To establish an effective management system that includes planning, organizing and supervising culture in the factory as well as at Head Office.

52.00 Status Of Income Tax Assessment

Income Year	Assessment Year	Present Status
2023-24	2024-25	Return has filed Us 180.
2022-23	2023-24	Appeal completed and Process for Traibunal.
2021-22	2022-23	Tribunal under process.

53.00 Contingent Liability

There is no contingent liability as on 30th June,2025.

54.00 General Comments and Observations

Previous period's figure have been regrouped/reclassified wherever considered necessary to confirm to current period's presentation. Figures have been rounded off to the nearest taka, as the currency represented in this financial statement.
All shares have been fully called and paid up.
Auditor's are paid only statutory audit fees.
No foreign exchange remitted to the relevant shareholders during the period under audit.
No amount of money was expended by the company for compensating any members of the Board for special service rendered.
There was no bank guarantee issued by the company on behalf of Directors.

JMI HOSPITAL REQUISITE MANUFACTURING LTD

Schedule for Property, Plant & Equipment- Production
As at 30 June, 2025

Annexure-1

Particulars	Freehold Assets											Total
	Land & Land Development	Factory Buildings	Building Suture	Machinery	Machinery-Suture	Electrical Installation	Furniture & Fixture	Computer & Other Equipments	Office Equipment	Motor Vehicles	Right of Use Assets**	
Rate of Depreciation	**0.00%**	**5.00%**	**5.00%**	**10.00%**	**10.00%**	**10.00%**	**10.00%**	**10.00%**	**15.00%**	**20.00%**	**44.44%**	
Cost												
Balance as on 01 July 2023	258,950,540	187,259,126	193,245,514	327,032,366	1,368,845,072	36,668,033	15,693,629	10,468,833	43,293,947	57,026,210	-	2,498,483,270
Addition during the year	50,000	1,808,160	-	20,381,216	50,600	946,475	4,716,262	3,170,307	33,229,008	81,500	-	64,433,528
Transfer During the Year	-	-	-	-	-	-	-	-	-	-	-	-
Balance as on 30 June, 2024	**259,000,540**	**189,067,286**	**193,245,514**	**347,413,582**	**1,368,895,672**	**37,614,508**	**20,409,891**	**13,639,140**	**76,522,955**	**57,107,710**	**-**	**2,562,916,798**
Balance as on 01 July 2024	259,000,540	189,067,286	193,245,514	347,413,582	1,368,895,672	37,614,508	20,409,891	13,639,140	76,522,955	57,107,710	-	2,562,916,798
Addition during the year	-	460,739	-	19,807,140	-	1,679,736	688,254	1,246,100	6,728,349	6,286,726	5,106,124	42,003,168
Borrowing Cost	-	-	-	-	-	-	-	-	-	-	-	-
Borrowing Cost Adjustment	-	-	-	-	-	-	-	-	-	-	-	-
Transfer During the Year	-	-	-	-	-	-	-	-	-	-	-	-
Balance as on 30 June, 2025	**259,000,540**	**189,528,025**	**193,245,514**	**367,220,722**	**1,368,895,672**	**39,294,244**	**21,098,145**	**14,885,240**	**83,251,304**	**63,394,436**	**5,106,124**	**2,604,919,966**
Accumulated Depreciation												
Balance as on 01 July 2023	-	62,351,493	33,135,179	176,937,241	424,119,262	16,862,938	7,787,380	3,707,450	22,306,171	42,769,397	-	789,976,510
Addition during the year	-	6,309,038	8,005,517	15,818,464	94,475,964	2,033,949	1,099,901	812,400	5,841,533	2,853,193	-	137,249,958
Adjustment	-		-	-	-	-	-	-			-	-
Balance as on 30 June, 2024	**-**	**68,660,531**	**41,140,696**	**192,755,705**	**518,595,225**	**18,896,887**	**8,887,281**	**4,519,850**	**28,147,704**	**45,622,591**	**-**	**927,226,468**
Balance as on 01 July 2024	-	68,660,531	41,140,696	192,755,705	518,595,225	18,896,887	8,887,281	4,519,850	28,147,704	45,622,591	-	927,226,468
Addition during the year	-	6,030,286	7,605,241	17,012,010	85,030,045	2,016,669	1,200,665	966,261	7,517,735	3,213,527	2,553,062	133,145,502
Adjustment	-		-	-	-	-	-	-			-	-
Balance as on 30 June, 2025	**-**	**74,690,817**	**48,745,937**	**209,767,715**	**603,625,270**	**20,913,556**	**10,087,946**	**5,486,111**	**35,665,439**	**48,836,118**	**2,553,062**	**1,060,371,970**
Written Down Value												
As on 30 June 2024	**259,000,540**	**120,406,754**	**152,104,818**	**154,657,877**	**850,300,447**	**18,717,621**	**11,522,610**	**9,119,290**	**48,375,251**	**11,485,119**	**-**	**1,635,690,329**
Balance as on 30 June, 2025	**259,000,540**	**114,837,207**	**144,499,577**	**157,453,007**	**765,270,402**	**18,380,688**	**11,010,199**	**9,399,129**	**47,585,865**	**14,558,318**	**2,553,062**	**1,544,547,995**
On Revaluation												
Balance as on 01 July 2023	119,230,444	101,221,643	-	-	-	-	-	-	-	-	-	220,452,087
Addition during the year	-	-	-	-	-	-	-	-	-	-	-	-
Borrowing Cost	-	-	-	-	-	-	-	-	-	-	-	-
Adjustment	-	-	-	-	-	-	-	-	-	-	-	-
Balance as on 30 June, 2024	**119,230,444**	**101,221,643**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**220,452,087**
Balance as on 01 July 2024	119,230,444	101,221,643	-	-	-	-	-	-	-	-	-	220,452,087
Addition during the year	-	-	-	-	-	-	-	-	-	-	-	-
Borrowing Cost	-	-	-	-	-	-	-	-	-	-	-	-
Adjustment	-	-	-	-	-	-	-	-	-	-	-	-
Balance as on 30 June, 2025	**119,230,444**	**101,221,643**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**220,452,087**

JMI HOSPITAL REQUISITE MANUFACTURING LTD

Schedule for Property, Plant & Equipment- Production
As at 30 June, 2025

Annexure-1

Particulars	Freehold Assets											Total
	Land & Land Development	Factory Buildings	Building Suture	Machinery	Machinery-Suture	Electrical Installation	Furniture & Fixture	Computer & Other Equipments	Office Equipment	Motor Vehicles	Right of Use Assets**	
Accumulated Depreciation												
Balance as on 01 July 2023	-	37,699,002	-	-	-	-	-	-	-	-	-	37,699,002
Addition during the year	-	3,176,132	-	-	-	-	-	-	-	-	-	3,176,132
Adjustment	-		-	-	-	-	-	-	-	-	-	-
Balance as on 30 June, 2024	**-**	**40,875,134**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**40,875,134**
Balance as on 01 July 2024	-	40,875,134	-	-	-	-	-	-	-	-	-	40,875,134
Addition during the year	-	3,017,325	-	-	-	-	-	-	-	-	-	3,017,325
Adjustment	-		-	-	-	-	-	-	-	-	-	-
Balance as on 30 June, 2025	**-**	**43,892,459**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**43,892,459**
Written Down Value												
As on 30 June, 2024	**119,230,444**	**60,346,509**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**179,576,953**
Balance as on 30 June, 2025	**119,230,444**	**57,329,184**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**176,559,628**
Total Written Down Value												
As on 30 June, 2024	**378,230,984**	**180,753,264**	**152,104,818**	**154,657,877**	**850,300,447**	**18,717,621**	**11,522,610**	**9,119,290**	**48,375,251**	**11,485,119**	**-**	**1,815,267,282**
As on 30 June, 2025	**378,230,984**	**172,166,391**	**144,499,577**	**157,453,007**	**765,270,402**	**18,380,688**	**11,010,199**	**9,399,129**	**47,585,865**	**14,558,318**	**2,553,062**	**1,721,107,622**

Allocation of Depreciation:	For the year ended 30 June 2025	For the year ended 30 June 2024	
Cost of Sales	121,390,696	125,191,443	*(Depreciation expenses on Plant & Machinery and Maintenance Equipment considered as direct expenses)*
General & Administrative Expenses	14,772,132	15,234,648	*(Other than depreciation expenses on Plant & Machinery and Maintenance Equipment considered as indirect expenses)*
Total	**136,162,828**	**140,426,090**	

** Right of use assets previously shown as operating expense but now it has been recognized as financial lease due to implementation of IFRS 16.

JMI HOSPITAL REQUISITE MANUFACTURING LTD

Schedule for Property, Plant & Equipment-Trading
As at 30 June 2025

Annexure-2

Particulars	Freehold Assets							Total
	Machinery	Office Equipment	Computer & Other Equipment	Electrical Installation & Equipment	Furniture & Fixure	Motor Vehicle	Right of Use Assets**	
Rate of Depreciation	**20.00%**	**15.00%**	**10.00%**	**10.00%**	**10.00%**	**20.00%**	**39.00%**	
Cost								
Balance as on 01 July 2023	16,189,235	128,322	620,567	3,517,534	10,315,928	9,635,216	6,715,053	47,121,855
Addition during the year	771,514	105,476	646,200	1,405,631	2,248,268	-	-	5,177,089
Borrowing Cost	-	-	-	-	-	-	-	-
Adjustment	-	-	-	-	-			-
Balance as on 30 June 2024	**16,960,749**	**233,798**	**1,266,767**	**4,923,165**	**12,564,196**	**9,635,216**	**6,715,053**	**52,298,944**
Balance as on 01 July 2024	16,960,749	233,798	1,266,767	4,923,165	12,564,196	9,635,216	6,715,053	52,298,944
Addition during the year	-	-	-	-	-	-	-	-
Borrowing Cost	-	-	-	-	-	-	-	-
Adjustment	-	-	-	-	-	-	-	-
Balance as on 30 June 2025	**16,960,749**	**233,798**	**1,266,767**	**4,923,165**	**12,564,196**	**9,635,216**	**6,715,053**	**52,298,944**
Accumulated Depreciation								
Balance as on 01 July 2023	5,260,763	38,549	265,539	935,829	1,867,352	7,233,484	5,402,710	21,004,226
Addition during the year	2,231,869	14,239	77,224	376,729	940,889	480,346	926,359	5,047,656
Adjustment	-	-	-	-	-	-	-	-
Balance as on 30 June 2024	**7,492,632**	**52,788**	**342,763**	**1,312,558**	**2,808,241**	**7,713,831**	**6,329,069**	**26,051,882**
Balance as on 01 July 2024	7,492,632	52,788	342,763	1,312,558	2,808,241	7,713,831	6,329,069	26,051,882
Addition during the year	1,893,623	27,151	92,400	361,061	975,596	384,277	385,984	4,120,092
Adjustment	-		-	-	-	-	-	-
Balance as on 30 June 2025	**9,386,255**	**79,940**	**435,164**	**1,673,619**	**3,783,836**	**8,098,108**	**6,715,053**	**30,171,974**
Written Down Value								
As on 30 June 2024	**9,468,117**	**181,010**	**924,004**	**3,610,607**	**9,755,955**	**1,921,385**	**385,984**	**26,247,061**
As on 30 June 2025	**7,574,494**	**153,858**	**831,603**	**3,249,546**	**8,780,360**	**1,537,108**	**-**	**22,126,969**


** Right of use assets previously shown as operating expense but now it has been recognized as financial lease due to implementation of IFRS 16.

JMI BURET SET

Volumetric Infusion Set



সতর্কবার্তাঃ



ব্যবহৃত JMI ব্যুরেট সেট পুনঃব্যবহার ও নকল করে বাজারজাত করা হচ্ছে, এতে রোগীরা ঝুঁকির মুখে পড়ছে এবং JMI এর ভাবমূর্তি ক্ষতিগ্রস্ত হচ্ছে।

অনুগ্রহ করে ব্যবহারের পর ব্যুরেট সেটের টিউব ও চেম্বার ছবি অনুযায়ী ধ্বংস করুন এবং প্রতারণা রোধে সহায়তা করুন।

JMI Hospital Requisite Manufacturing Ltd.

Reports of the Directors to the Shareholders and

Audited Financial Statements of the Subsidiary Company

For the year ended on 30 June 2025



JMI Hospital Requisite Manufacturing Ltd.

Directors Report to the Shareholders
JMI SPECIALIZED HOSPITAL LIMITED

Dear Shareholders,

Assalamu Alaikum Warahmatullah,
The Board of Directors of JMI Specialized Hospital Ltd. is pleased to present the Directors' Report, together with the audit report and audited financial statements for the year ended 30 June 2025. This report has been prepared in line with Section 184 of the Companies Act 1994 and the guidelines of the Bangladesh Securities and Exchange Commission.

Company Overview
Incorporated on 6 August 2023, JMI Specialized Hospital Ltd. is a subsidiary of JMI Hospital Requisite Manufacturing Limited. Operating from a state-of-the-art facility in Dhanmondi, Dhaka, the company is committed to delivering high-quality, specialized healthcare services to meet the growing needs of the community.

Parent Company
JMI Hospital Requisite Manufacturing Ltd., holding a 65% stake in the company, is a joint venture with the Republic of South Korea. As Bangladesh's pioneering manufacturer of health and hospicare products, it plays a key role in import substitution while setting high standards in quality and innovation.

Board of Directors
The following persons are the Members of the Board of Directors of the Company:

Name of Directors	Attended
Mrs. Suriya Akther Rina (Nominee of JMI Hospital Requisite Manufacturing Ltd.)	Chairman
Mr. Md. Abdur Razzaq	Managing Director
Dr. Saiful Islam	Director
Dr. Adnan Ahmed	Director
Mr. Md. Tousiful Karim, (Nominee of JMI Hospital Requisite Manufacturing Ltd.)	Director
Mr. Abdul Wahab Khan (Nominee of JMI Hospital Requisite Manufacturing Ltd.)	Director

Mrs. Suriya Akther Rina, Mr. Md. Tousiful Karim & Mr. Abdul Wahab Khan represent as nominee directors in the Board of JMI Specialized Hospital Ltd. in compliance with condition No. 2 of the Corporate Governance Code 2018 of Bangladesh Securities and Exchange Commission.

Principal Business Activities
The Company's core business activities are Medical service, Diagnostics, Pharmacy and others.

Operational Results
The company did not commence operational activities up to 30 June 2025. The operational results for the year ended 30 June 2025 are as follows:

Particulars	July 2024 to June 2025 (Amount in Taka)
Revenue	-
Gross profit	-
Net profit after tax	(143,882)

Shareholding

The shareholding position of the company as on 30 June 2025 is as follows:

Name of the shareholders	Shareholding (Shares)	% of shareholding
JMI Hospital Requisite Manufacturing Ltd.	2,10,00,000	65.00
Mr. Md. Abdur Razzaq	28,00,000	8.67
Dr. Saiful Islam	6,20,000	1.92
Dr. Tamjeed Alam	6,20,000	1.92
Dr. Adnan Ahmed	6,20,000	1.92
Others shareholders	30,00,000	20.57
Total	**3,23,00,000**	**100**

Statutory Auditors

"G. Kibria & Co., Chartered Accountants, the existing auditor of the company, has been recommended by the Board of Directors as the statutory auditor for the year ending June 30, 2026, subject to approval by the shareholders at the AGM of the company."

Acknowledgement

"I sincerely thank our Board of Directors, employees, buyers, consumers, suppliers, patrons, and well-wishers for their valuable contributions to our success. We also deeply appreciate the guidance and support of BSEC, DSE, CSE, CDBL, and our esteemed shareholders."

Md. Abdur Razzaq
Chairman





JMI Specialized Hospital Ltd.

Auditor's Report & Audited Financial Statements

For the year ended on 30 June 2025

G. KIBRIA & CO.
CHARTERED ACCOUNTANTS

gmni
member
an association of
legallyindependent
accounting firms
partnering for success

Independent Auditors' Report

To the Shareholders of JMI Specialized Hospital Limited

Report on the Audit of the Financial Statements

Qualified Opinion

We have audited the financial statements of JMI Specialized Hospital Limited ("the Company"), which comprise the statement of financial position as at June 30, 2025 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting Policy Information.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements give a true and fair view of the financial position of the Company as at June 30, 2025 and of its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB).

Basis for Qualified Opinion

We draw attention to note 4.01 to the financial statement, the company has recognized start-up cost of BDT 88, 202,738 under Capital Work in Progress (CWIP) which do not meet the definition of Directly Attributable Cost incompliance with IAS 16 Property, Plant and Equipment. Moreover, certain rental expenses have not been recognized incompliance with the IFRS 16 Leases.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB), and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company's or to cease operations, or has no realistic alternative but to do so.
Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Head Office : Sadharan Bima Sadan (5th Floor) 24-25, Dilkusha Commercial Area, Dhaka-1000, Bangladesh
Branch Office : Plot 51, Floor-2, Road 14, Block-G, Niketon, Gulshan-1, Dhaka-1212
TEL OFF : 02-223388071, 02-223355324, 48812331, 48812332
E-mail : gkibria@gkibriaandco.com, kibria03@hotmail.com, Web: http://gkibriaandco.com

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, we also report the following:

- we have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books; and
- the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account.

Place: Dhaka
Date: 25 October 2025
DVC No. 2510250392AS847876

For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

A.K. Gulam Kibria, FCA, (#392)
Partner

Head Office : Sadharan Bima Sadan (5th Floor) 24-25, Dilkusha Commercial Area, Dhaka-1000, Bangladesh
Branch Office : Plot 51, Floor-2, Road 14, Block-G, Niketon, Gulshan-1, Dhaka-1212
TEL OFF : 02-223388071, 02-223355324, 48812331, 48812332
E-mail : gkibria@gkibriaandco.com, kibria03@hotmail.com, Web: http://gkibriaandco.com

JMI SPECIALIZED HOSPITAL LIMITED
Statement of Financial Position
as at 30 June 2025

Particulars	Notes	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
ASSETS			
Non-Current Assets			
Capital Work in Progress(CWIP)	4.00	255,758,499	29,043,241
		255,758,499	**29,043,241**
Current Assets			
Advance, Deposit & Prepayments	5.00	224,298,745	127,969,905
Cash & Cash Equivalents	6.00	8,503,338	53,594,064
		232,802,083	**181,563,969**
Total Assets		**488,560,582**	**210,607,210**
EQUITY & LIABILITIES			
Equity			
Share Capital	7.00	323,000,000	200,000,000
Share Money Deposit	7.01	143,483,775	-
Retained Earnings	8.00	(201,542)	(57,660)
		466,282,233	**199,942,340**
Non-Current Liabilities			
Term Loan (Non Current maturity)		-	-
		-	-
Current Liabilities			
Term Loan (Current maturity)		-	-
Account & Other Payables	9.00	22,278,349	10,664,870
Income Tax Liability	10.00	-	-
		22,278,349	**10,664,870**
Total Equity & Liabilities		**488,560,582**	**210,607,210**

Accompanying notes form an integral part of these Financial Statements

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Signed in term of our report of even date annexed
For and on behalf of
G.Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Date: 25 October 2025
Place: Dhaka
DVC: 2510250392AS847876

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI SPECIALIZED HOSPITAL LIMITED
Statement of Profit or Loss and Other Comprehensive Income
as at 30 June 2025

Particulars	Notes	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
Revenue		-	-
Direct Expenses		-	-
Gross Profit/(Loss)		**-**	**-**
Operating Expenses			
Administrative Expenses	11.00	(152,835)	(90,152)
Selling & Distribution Expenses		-	-
Total Operating Expenses		**(152,835)**	**(90,152)**
Operating Profit		**(152,835)**	**(90,152)**
Financial Expense		-	-
Net Profit After Financial Expenses		**(152,835)**	**(90,152)**
Income From Others Sources	12.00	12,790	46,417
Net Profit Before Taxation		**(140,045)**	**(43,735)**
Provision for Income Tax Expense			
Current Tax	10.00	(3,837)	(13,925)
Deferred Tax		-	-
Profit after Tax for the period		**(143,882)**	**(57,660)**
Other Comprehensive Income:			
Deferred Tax		-	-
		-	**-**
Total Comprehensive Income for the period		**(143,882)**	**(57,660)**

Accompanying notes form an integral part of these Financial Statements

Company Secretary | **Chief Financial Officer** | **Managing Director** | **Chairman**

Signed in term of our report of even date annexed
For and on behalf of
G.Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Date: 25 October 2025
Place: Dhaka
DVC: 2510250392AS847876

A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI SPECIALIZED HOSPITAL LIMITED
Statement of Changes in Equity
For the year ended 30 June 2025

Particulars	Share Capital	Tax Holiday Reserve.	Share Money Deposit	Retained Earnings	Total amount in Taka
Balance as on 01.07.2024	200,000,000	-	-	(57,660)	199,942,340
Share Issued	123,000,000	-	143,483,775	-	266,483,775
Revaluation Surplus	-	-	-	-	-
Other Comprehensive Income	-	-	-	-	-
Net Profit During the Period	-	-	-	(143,882)	(143,882)
Balance as on 30.06.2025	**323,000,000**	**-**	**143,483,775**	**(201,542)**	**466,282,233**

For the year ended 30 June 2024

Particulars	Share Capital	Tax Holiday Reserve.	Share Money Deposit	Retained Earnings	Total amount in Taka
Balance as on 06.08.2023					-
Share Issued	200,000,000				200,000,000
Revaluation Surplus					-
Other Comprehensive Income					-
Net Profit During the Period				(57,660)	(57,660)
Balance as on 30.06.2024	**200,000,000**	**-**	**-**	**(57,660)**	**199,942,340**

Company Secretary | **Chief Financial Officer** | **Managing Director** | **Chairman**

Date: 25 October 2025
Place: Dhaka

JMI SPECIALIZED HOSPITAL LIMITED
Statement of Cash Flows
For the year ended 30 June 2025

Particulars	Notes	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
Cash flow from operating activities			
Cash Receipts from customers and others		12,790	46,417
Paid to suppliers and others		(84,868,196)	(117,395,187)
Income tax paid		(3,837)	(13,925)
Net cash generated from operating activities		**(84,859,243)**	**(117,362,695)**
Cash flow from investing activities			
Capital Work in Progress(CWIP)		(226,715,258)	(29,043,241)
Acquisition of Non-current Assets		-	-
Net cash generated from investing activities		**(226,715,258)**	**(29,043,241)**
Cash flow from financing activities			
Share Money Deposit		143,483,775	-
Finance Cost Paid		-	
Received from Share Capital		125,000,000	198,000,000
Net cash generated from financing activities		**268,483,775**	**198,000,000**
Net cash Surplus/(Deficit) for the year		**(43,090,726)**	**51,594,064**
Cash & Cash Equivalents at the Beginning of the year		51,594,064	-
Cash & Cash Equivalents at the End of the year		**8,503,338**	**51,594,064**
Cash & Cash Equivalents as Statement of Cash Flows			51,594,064
Cheque in transit *			2,000,000
			53,594,064

** Details of this cheque in transit are mentioned in the relevant note 6(iii).*

Accompanying notes form an integral part of these Financial Statements.

Company Secretary **Chief Financial Officer** **Managing Director** **Chairman**

Date: 25 October 2025
Place: Dhaka

JMI SPECIALIZED HOSPITAL LIMITED
Notes to the Financial Statements
For the year ended 30 June 2025

1.00 The Company and its Activities:

1.01 About the Company
JMI Specialized Hospital Limited. (JSHL) is a private Limited Company incorporated in Bangladesh under the Companies Act 1994 and incorporated as Private Limited Company as on 06.08.2023 It is a subsidiary company of JMI Hospital Requisite Manufacturing Ltd which was converted to Public Limited Company as on 30.11.2014 and also JMI Specialized Hospital Limited is franchising with Apollo Health and Lifestyle Limited 'India. under the brand name Apollo Clinic.

1.02 Nature of the Business
JMI Specialized Hospital Limited. engages in the provision of General medical services and JSHL operates through the following business segments: Medical Services, Diagnostics, Pharmacy, and Others. It offers internal medicine, neurology, diabetes, endocrinology, and

1.03 Registered Office
The registered office of the company is situated at 72/C, Progoti Shoroni, Middle Badda, Dhaka-1212.

1.04 Hospital Address
The Hospital of the Company is situated at 64 (Old 764) Satmasjid Road, Dhanmondi C/A, Dhaka, Bangladesh.

2.00 Basis for the Preparation of Financial Statements:

2.01 Basis of Accounting
The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs) and other applicable laws and regulations. The elements of the financial statements have been prepared on Historical Cost concept and on accrual basis in compliance with the Companies Act 1994.

2.02 Statement of Compliance
The financial statements have been prepared in compliance with the requirements of the Companies Act 1994, and other relevant local laws as applicable and in accordance with the International Financial Reporting Standards (IFRSs).

2.03 Use of Estimates and Judgments
The preparation of financial statements in conformity with the IFRSs including IASs require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure during and at the date of the financial Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates is recognized in the period in which the estimates is revised and in any future periods affected as required by IAS 8: Accounting Policies, Changes in Accounting Estimates and Errors.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, inventory valuation, accrued expenses, reserves, contingencies and other payable.

2.04 Going Concern

The Company has adequate resources to continue in operation for foreseeable future. For this reason, the board of directors continues to adopt going concern basis in preparing the financial statements. The current credit facilities and resources of the company provide sufficient funds to meet the present requirements of its existing businesses and operations.

3.00 Significant Accounting Policies

The accounting principles and policies in respect of material items of financial statements set out below have been applied consistently to all periods presented in these financial statements.

3.01 Revenue Recognition

In compliance with the requirements of IFRS-15 Revenue from contracts with customers, the company recognizes revenue when performance obligations in relation to sales has been transferred by the company. Revenue from sales is exclusive of VAT.

3.02 Property, Plant & Equipment

3.2.1 Recognition and Measurement

Property, Plant and Equipment are recognized, when and only when the necessary recognitions criteria set out in IAS 16: Property, Plant & Equipment are met, means it is probable that future economic benefits associated with the asset will be flow to the Company, controlled by the company and the cost of the asset can be measured reliably. Items of property, plant and equipment are measured at cost/revaluation less accumulated depreciation

Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labor, any other costs directly attributable to bringing the asset to a working condition for its intended use and the present value of dismantling and removing the items and restoring the site on which they are located if any.

3.2.2 Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

3.2.3 Depreciation

Depreciation is the systematic allocation of depreciable amount of an asset over its useful life, In accordance with the provisions of IAS 16: Property, Plant and Equipment. depreciation has been charged from date of purchase or ready to use for addition of fixed assets. Depreciation is charged on all fixed assets except land and land development on reducing balance method.

3.2.4 Retirements and Disposal

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain loss on such disposal is reflected in Statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets at disposal date and net sales proceeds. When revalued assets are sold or disposed, the balance of revaluation reserve is transferred to retained earnings.

3.2.5 Revaluation of Property Plant & Equipment

The Revaluation surplus, difference between revalued amount and carrying value of assets at revaluation date, is recognized as revaluation reserve after recognizing necessary deferred tax arisen on revaluation reserve. The excess deprecation difference between deprecation at revalued amount and depreciation at cost value is being transferred from revaluation reserve to retained earnings through statement of changes in equity.

3.03 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. The company is recognizing financial instrument in its financial statements when it becomes a party under the instrument.

3.3.1 Financial Assets

Financial assets of the company include cash and cash equivalents, accounts receivable and other receivables. The company initially recognizes receivable on the date they are originated. All others financial assets are recognized initially on the date at which the company becomes a party to the contractual provisions of the transaction. The company derecognizes a financial asset when and only when the contractual rights or probabilities of receiving the cash flows from the asset expire or it transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risk and rewards of ownership of financial asset are transferred.

3.3.1(a)Accounts Receivable

Accounts receivable is created at original invoice amount less any provisions for doubtful debts. Provisions are made where there is evidence of a risk of non-payment, taking into account aging, previous experience and general economic conditions. When an accounts receivable is determined to be uncollected it is written off, firstly against any provision available and then to the statement of profit or loss and other comprehensive income.

3.3.1(b)Cash and Cash Equivalents

Cash and Cash Equivalents are comprised of cash in hand and cash at bank that are readily convertible to known amount of cash and that are subject to an insignificant risk of change in value.

3.3.2 Financial Liability

Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. Financial liabilities include payable for expenses, liability for capital expenditure and other current liabilities.

3.04 Impairment

(a) Financial Assets

Accounts receivable and other receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy etc.

(b) Non-Financial Assets

An asset is impaired when it carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impairment loss if, and only if, the recoverable amount of the asset is less than it carrying amount. Impairment loss is recognized immediately in profit or loss, unless the asset is carried at revalued amount. Any impairment loss of a revalued asset shall be treated as a revaluation decrease. WIP are valued on the basis of stage of completion and finished goods are valued at cost of material plus standard conversion cost.

3.05 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present condition and realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale. WIP are valued on the basis of stage of complication and finished goods are valued at cost of material plus standard conversion cost.

3.06 Provisions

Provisions and accrued expenses are recognized in the financial statements in line with the International Accounting Standards (IAS) 37 "Provisions, Contingent Liabilities and Contingent Assets" when:

− The company has a legal or constructive obligation as a result of past events.
− It is probable that an outflow of economic benefit will be required to settle the obligations.
− A reliable estimate can be made of the amount of the obligations.

3.07 Income Tax Expenses:

Income tax expenses comprise of current and deferred tax. Income tax expenses are recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted for in accordance with the requirements of IAS 12: Income Tax.

Current Tax

Current tax is the expected tax payable on the taxable income for the period/period and any adjustment to tax payable in respect of previous periods.

Deferred Tax

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and are accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognized for all taxable temporary difference. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which such differences can be utilized. Deferred tax is charged or credited to the Statement of Profit or Loss and Other Comprehensive Income.

3.08 Interest Income

Interest income is recognized when accrued on a time proportion basis.

3.09 Foreign Currency Transaction

The financial records of the company are maintained and the financial statements are stated in Bangladesh Taka. Any foreign currency transactions are recorded at Bangladeshi taka after converting into Taka by the exchange rate ruling on the date of transaction and the period balance at foreign currency are converted into Bangladeshi taka at the exchange rate prevailing on the reporting date as per IAS-21: The effects of exchanges in foreign currency rate.

3.10 Payable and Accruals

Liabilities are recognized for amounts to be paid in future date for the goods and services received by the Company up to 30 June 2025 and incorporated in the Financial Statements.

3.11 Events after the Reporting Period

Even after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

3.12 Components of Financial Statements

The presentation of Financial Statements is in accordance with guidelines provided by IAS 1: Presentation of Financial Statements.

The Financial Statements comprises :

a) a Statement of Financial Position as at June 30, 2025;
b) a Statement of Profit or Loss and Other Comprehensive Income for the year ended June 30, 2025;
c) a Statement of Changes in Equity for the year ended June 30, 2025;
d) a Statement of Cash Flows for the year ended June 30, 2025;
e) Notes, comprising summary of significant accounting policies and explanatory information.

3.13 Reporting Period

The financial statements cover the accounting period from 01 July 2024 to 30 June 2025.

JMI SPECIALIZED HOSPITAL LIMITED
Notes to the Financial Statements - as at 30 June 2025

		Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
4.00 Capital Work in Progress(CWIP)			
The above balances are made up as follows:			
Balance as per last account		29,043,241	-
Add : Addition During the year	4.01	226,715,258	29,043,241
		255,758,499	**29,043,241**
4.01 Addition During the period			
Interior Decoration-Civil CWIP		226,698,202	27,611,511
Network Installation-CWIP		17,056	1,431,730
		226,715,258	**29,043,241**

JMI Specialized Hospital Ltd. (JSHL) rented a commercial building that was converted into a hospital, with development activities including building improvements, medical equipment installation, and ERP system implementation completed by 30 June 2025. The rent, related service charges and other related admin expense and salaries (a total of BDT 8.82 Crore) incurred during this development phase, being directly attributable to bringing the asset to the condition necessary for its intended use, have been capitalized as "Startup Cost" in accordance with IAS 16 – Property, Plant and Equipment and IAS 38 – Intangible Assets. The Company, a licensee of Apollo Healthcare India, commenced operations in August 2025 and has since demonstrated promising revenue growth. The Board of Directors has approved an increase in share capital through the issuance of new shares at a premium and resolved to utilize the resulting share premium account to write off the capitalized startup costs, subject to compliance with applicable laws and IFRS requirements.

The details of Capital Work in Progress(CWIP) has been shown in Annexure-1

5.00 Advance, Deposit & Prepayments			
The above balances are made up as follows:			
Advance against Others :			
Advance Against Construction Materials		172,013,274	91,318,217
Advance Against Security Deposit		50,479,500	36,000,000
Advance Against Others		1,805,971	651,688
Advance Income Tax	5.01	-	-
		224,298,745	**127,969,905**
5.01 Advance Income Tax			
Opening		-	-
Add: Addition During the year		3,837	13,925
Less: Transferred to Provision of income tax		3,837	13,925
		-	-
6.00 Cash & Cash Equivalents			
The above balance are made up as follows:			
Cash in Hand :			
Cash in Hand		467,987	1,058,455
		467,987	**1,058,455**
Cash at Bank:			
Janata Bank PLC. CD # 0100248987132		3,760,100	5,081,652
Pubali Bank PLC, A/C# 3478102001960		3,896,469	45,453,957
Pubali Bank A/C # 0939901049779		2,328	-
Pubali Bank A/C NO: 3478901023844		167,314	-
DBBL A/C# 1711100164718		209,141	-
		8,035,351	**50,535,609**
Cheque in Transit :			
Cheque in Transit *		-	2,000,000
		-	**2,000,000**
		8,503,338	**53,594,064**

i) The bank balances reconciliation has been performed with respective bank statements and found in
ii) All Cash & Cash Equivalents are readily available for use.

* iii) This amount represented a cheque in transit at the end of previous year, which has been realized during the current year. In the prior year's financial statements, It was presented under *Call In Arrear*. For the fair Presentation, the comparative figure has been reclassified to Cash & Cash Equivalents in accordance with paragraph 41 of IAS 1.

JMI SPECIALIZED HOSPITAL LIMITED
Notes to the Financial Statements - as at 30 June 2025

	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
7.00 Share Capital		
a) **Authorized Capital**		
50,000,000 Ordinary Shares of BDT. 10/- each	500,000,000	500,000,000
b) **Issued, Subscribed & Paid up Share Capital**		
32,300,000 Ordinary Shares of BDT. 10/- each fully paid up in each	323,000,000	200,000,000

c) **Composition of Shareholdings:**

Name of Shareholders	No. of Shares	%	Amount in BDT As at 30.06.2025	Amount in BDT As at 30.06.2024
JMI Hospital Requisite Manufacturing Ltd.	21000000	65.02%	210,000,000	130,000,000
Md. Abdur Razzaq	2800000	8.67%	28,000,000	28,000,000
Dr. Saiful Islam	620000	1.92%	6,200,000	4,000,000
Dr. Tamjeed Alam	620000	1.92%	6,200,000	4,000,000
Dr. Adnan Ahmed	620000	1.92%	6,200,000	4,000,000
Dr. A.H.M. Shamsul Alam	200000	0.62%	2,000,000	2,000,000
Dr. Md. Fazlul Kadir	200000	0.62%	2,000,000	2,000,000
Dr. Iffat Ara	200000	0.62%	2,000,000	2,000,000
Dr. Mahmood Hasan	200000	0.62%	2,000,000	2,000,000
Dr. Md. Mahabub Hossain	200000	0.62%	2,000,000	2,000,000
Dr. Rezwanur Rahman	200000	0.62%	2,000,000	2,000,000
Dr. Md. Lutful Kabir	200000	0.62%	2,000,000	2,000,000
Dr. Md. Elias Bhuiyan	200000	0.62%	2,000,000	2,000,000
Dr. Nazir Ahmed	200000	0.62%	2,000,000	2,000,000
Dr. S. M. Zubayir Hassan	200000	0.62%	2,000,000	2,000,000
Dr. Najmun Nahar	200000	0.62%	2,000,000	2,000,000
Dr. Rafael Mursalin	200000	0.62%	2,000,000	2,000,000
Dr. Shibly Muhammad Amimul Ihsan	200000	0.62%	2,000,000	2,000,000
Dr. Amrin Sultana	200000	0.62%	2,000,000	2,000,000
Dr. Md. Arman Ali	200000	0.62%	2,000,000	2,000,000
Shaz Mohammad Chowdhury	840000	2.60%	8,400,000	-
Dr. Md. Khairul Kabir Patwary	200000	0.62%	2,000,000	-
Dr. Md. Sozib Khan	200000	0.62%	2,000,000	-
Dr. Kamrun Nahar	200000	0.62%	2,000,000	-
Dr. Nafisa Khanum	200000	0.62%	2,000,000	-
Dr. Sabrin Akhter Nur	200000	0.62%	2,000,000	-
Dr. Md. Noor Kutubul Alam	200000	0.62%	2,000,000	-
Dr. Md. Samiul Hasan	200000	0.62%	2,000,000	-
Dr. Manas Kanti Mazumder	200000	0.62%	2,000,000	-
Dr. Fatema Jannatul Afrose	200000	0.62%	2,000,000	-
Dr. Rabeya Afroz	200000	0.62%	2,000,000	-
Dr. Rowshan Ara	200000	0.62%	2,000,000	-
Dr. Rita Mazumder	200000	0.62%	2,000,000	-
Dr. Mushfiqur Rahman	200000	0.62%	2,000,000	-
Dr. Ahmed Hosain	200000	0.62%	2,000,000	-
Total	**32,300,000**	**100%**	**323,000,000**	**200,000,000**

JMI SPECIALIZED HOSPITAL LIMITED
Notes to the Financial Statements - as at 30 June 2025

	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024

7.01 Share Money Deposit

Name of Shareholders	No. of Shares	%	Amount in BDT As at 30.06.2025	Amount in BDT As at 30.06.2024
JMI Hospital Requisite Manufacturing Ltd			89,900,000	
Dr. A.H.M. Shamsul Alam			1,000,000	
Dr. Saiful Islam			7,000,000	
Dr. Tamjeed Alam			12,000,000	
Dr. Adnan Ahmed			10,000,000	
Shaz Mohammad Chowdhury			3,583,775	
Dr. Kamrun Nahar			1,000,000	
Dr. Md. Noor Kutubul Alam			1,000,000	
Dr. Manas Kanti Mazumder			1,000,000	
Dr. Fatema Jannatul Afrose			1,000,000	
Dr. Rabeya Afroz			1,000,000	
Dr. Rowshan Ara			2,000,000	
Dr. Rita Majumder			1,000,000	
Dr. Mushfiqur Rahman			1,000,000	
Dr. Ahmed Hosain			1,000,000	
Dr. Iffat Ara			1,000,000	
Dr. Mohammed Kamrul Hasan			5,000,000	
Dr. Rafael Mursalin			1,000,000	
Dr. S. M. Zubayir Hassan			1,000,000	
Dr. Shibly Muhammad Amimul Ihsan			2,000,000	
Total	**-**		**143,483,775**	**-**

8.00 Retained Earnings

The above balance are made up as follows:		
Opening Balance	(57,660)	-
Net Profit during the year	(143,882)	(57,660)
Adjustment for Revaluation Reserve	-	-
	(201,542)	**(57,660)**

9.00 Accounts & Other Payable

The above balance are made up as follows:		
Payable to Suppliers	12,334,539	2,474,006
Audit Fee Payable	57,500	57,500
Salary & Allowance Payable	4,746,981	533,316
Salary Tax Payable	36,494	2,817
VAT Payable Account	2,372,143	199,096
Payable to Others	2,730,692	7,398,135
	22,278,349	**10,664,870**

10.00 Income Tax Liability

This has been made up as under:		
Balance as per Account	-	-
Add: Provision for the year	3,837	13,925
	3,837	**13,925**
Less: Source Tax	3,837	13,925
Less: Advance income tax		-
Tax Payable	**-**	**-**

JMI SPECIALIZED HOSPITAL LIMITED
Notes to the Financial Statements - as at 30 June 2025

	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
11.00 Administrative Expenses		
The above balances are made up as follows:		
Audit Fee	57,500	57,500
Bank Charge	95,335	32,652
Total :	**152,835**	**90,152**
12.00 Income From Others Sources		
The above balances are made up as		
Bank Interest and Others	12,790	46,417
Total :	**12,790**	**46,417**

JMI SPECIALIZED HOSPITAL LIMITED
Notes to the Financial Statements - as at 30 June 2025

	Amount in BDT 30 June 2025	Amount in BDT 30 June 2024
13.00 Reconciliation between net profit to operating cash flow:		
Profit/(loss) before tax	(140,045)	**(43,735)**
Other Income	-	-
Finance cost	-	-
Operating profit	**(140,045)**	**(43,735)**
Adjustment:		
Depreciation	-	-
Changes in Working capital:		
(Increase)/Decrease of Advance, Deposit & Prepayment expect AIT,	(96,328,840)	(127,969,905)
Increase/(Decrease) Accounts & Other Payable except interest payable	11,613,479	10,664,870
	(84,855,406)	**(117,348,770)**
Tax paid	(3,837)	(13,925)
Net cash generated from operating activities	**(84,859,243)**	**(117,362,695)**
	-	-

JMI SPECIALIZED HOSPITAL LIMITED
Capital Work in Progress (CWIP)
As at 30 June 2025

Annexure-1

Amount in BDT

Particulars	As at 01.07.2024	Total Addition	As at 30.06.2025
Computer & Others Equipment	1,794,198	14,935,425	16,729,622
Electrical Installation and Equipment	4,095,970	14,804,825	18,900,795
Furniture & Fixtures	1,970,749	10,702,886	12,673,635
Building Construction and Renovation	16,304,688	9,166,597	25,471,286
Network Installation CWIP	4,877,636	22,679	4,900,315
Air Condition	-	475,607	475,607
Medical Equipment	-	7,343,060	7,343,060
Medical Equipment-LC	-	81,061,441	81,061,441
Start-up Cost	-	88,202,738	88,202,738
	29,043,241	**226,715,258**	**255,758,499**

One Stop Solution *for* Hospital CSSD



JMI Drying Cabinet




JMI Ultrasonic Cleaner



JMI Washer disinfector



JMI Steri kit
(Packaging & Indicators)



JMI Auto Sealer



JMI Steam Sterilizer



JMI Plasma Sterilizer



JMI ETO Sterilizer



JEOSTER
(EO Gas Cartridge)

- Turnkey Solution for Central Sterile Supply Dpt.
- Strong Distribution around the Country
- Service & Maintenance for Lifetime
- Customized Manufacturing Solution 5L-1000L

Our Certification



Regulation No. 54-Law/2010[(Clause 8(1)]

Bangladesh Standards and Testing Institution

Ministry of Industries

Management Systems Certification Wing

116/A, Tejgaon Industrial Area, Dhaka-1208, Bangladesh

Certificate

This is to certify that

the **Environmental Management Systems (EMS)** of

JMI Hospital Requisite Manufacturing Ltd.

Vitikandi, Gazaria, Munshiganj, Bangladesh

has been assessed by MSC wing of BSTI and registered

in compliance with

ISO 14001: 2015

Scope of Certification :

Manufacturing of Medical Devices and its components

Certificate No. : DHK-EMS-0000000000010

Tracking No: MSC-CI-20230905-0001

Date of Issue : 04-10-2023

Date of Registration : 21-08-2023


Date of Expiry : 20-08-2026

Engr. Md. Abdur Rashid
Head of MSC Wing

Md. Abdus Sattar
Director General(Grade-1),BSTI

The conditions of the certificate are specified in the certification agreement.
This certificate must be returned if cancelled or withdrawn.

MSC-F 9.2-26



◆ ZERTIFIKAT ◆ CERTIFICATE ◆ СЕРТИФИКАТ ◆ CERTIFICADO ◆ CERTIFICAT

CERTIFICATE

CERTIFIED STAUNCHLY MANAGEMENT SYSTEM

This is to Certify that the Management System of

JMI Hospital Requisite Manufacturing Ltd.

Factory Address: Vitikandi, Gazaria-1510, Munshiganj, Bangladesh
Registered Office: GA-72/C, Progoti Shoroni, Middle Badda, Dhaka-1212.

has been found to conform to the Medical Devices – Quality Management System standard:

ISO 13485:2016

This certificate is valid for the following scope of operations:

Manufacturer of Surgical Face Mask, Respirator (KN95), Hand Gloves, Alcohol Prep Pad, Surgical Suture, Vacuum Blood Collection Tube, Blister Film, Hypodermic Needle, Spinal Needle, Central Venous Catheter, Hemodialysis Catheter, Blood Pressure Transducer, Foley Balloon Catheter, Pressure Monitoring Line, Anesthesia Circuit, Breathing Circuit, Huber Needle, Urine Drainage Bag, Blood Collection Needles, Buret Set, Surgical Scalpel, Insulin Syringe, Autoclave/Sterilizer, Oxygen Mask with Tubing, Nebulizer Mask with Chamber and Tube, Nasal Oxygen cannula, Infusion Set.

:: Certificate No :: ***BD55124H***

Date of initial registration	*Date of this Certificate*	*Surv. audit on or before / Certificate expiry*	*Recertification Due*
26 June 2023	*04 September 2024*	*25 June 2025*	*25 June 2026*

This Certificate remains valid subject to satisfactory surveillance audits.

Director

For verification and updated information concerning the present certificate visit to http://staunchlyservices.com/search_certified_client.php
This Certificate is the property of Staunchly Management & System Services Limited and shall be returned immediately when demanded

STAUNCHLY MANAGEMENT AND SYSTEM SERVICES LIMITED
International Office: Labrynth Business Centre, 43 Middle Hill Gate, Stockport Great Manchester, England-SK1 3DG
Phone: +44-7404823687
(Company Registered in England with Company Number 11488683

STAUNCHLY MANAGEMENT AND SYSTEM SERVICES PVT. LTD.
Corporate Office: 303, U-60, 3rd Floor Shakarpur, Delhi-110019, India
Phone: +91-6389519394
Web :- www.staunchlyservices.com
E-mail :- info@staunchlyservices.com

CERTIFIED STAUNCHLY MANAGEMENT SYSTEM
EGAC Accredited MSCB CAB # 011804
MEMBER OF MULTILATERAL RECOGNITION ARRANGEMENT IAF

SMS/FM/001/REV07



GOVERNMENT OF THE PEOPLE'S REPUBLIC OF BANGLADESH
MINISTRY OF HEALTH & FAMILY WELFARE
DIRECTORATE GENERAL OF DRUG ADMINISTRATION
DGDA

CERTIFICATE OF GOOD MANUFACTURING PRACTICE (GMP)
FOR PHARMACEUTICAL (PRODUCT(S))

Certificate Number: DGDA/6-229/2019/ 14772 Date: 08 AUG 2023

It is hereby certified that **M/s. JMI Hospital Requisite Manufacturing Ltd.**, a drug (Components of Medical Devices, Medical Devices, Surgical Products & Medical Equipment's) manufacturing, exporting and marketing organization, has been given license to manufacture and sell its products freely in the People's Republic of Bangladesh, as lawfully required and granted in pursuance of **The Drugs Acts 1940 (XXIII of 1940) & The Drugs (Control) Ordinance, 1982, and its Amendment Act 2006.**

On the basis of the inspection carried out on 30-06-2022 & 06-01-2023, we certify that the site indicated in this certificate complies with Good Manufacturing Practices for the capacity forms, categories and activities listed in Table -1.

1. Name and Address of site: **JMI Hospital Requisite Manufacturing Ltd.**, Vitkandi, Gazaria-1510, Munshiganj, Bangladesh
2. Manufacturer's license Number and Date of issue: Biological-298 Date: 17-02-2014
3. Table-1

Form(s) of Product(s)	Category (ies)	Activity (ies)
Scalp Vein Set / Butterfly needle (Non- Sterile)	Size: 19G, 20G, 21G, 22G, 23G, 24G, 25G, 27G	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Product Analysis & Release, Storage and Delivery.
Bulk Needle / Hypodermic Needle (Non-Sterile)	Size: 18G, 19G, 20G, 21G, 22G, 23G, 24G, 25G, 26G, 27G	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Product Analysis & Release, Storage and Delivery.
Components of I.V. Infusion Set	Assembled Air Vent/Non Vent Drip Chamber, Slider with Roller/ Flow Regulator, Fluid Filter/ Precision Filter, Y-Injection Port, Luer Slip/Lock Connector.	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Product Analysis & Release, Storage and Delivery.
Cannula (Non-sterile)	Size: 18G, 19G, 20G, 21G, 22G, 23G, 24G, 25G, 26G, 27G	Quality Control of Incoming Materials, In-process Control, Manufacturing, Packaging, Product Analysis & Release, Storage and Delivery.



Components of I. V. Cannula	Intravenous Cannula: 14G, 16G, 18G, 20G, 22G, 24G, 26G	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Product Analysis & Release, Storage and Delivery.
Components of Blood Transfusion Set	Assembled Air Vent Blood Drip Chamber (B.T.S) (Blood Filter, Fabric filter). Slider with Roller,	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Product Analysis & Release, Storage and Delivery.
Components of Urine Drainage Bag /Drain Bag	Urine Drainage Bag/Drain Bag	Quality Control of Incoming Materials, In-process Control, Manufacturing, Printing, Assembling, Packaging, Product Analysis & Release, Storage and Delivery.
JMI Latex Examination Gloves (Powdered)	Latex Examination Gloves (Small, Medium, Large)	Quality Control of Incoming Materials, In-process Control, Packaging, Product Analysis & Release, Storage and Delivery.
JMI Latex Surgical Gloves (Powdered)	Sterile Latex Surgical Gloves (6.0,6.5,7.0,7.5, 8.0)	Quality Control of Incoming Materials, In-process Control, Packaging Sterilizing, Product Analysis & Release, Storage and Delivery.
JMI Buret Set	Volumetric Infusion Set	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Delivery.
JMI Alcohol Prep Pad	Alcohol Prep Pad/ Alcohol Swab	Quality Control of Incoming Materials, In-process Control, Packaging, Product Analysis & Release, Storage and Delivery.
J-LENE (Monofilament, Polypropylene blue, Synthetic Non-absorbable Surgical Suture USP)	**Needle**: Stainless steel (Curvature: 1/2 circle, 3/8 circle, 1/4 circle, 5/8 circle, 1 shape, Compound curved, 1/2 curved, Straight) **Thread:** Polypropylene, non-absorbable, synthetic USP Size: 12-0, 11-0, 10-0, 9-0, 8-0, 7-0, 6-0, 5-0, 4-0, 3-0, 2-0,0,1, 2, 3, 4, 5)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Delivery.



J-SILK (Braided Silk Black, Natural non-absorbable Surgical Suture USP)	**Needle**: Stainless steel (Curvature: 1/2 circle, 3/8 circle, 1/4 circle, 5/8 circle, 1 shape, Compound curved, 1/2 curved, Straight) **Thread:** Silk, non-absorbable, natural USP Size: 8-0, 8-0,7-0, 6-0, 5-0, 4-0, 3-0, 2-0,0,1, 2, 3, 4)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Delivery.
J-CRYL (Braided coated Polyglactin 9:1, synthetic absorbable, surgical suture USP)	**Needle:** Stainless steel (Curvature: 1/2 circle, 3/8 circle, 1/4 circle, 5/8 circle, 1 shape, Compound curved, 1/2 curved, Straight) **Thread:** Polyglactin 910, absorbable, synthetic, USP size: 12-0, 11-0, 10-0, 9-0, 8-0, 7-0, 6-0, 5-0, 4-0, 3-0, 2-0,0,1, 2, 3, 4, 5)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
J-GUT Chromic (Catgut Chromic, natural, absorbable, surgical suture USP)	**Needle:** Stainless steel (Curvature: 1/2 circle, 3/8 circle, 1/4 circle, 5/8 circle, 1 shape, Compound curved, 1/2 curved, Straight) **Thread:** Catgut Chromic, absorbable, natural (USP Size: 9-0, 8-0, 7-0, 6-0, 5-0, 4-0, 3-0, 2-0,0,1, 2, 3, 4)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
J-GUT Plain (Catgut Plain, natural, absorbable surgical suture USP)	**Needle:** Stainless steel (Curvature: 1/2 circle, 3/8 circle, 1/4 circle, 5/8 circle, 1 shape, Compound curved, 1/2 curved, Straight) **Thread:** Catgut Plain, absorbable, natural (USP Size: 9-0, 8-0, 7-0, 6-0, 5-0, 4-0, 3-0, 2-0,0,1, 2, 3, 4)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Butterfly Needle for Blood Collection	Blood Collection Needle (21G, 22G, 23G)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Sterile Disposable Scalpel	Sterile Disposable Scalpel (Size: 10, /BA, 11, 12, 15, 20, 21, 22, 23, 24)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.



JMI Sonoreed (Atraumatic Needle for Peripheral Nerve Blocks)	Sonoreed (Atraumatic Needle for Peripheral Nerve Blocks) Size: 20G/21G/22Gx25mm 20G/21G/22Gx32mm 20G/21G/22Gx40mm 20G/21G/22Gx100mm	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Oxygen Mask with tubing	Oxygen Mask with Tubing (S,M ,L, XL)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Nasal Oxygen Cannula	Nasal Oxygen Cannula (Neonatal, Infant, Child, Adult)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Nebulizer Mask with Chamber & Tubing	Nebulizer Mask with Chamber & Tubing (S,M ,L, XL)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Packaging, Sterilizing, Product Analysis & Release, Storage and Delivery.
JMI Guedel Airway (Oropharyngeal Airway)	Guedel Airway / Oropharyngeal Airway (000, 00, 0, 1, 2, 3, 4, 5, 6/ 40,50,60,70,80,90,100,110,120)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Packaging, Sterilizing, Product Analysis & Release, Storage and Delivery.
Shin-ject insulin syringe 1ml	Insulin Syringe 1 ml (U- 40) Insulin Syringe 1 ml (U- 100)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.



JMI Autoclave/ Steam Sterilizer	Autoclave/ Steam Sterilizer (35,,100,,300,,500,,750,,1000,L)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Sterile Latex Surgical Gloves (Powdered Free)	Latex Surgical Gloves (Powdered Free) (6.0,6.5,7.0,7.5)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Sterile Swab Stick	Sterile Swab Stick	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
JMI Nitrile Examination Gloves	Nitrile Examination Gloves	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.
J-FGN	Polydioxanone Suture (Monofilament, Synthetic, Absorbable surgical suture USP)	Quality Control of Incoming Materials, In-process Control, Manufacturing, Assembling, Packaging, Sterilizing, Product Analysis & Release, Storage and Product Delivery.



The responsibility for the quality of the individual batches of the pharmaceutical/ Medical devices products manufactured through this process lies with the manufacturer.

The manufacturing plant in which the pharmaceutical products (Components of Medical Devices, Medical Devices, Surgical Products and Medical Equipment's) are produced is subject to inspection at suitable intervals.

The manufacturer conforms to the requirements for good practices in the manufacture and quality control (**GMP**) of drugs, as required under law in this country, as well as recommended by the World Health Organization (**WHO**) in respect of pharmaceutical products to be manufactured, sold or distributed within the country of origin or to be exported.

This Certificate will remain valid for a period of 2 (Two) years from the date of issue. It becomes invalid if the activities and/or categories certified hereby are changed or if the site is no longer considered to be in compliance with **GMP**.

Name of Authorized Person	**Major General Mohammad Yousuf**
Address of the certifying Authority	**Directorate General of Drug Administration** Mohakhali, Dhaka-1212
Telephone	+88-022222-40803
Fax	+88-02-9880854
Email	dgda.gov@gmail.com
Web	www.dgda.gov.bd

Stamp and date:

Major General Mohammad Yousuf
Director General
Directorate General of Drug Administration
&
Licensing Authority (Drugs)
Government of the People's Republic of Bangladesh

BANGLADESH ASSOCIATION OF PUBLICLY LISTED COMPANIES

Renewed Certificate

This is to certify that

JMI HOSPITAL REQUISITE MANUFACTURING LIMITED

is an Ordinary Member of Bangladesh Association of Publicly Listed Companies and is entitled to all the rights and privileges appertaining thereto.

This certificate remains current until 31st December, 2025.

Ref. No: CM-2025/178

Date of issue : March 24, 2025

BAPLC

Secretary General

Proxy Form

JMI Hospital Requisite Manufacturing Ltd.

Unique Heights, Level-11, 117 Kazi Nazrul Islam Avenue, Ramna, Dhaka-1217

"This proxy form is for the 17th AGM of the shareholders of **JMI Hospital Requisite Manufacturing Limited,** which will be held through a hybrid system. Shareholders may attend physically at Sky City Hotel (8th floor), 47, Siddeshwari, Circular Road, Malibag, Dhaka or virtually via the digital platform at *https://jmihrml.bdvirtualagm.com* on **Thursday, January 22, 2026, at 11:00 a.m.**

I/We.....

BO # | | | | | | | | | | | | | | | |

Of.....to be my/our proxy to attend and vote on my/our behalf at the 17th AGM of **JMI Hospital Requisite Manufacturing Limited,** to be held on **Thursday, January 22, 2026, at 11:00 a.m.** through a hybrid system (physical and online via *https://jmihrml.bdvirtualagm.com)*."

Revenue Stamp of Tk. 100/-

_____
(Signature of Proxy)

_____
(Signature of Share Holder)

Notes: The proxy form duly stamped must be sent through email at cs@jhrml-bd.com or submitted to the corporate office of the company, not later than 72 hours before the meeting. Proxy form will be invalid if not signed and stamped as shown above.

The signature of the shareholder should agree with the specimen signature registered by the Company.

Signature verified

Authorized Signature
JMI Hospital Requisite Manufacturing Ltd.

The 16TH

Annual General Meeting



The 16th Annual General Meeting of the shareholders of JMI Hospital Requisite Manufacturing Limited held under virtual platform on January 23, 2025.

Scan here to find our details:

Corporate Office:
Unique Heights (Level-11),
117, Kazi Nazrul Islam Avenue,
Ramna, Dhaka-1217.

Registered Office:
GA 72/C, Progoti Shoroni,
Middle Badda, Dhaka-1212,
Bangladesh.

Factory:
JMI Industrial Park, Vitikandi,
Gazaria-1510, Munshiganj,
Bangladesh.

Contact : +88-02-55138723-24

E-mail : cs@jhrml-bd.com

Website : www.jhrml-bd.com